 
   ADI-PEG 20  
POLARIS2015 -003 RANDOMIZED, DOUBLE- BLIND, PHASE 2/3 STUDY IN 
SUBJECTS WITH MALIGNANT PLEURAL MESOTHELIOMA TO ASSESS ADI -PEG 
20 WITH PEMETREXED AND CISPLATIN (ATOMIC- MESO  PHASE 2/3 STUDY)  
(NCT 02709512)  
 
This supplement contains the following items:  
 
1. Protocol version 6 (21Sept2021). 
2.  Statistical analysis plan  version 4 (04Jan2022). 
 
 
  
 
  
 
  
 
 
 
 
  
 
CONFIDENTIAL  
This document and the information contained herein or attached hereto ("Confidential Material")  is confidential and proprietary to Polaris Group 
(Polaris). The Confidential Material should only  be viewed by those individuals or companies that have been given prior authorization to do so by 
Polaris ("Authorized Users"). The Confidential Material should not be made available in any  form to any person or company, other than the  
Authorized User and their respective employees  or associates on a need -to-know basis, without the prior written consent from Polaris.  This trial 
was conducted in accordance with the ethical principles of Good Clinical Practice,  according to the ICH Harmonized Tripartite Guideline.  
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 1 of 87  
  
Polaris Group 
 
  
Randomized, Double-Blind, Phas e 2/3 Study in Subjects with Malignant Pleural 
Mesothelioma to Assess ADI -PEG  20 with Pemetrexed and Cisplatin (ATOMIC -Meso  
Phase 2 /3 Study) 
   
Protocol Number:  POLARIS20 15-003 
  
EudraCT Number:  2015-004281-28 
  
Date:     21 September  2021 
  
Version:   01 (Original): 10 December  2015  
                                    Version 2: 26 February 2016 
   Version 3: 25 August 2016 
   Version 4:  05 December 2016    Version 5:  12 November 2019    Version 6:  21 September  2021 
  
Sponsor:   Polaris Group  
    10675 Sorrento Valley Road, Suite 200 
San Diego, CA  92121 USA Phone: (858) 452-6688 
 
 
 
 
Confidentiality Statement 
 
This document and the information contained herein or attached hereto ("Confidential Material") is 
confidential and proprietary to Polaris Group (Polaris). The Confidential Material should only be viewed by 
those individuals or companies that have been given prior authorization to do so by Polaris ("Authorized 
Users"). The Confidential Material should not be made available in any form to any person or company, 
other than the Authorize d User and their respective employees or associates on a need -to-know basis, 
without the prior written consent from Polaris.
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 2 of 87  
 1 TABLE OF CONTENTS  
1 TABLE OF CONTENTS  .........................................................................................2  
 Study Administrative Structure ....................................................................6  
 Signature Page ................................................................ .............................7  
 Synopsis ................................................................................................ .......8  
 Schedule of Assessments and Procedures  ..................................................12  
1.4.1  Screening and Schedule of Assessments and Procedures  ..........................12  
1.4.2  Study Assessments and Procedures  ...........................................................15  
1.4.3  Follow-up Period .......................................................................................17  
 List of Abbreviations .................................................................................18  
2 INTRODUCTION AND BACKGROUND  ..........................................................21  
 Introduction ................................................................................................21  
2.1.1  Mesothelioma  .............................................................................................21  
2.1.2  Amino Acid Deprivation Therapy .............................................................25  
2.1.3  Arginine Auxotrophy in Cancer Cells .......................................................25  
2.1.4  Development of ADI- PEG 20  ....................................................................26  
2.1.5  Current ADI -PEG 20 Clinical Trials  .........................................................27  
2.1.6  Cisplatin  .....................................................................................................27  
2.1.7  Pemetrexed  .................................................................................................27  
2.1.8  Phase 2 St udy of ADI- PEG 20 Monotherapy in ASS1- deficient 
MPM in the United Kingdom (ADAM Study) ..........................................28  
2.1.9  Phase 1 Study of ADI- PEG 20 Plus Pem etrexed and Cisplatin in 
MPM and Non-squamous Non- Small Cell Lung Cancer (NSCLC) 
(TRAP Study)  ............................................................................................29  
2.1.10  Rationale for Combining ADI-PEG 20 with Pemetrexed and 
Cisplatin  .....................................................................................................30  
 Description of Investigational Product ......................................................31  
 Summary of Findings to Date ....................................................................32  
2.3.1  Clinical Experience with Hepatocellular Carcinoma  .................................32  
2.3.2  Clinical Experience with Metastatic Melanoma  ........................................32  
2.3.3  Clinical Experience in MPM .....................................................................32  
2.3.4  Adverse Events ..........................................................................................32  
 Study Rationale ..........................................................................................32  
3 STUDY OBJECTIVES  ..........................................................................................33  
 Primary Objectives  .....................................................................................33  
 Secondary Objectives  .................................................................................33  
4 STUDY DESIGN ....................................................................................................34  
 Design Summary ........................................................................................34  
4.1.1  Continue d Treatment after 6 Weeks of Treatment of ADIPemCis  ............34  
4.1.2  Blinded and Open-Label Extension at Study End .....................................34  
4.1.3  Anticipated Number of Subjects and Target Accrual  ................................35  
 Criteria for Study Termination  ...................................................................35  
5 STUDY POPULATION .........................................................................................36  
 Inclusion Criteria  .......................................................................................36  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 3 of 87  
 
 Exclusion Criteria  ......................................................................................37  
 Criteria for Subject Withdrawal  .................................................................38  
 Withdrawal Procedures  ..............................................................................38  
6 STUDY PROCEDURES  ........................................................................................39  
 Screening Procedures .................................................................................39  
6.1.1  ASS1 Expression Screening ......................................................................39  
6.1.2  Study Screening .........................................................................................39  
 Clinic Visits  ...............................................................................................40  
6.2.1  End of Treatment .......................................................................................40  
6.2.2  Follow-up Period .......................................................................................40  
7 STUDY DRUGS  .....................................................................................................41  
 Identity of Investigational Product and Standard, Background 
Chemotherapies ..........................................................................................41  
7.1.1  Drug Name(s)  .............................................................................................41  
7.1.2  Storage Conditions .....................................................................................41  
 Blinding of Investigational Product ...........................................................41  
 Study Treatment .........................................................................................42  
7.3.1  Dose and Administration  ...........................................................................42  
7.3.2  Rationale and Dose Selection  ....................................................................42  
7.3.3  Dose Adjustments ......................................................................................43  
7.3.4  Switching from Cisplatin to Carboplatin  ...................................................45  
7.3.5  Missed Doses .............................................................................................45  
7.3.6  Subject Replacement  ..................................................................................45  
7.3.7  Optional Single Agent Treatment ..............................................................46  
7.3.8  Data Safety and Monitoring Board (DSMB) .............................................46  
7.3.9  Duration of the Study .................................................................................46  
7.3.10  Estimated Study Drug Requirements .........................................................46  
7.3.11  Study Drug Dispensing ..............................................................................47  
7.3.12  Packaging and Labeling .............................................................................47  
7.3.13  Study Drug Handling .................................................................................47  
7.3.14  Study Drug Storage ....................................................................................48  
7.3.15  Study Drug Accountability and Return......................................................48  
7.3.16  Cross -Over  .................................................................................................48  
7.3.17  Compliance ................................................................................................48  
 Prior and Concomitant Therapy .................................................................49  
7.4.1  Non-Permitted Concomitant Therapies .....................................................49  
7.4.2  Permitted Concomitant Therapies  ..............................................................49  
8 EFFICACY ASSESSMENTS  ................................................................................50  
 Efficacy Parameters  ...................................................................................50  
8.1.1  Timing and Methods of Efficacy Assessments  ..........................................50  
 Appropriateness of Efficacy Assessments  .................................................51  
9 SAFETY ASSESSMENTS  ....................................................................................51  
 Vital Signs  ..................................................................................................51  
 Laboratory Tests  ........................................................................................51  
 ECG ............................................................................................................53  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 4 of 87  
 
 Physical Examination .................................................................................53  
 Adverse Events ..........................................................................................53  
9.5.1  Assessment of Adverse Events – Relationship to Study Drug ..................53  
9.5.2  Recording of Adverse Events ....................................................................54  
9.5.3  Following Adverse Events .........................................................................55  
9.5.4  Discontinuation due to Adverse Events .....................................................55  
9.5.5  Pregnancy ...................................................................................................55  
9.5.6  Post-treatment Adverse Events  ..................................................................56  
9.5.7  Serious Adverse Events  .............................................................................56  
9.5.8  Reporting Serious Adverse Events ............................................................57  
 Appropriateness of Safety Assessments  ....................................................58  
10 PHARMACODYNAMIC, PHARMACOKINETIC,IMMUNOGENICITY AND 
OTHER ASSESSMENTS  ......................................................................................58  
 Pharmacodynamic Parameters  ...................................................................58  
 Immunogenicity Parameters  ......................................................................58  
 Pharmacokinetics  .......................................................................................58  
 Exploratory Research  .................................................................................58  
11 STATISTICAL CONSIDERATIONS  ..................................................................59  
 Statistics and Sample Size Considerations  ................................................59  
 Analysis Populations ..................................................................................59  
 Demographics and Baseline Characteristics  ..............................................60  
 Safety Analysis  ..........................................................................................60  
11.4.1  Adverse Events ..........................................................................................60  
 Efficac y Analysis .......................................................................................61  
11.5.1  Primary Efficacy Endpoints .......................................................................61  
11.5.2  Key Secondary Efficacy Endpoints ...........................................................61  
 Multiplicity Adjustment  .............................................................................61  
 Interim Analysis  .........................................................................................61  
 Pharmacodynamics ....................................................................................62  
 Immunog enicity  .........................................................................................62  
 Pharmacokinetics  .......................................................................................62  
12 ETHICS  62 
 Institutional Review Board / Independent Ethics Committee  ....................62  
 Ethical Conduct of the Study .....................................................................63  
 Informed Consent.......................................................................................63  
 Changes to Protocol  ...................................................................................63  
13 STUDY MONITORING  ........................................................................................63  
 Data Reporting and Electronic Case Report Forms ...................................63  
13.1.1  Pre-Study Requirements ............................................................................64  
13.1.2  Study Master Files  .....................................................................................64  
13.1.3  Study Records ............................................................................................64  
13.1.4  Electronic Case Report Forms (eCRFs)  .....................................................64  
 Access to Source Data/Documents  ............................................................65  
 Confidentiality  ...........................................................................................65  
 Retention of Data  .......................................................................................65  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 5 of 87  
 
 Quali ty Control and Quality Assurance  .....................................................65  
14 ADMINISTRATIVE INFORMATION ...............................................................65  
 Financing and Insurance ............................................................................65  
 Publication Policy  ......................................................................................66  
 Protocol Amendments  ................................................................................66  
 Premature Trial Termination  ......................................................................66  
 Language ....................................................................................................66  
15 REFERENCES  .......................................................................................................67  
16 APPENDIX A: MODIFIED RECIST CRITERIA FOR MALIGNANT 
PLEURAL MESOTHELIOMA ............................................................................77  
17 APPENDIX B: RECIST 1.1 CRITERIA  .............................................................78  
18 APPENDIX C: PERFORMANCE STATUS PERFORMANCE SCALES  
(KARNOFSKY, ECOG -WHO -ZUBROD)  ..........................................................87  
 
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 6 of 87  
 
 Study Administrative Structure  
 
Randomized, Double- Blind  Phase 2 /3 Study in Subjects with Malignant Pleural Mesothelioma to 
Assess ADI -PEG 20 with Pemetrexed and Cisplatin ( ATOMIC-Meso Phase 2/3 Study) 
 
Sponsor: Polaris Group  
Sponsor’s Responsible Medical Officer:  John S. Bomalaski, MD 
Sponsor’s Contact: John S. Bomalaski, MD 
Lead Investigator and Lead Clinical Study Center:  Peter Szlosarek, MD PhD  
Centre for Experimental Cancer Medicine (CECM)  
Barts Cancer Institute  (BCI) 
Queen Mary University of London Lower Ground Floor Old Anatomy Building Charterhouse Square London, EC1M 6BQ, UK  
Tel: 020 7882  3559 
Fax: 020 7882 8490 
Email: p.w.szlosarek@qmul .ac.uk  
Study Monitoring: Polaris Group  and its representatives  
Clinical Laboratory:  Central Laboratory  
Pharmacodynamic and Pharmacokinetic  
Analytical Laboratory:  Central Laboratory  
Immunogenicity Analytical Laboratory:  Central Laboratory  
Diagnostic Imaging Review:  Blinded Independent Central Review  
Polaris Group  
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin  
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 7 of 87 
 Signature Page  
Polaris Group Approval:  
 
John S. Bomalaski, MD  Date  
Executive Vice -President, Medical Affairs  
21 September 2021
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 8 of 87  
 
 Synopsis  
 
Protocol Title:  Randomized , Double -Blind  Phase 2 /3 Study in Subjects with Malignant 
Pleural Mesothelioma to Assess ADI -PEG 20 with Pemetrexed and 
Cisplatin (ATOMIC -Meso Phase 2/3 Study ) 
Sponsor:  Polaris Group  
Study Phase:  Phase 2/3 
Indication:  Unresectable malignant pleural mesothelioma  (MPM ) 
Rationale:  In a previous randomized phase 2 study of ADI-PEG 20 monotherapy in 
MPM tumors with low argininosuccinate synthetase (ASS1 ) expression 
(ASS1 -deficient) (ADAM Study), ADI -PEG 20 treatment resulted in 
significantly prolonged progression free survival (PFS) compared to best supportive care. In an ongoing phase 1 study of ADI-PEG 20 with pemetrexed and cisplatin (ADIPemCis)  in MPM or non-squamous 
non-small cell lung carcinoma (NSCLC) subjects with ASS1 -deficient 
tumors  (TRAP study ), this combination has resulted in a significant 
number of objective responses. Interestingly, most of the subjects have a non-epithelioid histology, and known poorest prognosis of the MPM histologies. Apparent prolonged PFS and OS have also been observed i n 
these MPM treated subjects. This phase 2 /3 study will treat only MPM 
using the same three drug regimen . In addition, it will enroll only 
biphasic and sarcomatoid histologies.   
Objectives:  The primary objective of this study is:  
• Determine  efficacy  as determined by the objective response rate 
(RR) , measured by modified RECIST for local pleural disease and 
RECIST 1.1 criteria  for metastatic lesions (phase 2 portion) , and OS 
(phase 3 portion) 
The key secondary objective of the phase 2 portion is: 
• Determine the duration of response (DOR)  
The key secondary objective of the phase 3  portion is : 
• Assess progression free survival (PFS)  
Other secondary objectives of this study include:  
• Assessment of safety and tolerability of ADI-PEG 20 in combination 
with pemetrexed and cisplatin   
• Determine the pharmacodynamics of ADI-PEG 20 in combination 
with pemetrexed and cisplatin  
• Determine the immunogenicity of ADI-PEG 20 in combination with pemetrexed and cisplatin  
• Determine the pharmacokinetics of ADI -PEG 20 in combination 
with pemetrexed and cisplatin  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 9 of 87  
 The goal of the phase 2 portion of the trial is to provide data to support 
accelerated approval by the United States Food & Drug Administration, 
and the goal of the phase 3 portion of the trial is to provide a confirmatory study that would be ongoing at the time of the marketing application.  
Number of Sites:  Global – to be determined  
Study Design:  This is a phase 2 /3, randomized, double- blind  trial.  Weekly 
ADI-PEG  20 at 36 mg/m2 (or placebo) will be combined  with 
pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 both given every 3 
weeks as first -line chemotherapy to non-epithelioid (biphasic and 
sarcomatoid)  MPM .  Eligible subjects will be randomized in a 1:1 ratio 
to ADIPemCis  or PlaceboPemC is.  The randomization will be stratified 
by histology (biphasic or sarcomatoid ).  Subjects may receive a 
maximum of 6 , 3-week cycles of ADIPemCis or PlaceboPemCis  for a 
total of 18 weeks of treatment. Those subjects completing ADIPemCis  
or PlaceboPemCis tre atment  may continue on ADI- PEG  20 or Placebo  
monotherapy if they have SD or better. Subjects who do not or who would not tolerate cisplatin may be switched to carboplatin.  
Planned Sample Size:  Approximately 176 subjects (88 per arm) will be enrolled in the phase 2 
portion of the trial (phase 2 primary outcome measure = RR) and 386 
subjects (193  per arm) in the whole phase 2/3 trial  (phase 3 primary 
outcome measure = OS).  
Sample size justification: The sample size calculation for the first efficacy endpoint ( RR) assumed that the objective response rate in the 
PlaceboPemCis arm was 15%.  A total sample size of 176 subjects ( 88 
per arm)  in the phase 2 portion of the study will provide approximately 
87% power to detect an improvement in the RR from 15% to 35% at the 
interim analysis . 
The sample size calculation for the OS assumed that t he median OS was 
6 months in the PlaceboPemCis arm . Assuming a  median OS of 8.4 
months in the ADIPemCis arm (corresponding to a 40% improvement in 
survival and a hazard ratio [ HR] of 0.714), 338 OS events will provide 
power of approximately 87% for the OS analysis.  Assuming uniform accrual over a 24 -month period and a total study duration of 36 months, 
the planned total sample size in the study was 386 subjects.   
Subject Selection Criteria:  
      
 Selection Inclusion Criteria Summary:  
• Histologically proven unresectable MPM  of biphasic or sarcomatoid  
histology 
• Naïve to chemotherapy or immunotherapy  
• ECOG PS 0 -1 
• Expected survival of at least 3 months 
• Age 18 years or over (there is no upper age limit) 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 10 of 87  
  
 
    
 
    
 • Measurable  disease by modified RECIST  criteria for MPM for local 
pleural disease and RECIST 1.1 criteria for metastatic lesions   
• Written (signed and dated) informed consent and must be capable of co-operating with treatment and follow up  
• Adequate hematologic, hepatic, and renal function  
Selection Exclusion Criteria Summary:  
• Radiotherapy (except for palliative reasons)  in the previous two 
weeks before study treatment  
• History of unstable cardiac disease  
• Ongoing toxic manife stations of previous treatments    
• Symptomatic brain or spinal cord metastases  (patients must be stable 
for > 1 month post radiotherapy or surgery) 
• Major thoracic or abdominal surgery from which the patient has not yet recovered.
 
Study Drug:  ADI-PEG 20  
Dose and Route of Administration:  ADI-PEG 20  (or Placebo) 
Dose :  36 mg/m2 (or Placebo) given weekly 
Route of Administration : Intramuscular (IM)  
Pemetrexed  
Dose:  500 mg/m2 every 3 weeks 
Route of Administration: Intravenous  
Cisplatin  
Dose:  75 mg/m2 every 3 weeks 
Route of Administration: Intravenous 
Carbo platin  
Dose:  area under the plasma concentration –time curve (AUC) 5 
mg/ml/m2 every 3 weeks 
Route of Administration: Intravenous 
Safety Monitoring: 
Response Criteria:  Performed by the sponsor and its representatives  
Safety: Adverse events (AEs) , laboratory tests, ECGs and physical 
examinations  
Efficacy: RR, DOR, PFS, and OS ; RR and DOR will be based on the 
tumor response assessments by blinded independent central review 
(BICR)  for phase 2 and PFS w ill be derived based on the tumor 
response assessments by the investigator for phase 3 . BICR results will 
be used for decisions on continued treatment in the phase 2 portion.   
Statistical Analysis:  Analysis P opulations: All efficacy analyses will be completed in the 
intent- to-treat (ITT) population and additional analyses will be 
performed in the per -protocol (PP) population .  The safety population 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 11 of 87  
 (all treated subjects) will be used for all safety summaries and analyses.   
Efficacy Analyses:  The analy sis of RR will be performed at the first 
interim analysis at the end of the phase 2 portion.  The treatment groups 
will be compared using the Cochran- Mantel -Haenszel (CMH) test, 
stratified by tumor histology  (biphasic versus sarcomatoid). The 
significance level and coverage probability to be used in the RR analysis will be based on α=0.05 (two-sided). The RR will only be tested once at the end of the phase 2 regardless of its significance.  
  
The primary analysis of O S will be performed at the final analysis.  The 
treatment effect on OS will be evaluated  using the stratified log -rank test 
(stratified by tumor histology). The significance level to be used in the 
OS analysis at the final analysis will be based on α=0.05 (two -sided).  
There will  be an interim analysis of OS once 50% of the planned OS 
events for phase 3 have occurred and will be used to determine whether to terminate the study for futility or for possible sample size re -
estimation for the phase 3 portion of the trial as described in  the 
Statistical Analyses Plan (SAP).  
Safety Analyses : Safety will be assessed by comparing adverse events, 
vital signs, laboratory results, and physical examination results. 
Pharmacodynamics:  Pharmacodynamics (peripheral blood arginine 
and citrulline levels) will be summarized for all subjects by time point 
for the observed value and by duration of arginine depletion and citrulline increase.
  
Immunogenicity: Immunogenicity (antibodies to ADI -PEG 20) will be 
summarized for all subjects from the ADIPemCis arm by time point for 
the observed value as well as for the change from baseline value.  
Pharmacokinetics : Pharmacokinetics (peripheral blood ADI-PEG 20 
levels) will be summarized for all subjects from the ADIPemCis arm.  
 
 
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 12 of 87  
 
 Schedule of Assessments and Procedures 
 
1.4.1 Screening  and Schedule of Assessments and Procedures   
 
Table 1.4.1 Study Assessments and Procedures: Pre -study (Screening) and Cycles  1 to 4o 
 Screening Assessments  Cycle 1  Cycle 2 Cycle 3 Cycle 4 
   Day of Cycle (Week of Treatment)  
Study Procedure  Within 4 
weeks 
(Day -28 to 0)  Within 1 
week (Day  
-7 to 0)  1 
(1) 8 
(2) 15 
(3) 1 
(4) 8 
(5) 15 
(6) 1 
 (7) 8 
(8) 15 
  (9) 1 
(10) 8 
(11) 15 
(12) 
               
Review of Inclusion and Exclusion Criteria
 X              
Informed Consent Xa              
Demographics  X              
Medical History  X X (update)              
Physical Examinationb  X  Xm   X   X   X   
Vital Signsc  X X X X X X X X X X X X X 
Height  X             
Weight/ Body Surface Area (BSA)   X 
 Xm   X   X   X   
Performance Status 
(ECOG)   X Xm            
AE Assessmentd   X   X   X   X   
Concomitant Medications   X X   X   X   X   
Radiological Tumor 
Disease Assessment (CT, MRI)
e X       X      X 
Serum Pregnancy Testf  X             
ECG   X    Xn        Xn 
Clinical Laboratory Tests
g  
   Hematology   X Xm X  X X  X X  X X  
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 13 of 87  
  Screening Assessments  Cycle 1  Cycle 2 Cycle 3 Cycle 4 
Study Procedure  Within 4 
weeks (Day 
-28 to 0)  Within 1 
week 
(Day -7 to 0)  1 
(1) 8 
(2) 15 
(3) 1 
(4) 8 
(5) 15 
(6) 1 
(7) 8 
(8) 15 
(9) 1 
(10) 8 
(11) 15 
(12) 
   Chemistry   X Xm   X   X   X  X 
   Creatinine Clearanceh  X             
Special Blood 
Samplingi  
   Arginine + Citrulline    X X  X   X   X   
   Anti-ADI- PEG 20 Abs    X X  X   X   X   
   ADI-PEG 20 Levels    X X  X   X   X   
ADI-PEG 20 or Placebo 
Administrationj   X X X X X X X X X X X X 
Pemetrexed Administration
k   Xl   X   X   X   
Cisplatin 
Administrationk, p   Xl   X   X   X   
Note:  Visits may occur ± 3 days of the planned date  except for PemCis administration on cycle 1 
Day 3 . All study evaluations and related procedures may occur 3  days prior to dosing except for 
CT or MRI which may occur ± 7 days of the planned date.  See Appendices for more on modified 
RECIST response criteria for MPM local pleural disease ( Appendix A ), RECIST  1.1 response 
criteria for metastatic lesions (Appendix B ) and performance status ( Appendix C ). 
a. The informed consent window is extended to -42 days without requiring a reconsent.  
b. Physical examination i s to be performed on Day 1 of each cycle and is symptom directed as 
clinically indicated.  
c. Vital signs to be obtained before and 1 hour ± 15 minutes after ADI- PEG 20 or placebo 
treatment.  
d. Subjects will be assessed for AEs on Day 1 of each cycle and weekly thereafter or as clinically 
indicated. 
Adverse events, including serious adverse events and toxicities –These will be recorded after the first administration of study treatment until 30 days after last study drug administration.  
Adverse events related to ADI -PEG 20 that were still ongoing at End-of- Treatment (EOT) 
visit should be followed up until resolution or stabilization.  Any medical sign or symptom a subject may experience post signing of ICF and before first administration of study treatment should be recorded as part of medical history.  If any toxicity or medical sign or symptom a 
subject may experience post signing of ICF meets the definition of Serious Adverse Event 
(SAE) per Section 9.5.7 they must be reported as an SAE per Section 9.5.8 .  
e. Baseline CT with contrast or MRI of the involved organs is  to be conducted within 28 days 
prior to subject receiving the first ADI- PEG 20  or placebo dose  (this may b e conducted prior 
to signing informed consent if part of standard of care).  Scans are to be performed every 6 weeks (preferably  in the week after 2 cycles of ADIPemCis or PlaceboPemCis dosing) and 
after every 8
th weekly dose of ADI-PEG 20 or placebo durin g ADI -PEG 20 or placebo only 
treatment.  Tumor measurements must be noted.  CT with contrast must be used unless the 
subject is allergic to intravenous contrast despite use of diphenhydramine and corticosteroids, 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 14 of 87  
 in this case CT without contrast (if border s are distinct) is the second choice and MRI a third 
choice if borders are not well -defined on CT. The same imaging modality is to be used 
throughout the study. Details are provided in the Imaging Manual. For subjects with tumor 
responses (complete respons e and partial response), scans will continue according to the 
regular schedule.  Imaging should follow calendar days; do not adjust for changes in dosing 
schedule.   Subjects withdrawn from treatment for reasons other than PD may continue to 
receive regular  scans until PD. 
f. Female subjects only, serum HCG.  
g. Blood samples to be collected before ADI- PEG 20  or placebo administration.  Hematology 
and Chemistry sampling from C ycle X/ Day 1 should follow the chemotherapy administration 
day in case of a chemotherapy dosing delay.  Local  blood samples may be collected as part of 
standard of care on chemotherapy days and the results used for dosing decisions without 
waiting on central results provided central samples are also collected  at the same time and sent 
in for testing.  Clinically significant local laboratory findings that directly inform a dosing decision will be recorded as an adverse event.  See Section 9.2 for specific studies.    
h. Creatinine clearance ≥ 45 mL/min (estimated, using Cockcroft and Gault formula).  
i. Blood samples to be collected before ADI- PEG 20 or placebo administration for arginine and 
citrulline (pharmac odynamics), antibody to ADI-PEG 20 (immunogenicity), and ADI- PEG 20  
levels (pharmacokinetics).  Special blood sampling should follow calendar days; do not adjust 
for changes in dosing schedule.  See Section 10 for specific studies.   
j. ADI-PEG 20  or placebo is to be administered before  pemetrexed and cisplatin on days when 
all three drugs are given, except during cycle 1 where the chemotherapy is administered on 
Day 3.  Pemetrexed and cisplatin administration is to begin at least 60 minutes after  ADI-PEG 
20 or placebo administration  on the same day .  
k. Supportive and pre -medications to include the following or as per local policy (see Section 
7.4.2.2 for further details):  
• Folic acid 400 mcg daily, oral 
• Hydroxycobalamin 1000 mcg i.m. injection  
• Dexamethasone 4 mg bd (3 doses) preceding hospital visit by 24 hours. Dexamethasone 
may also be administered i.v. and at a dose per local policy.  
• Anti-emetic e.g. 5HT3 antagonist, domperidone and dexamethasone 8 mg 
• Furosemide 40 mg oral once 
l. PemCis to be administered on Day 3 of cycle 1  
m. These assessments at week 1 may be omitted if performed within 72 hours of the first dose.  
n. ECG to be performed 1 hour ± 15 minutes after ADI -PEG 20 or placebo treatment.  This 
assessment should include the QT/QTc interval using Fridericia’s correction: QTc = 
QT/RR0.33  
o. During the chem otherapy treatment period (Cycles 1 -6), a cycle is 3 weeks.  During the Single 
Agent period, beginning on Week 19, a cycle is defined as every 4 weeks. 
p. Cisplatin is the recommended chemotherapy for use in the initial and subsequent cycles. However, subjects who do not tolerate cisplatin or who would not be expected to tolerate cisplatin may have carboplatin substituted for cisplatin at any cycle including the initial cycle at the discretion of the investigator.  
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 15 of 87  
 1.4.2 Study Assessments and Procedures  
 
Table 1.4.2 Study Assessments and Procedures: Weeks 13 to 18, ADI -PEG 20  or Placebo  Single Agent 
Treatment, End of Treatment, and Follow up  
 Cycle  5j Cycle  6j Cycles 7 and Beyond   
Study Procedure  1 
(13) 8 
(14) 15 
(15) 1 
(16) 8 
(17) 15 
(18) Single Agent ADI -PEG  20/Placebok  EOTa 
19 20 21 22 23 24 25 26j  
Physical Examinationb X   X   As clinically indicated  X 
Vital Signsc X X X X X X X X X X X X X X X 
Weight/ Body Surface Area 
(BSA)  X   X   X         
AE Assessmentd X   X   X   X   X  X 
Concomitant Medications  X   X   X   X   X X X 
Radiological Tumor Disease 
Assessment (CT, MRI)e      X        X  
ECG     As clinically indicated   
Clinical Laboratory Testsf  
   Hematology  X X  X X   X   X   X X 
   Chemistry  X   X  X  X  X  X  X X 
Special Blood Samplingg  
   Arginine + Citrulline  X   X   X   X   X   
   Anti-ADI- PEG 20 Abs  X   X   X   X   X   
   ADI-PEG 20 Levels  X   X   X   X   X   
ADI-PEG 20  or Placebo  
Administrati onh X X X X X X X X X X X X X X  
Pemetrexed Administrationi X   X            
Cisplatin Administrationi,l X   X            
Note:  Visits may  occur ± 3 days of the planned date . All study evaluations and related procedures may occur 
3 days prior to dosing except for CT or MRI which may occur + 7 days of the planned date, but preferably after 
every two (2) cycles of ADIPemCis or PlaceboPemCis and after every 8th weekly dose of ADI- PEG 20  or 
placebo  during ADI- PEG 20 or placebo only treatment.   
See Appendices for more on modifie d RECIST response criteria fo r local pleural disease  (Appendix A ), 
RECIST  1.1 response criteria for metastatic lesions  (Appendix B ) and performance status ( Appendix C ). 
a. EOT visit to occur 7 -30 days (preferably 30 days) after last dose of treatment. 
b. Physical examination is to be performed on Day 1 of each cycle and is symptom directed as clinically 
indicated. 
c. Vital signs to be obtained before and 1 hour ± 15 minutes after ADI- PEG 20 or placebo treatment.  
d. Subjects will be assessed for AEs on Day 1 of each cycle and weekly thereafter or as clinically indicated.  
Adverse events, including serious adverse events and  toxicities – Baseline toxicities/symptoms will be 
recorded starting with the signing of the informed consent form (ICF) .  These will be recorded until 30 days 
after last study drug administration.  Adverse events related to ADI -PEG 20 or placebo that were still 
ongoing at EOT  visit should be followed up until resolution or stabilization.  Any medical sign or symptom 
a subject may experience post signing of ICF and before first administration of study treatment should be 
recorded as part of medical history.   If any toxicity or medical sign or symptom a subject may experience 
post signing of ICF meets the definition of SAE per Section 9.5.7 they must be reported as an SAE per 
Section 9.5 .8.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 16 of 87  
 e. Scans are to be performed every 6 weeks (preferably in the week after  2 cycles of  ADIPemCis or 
PlaceboPemCis dosing ) and after every 8th weekly dose of ADI-PEG 20 or placebo during ADI-PEG 20 or 
placebo only treatment.  Tumor measurements must be noted.  The same imaging modality is to be used 
throughout the study. For subjects with tumor responses (complete response and partial response), scans will continue according to the regular schedule.   Imaging should follow calendar days; do not adjust for 
changes in dosing schedule.  Subjects withdrawn from treatment for reasons other than PD may continue to 
receive regular scans until PD. 
f. Blood samples to be collected before ADI- PEG 20 or placebo administration. Hematology and Chemistry 
sampling from C ycle X/ Day 1 should follow the chemotherapy administration day in case of a 
chemotherapy dosing delay.  Local blood samples may be collected as part of standard of care on chemotherapy days and results used for dosing decisions without waiting on central results prov ided central 
samples are also collected at the same time and sent in for testing.  Clinically significant local laboratory findings that directly inform a dosing decision will be recorded as an adverse event.   See Section 9.2 for 
specific studies.  
g. Blood s amples to be collected before ADI -PEG 20 or placebo administration for arginine and citrulline 
(pharmacodynamics), antibody to ADI-PEG 20 (immunogenicity), and ADI-PEG 20 levels (pharmacokinetics). Special blood sampling should follow calendar days; do not adjust for changes in dosing schedule.  See Section 10 for specific studies.  Special blood sampling is not required during ADI-
PEG 20 or placebo only treatment after 25 weeks. 
h. ADI-PEG 20 or placebo is to be administered before  pemetrexed and cisplatin on days when all three drugs 
are given.  Pemetrexed and cisplatin administration is to begin at least 60 minutes after  ADI -PEG 20 or 
placebo administration  on the same day .  
i. Supportive and pre -medicat ions to include the following or as per local policy (see Section 7.4.2.2 for 
further details):  
• Folic acid 400 mcg daily, oral 
• Hydroxycobalamin 1000 mcg i.m. injection  
• Dexamethasone 4 mg bd (3 doses) preceding hospital visit by 24 hours. Dexamethasone may also be administered i.v. and at a dose per local policy. 
• Anti-emetic e.g. 5HT3 antagonist, domperidone and dexamethasone 8 mg  
• Furosemide 40 mg oral once 
j. Subjects who remain on treatment after 26 wee ks and up to 2 years of study treatment will continue to 
follow the schedule in Table 1.4.2. 
 For example, week 27 will follow visit assessments for week 19; week 
28 will follow week 20 and so on.  Therefore, CT scans will be obtained every 8 weeks for those still on treatment.  
k. During the chemotherapy treatment period (Cycles 1 -6), a cycle is 3 weeks.  During the Single Agent 
period, beginning on Week 19, a cycle is defined as every 4 weeks. 
l. Cisplatin is the recommended chemotherapy for use in the initial and subsequent cycles. However, subjects who do not tolerate cisplatin or who would not be expected to tolerate cisplatin may have carboplatin 
substituted for cisplatin at any cycle including the initial cycle at the discretion of the investigator.  
   
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 17 of 87  
  
1.4.3 Follow- up Period  
 
Table 1.4.3  Study Assessments and Procedures: Follow -up* begins 30 days ± 7 days 
After End of Treatment Visit  
Study Procedure  Every 3 Months (± 1 week) until end of study  
Survival status X 
*Via telephone, email or clinic visit  
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 18 of 87  
 
 List of Abbreviations  
 
Abbreviation  Definition  
ADI Arginine deiminase 
AE Adverse event 
ALK  Anaplastic lymphoma kinase 
ALL  Acute lymphocytic leukemia  
ALT  Alanine transaminase (also known as SGPT)  
ALP  Alkaline phosphatase 
ANC  Absolute neutrophil count 
ASL  Argininosuccinate lyase 
ASS1  Argininosuccinate synthetase (also known as ASS)  
AST  Aspartate transaminase (also known as SGOT)  
BSA  Body surface area  
BSC  Best supportive care 
BUN  Blood urea nitrogen  
CBC  Complete blood count 
CFR  Code of Federal Regulations 
CLIA  Clinical Laboratory Improvement Amendments  
CPO  Conditional P ower for OS  
CR Complete response  
CRF  Case report form  
CRO  Contract research organization  
CT Computed tomography 
CTC  Common toxicity criteria  
CTCAE  Common terminology criteria for adverse events  
DCR  Disease Control Rate  
DesigneRx  DesigneRx Pharmaceuticals, Inc.  
DHFR  Dihydrofolate reductase  
DLT  Dose Limiting Toxicity  
 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 19 of 87  
 Abbreviation  Definition (Continued)  
DOR  Duration of response  
DSMB  Data Safety Monitoring Board 
ECOG  Eastern Cooperative Oncology Group 
EGFR  Epidermal growth factor receptor  
EOT  End-of-treatment 
FDA  US Food and Drug Administration 
GCP  Good Clinical Practice  
HCC  Hepatocellular carcinoma 
HCG  Human chorionic gonadotropin 
HIV Human immunodeficiency virus 
ICF Informed Consent Form 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IHC Immunohistochemistry  
IM Intramuscular  
IRB Institutional Review Board  
ITT Intent- to -treat 
MPM  Malignant pleural mesothelioma  
MRI  Magnetic Resonance Imaging  
MTD  Maximum Tolerated Dose  
NSCLC  Non-small cell lung carcinoma  
ORR  Overall response rate  
OS Overall survival  
PD Progressive disease  
PE Physical examination  
PFS Progression free survival  
PR Partial response 
PS Performance status  
PT Prothrombin time  
PTT Partial thromboplastin time  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 20 of 87  
 Abbreviation  Definition (Continued)  
QTcF  Fridericia’s correction formula  
RBC  Red blood cell count 
RECIST  Response Evaluation Criteria in Solid Tumors 
R2PD  Recommended phase 2 dose 
RR Response rate  
SAE  Serious adverse event  
SD Stable disease 
TBD  To be determined 
TTP Time to progression  
TYMS  Thymidylate synthase (also known as TS) 
SOP Standard operating procedures 
TEAE  Treatment -emergent adverse event  
TMF Trial Master File  
USA  United States of America  
WBC  White blood cell count 
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 21 of 87  
 2 INTRODUCTION AND BACKGROUND  
 
 Introduction 
 
The following background information is being provided in addition to the information provided in the Investigator’s Brochure.  
 2.1.1 Mesothelioma  
 Mesotheliomas are neoplasms arising from mesothelial cells lining the pleura, peritoneum, tunica 
vaginalis testis and pericardium ( Kao 2010, Mira rabshahii 2012
).  Approximately 80- 85% are 
malignant pleural mesothelioma (MPM ), 15-20 % are peritoneal, and vaginal and pericardial occur 
rarely ( Moolgavkar 2009 , Kao 2010, McDonald 2010, Turner 2012 ).  MPM is an aggressive 
thoracic malignancy associated with exposure to asbestos, and its worldwide incidence is anticipated to i ncrease during the first half of this century (
Fennell 2008 ).   
 2.1.1.1 Mesothelioma: Histologic Subtypes Predict Prognosis  
 Malignant mesothelioma has three histologic subtypes, epithelioid, sarcomatoid and biphasic. Most patients  present with advanced disease; the median age at diagnosis is 72 years and the median OS  
is approximately 1 year ( Ettinger 2016
). The majority of cases are epithelioid, which has the best 
prognosis. Sarcomatoid has the wor st while biphasic (mixed epithelioid with sarcomatoid) has 
intermediate prognosis , with predominantly sarcomatoid biphasic having a worse prognosis than 
predominantly epithelioid biphasic ( Bueno 2016 ). This has been confirmed by recently published 
epidemiology studies in the US (Surveillance, Epidemiology, and End Results [ SEER ] database 
from 2004-2010, Meyerhoff 2015 ), Australia (cases of malignant mesothelioma betwee n 2002 and 
2009 from the New South Wales Dust Diseases Board , Linton 2014 ), UK-Scotland (data from 
2002-2012 from the National Health Service Grampian pathology database in the northeast of Scotland, 
Marshall 2015 ), UK-Wales+England (data from 2008-2012 from the National Lung 
Cancer Audit, Beckett 2015, Canada (data from 1991- 2012 from Ottawa Hospital, Saint -Pierre 
2015 ), and France (data from 1998-2016 from the French MESOBANK, Galateau Salle 2018 ). The 
statistics from the se publications are summarized below and show the OS in months (m) :  
 
Reference  Number  Years  Epithelioid  Sarcomatoid  Biphasic  Non-epithelioid  
US SEER  1183  2004 -2010  69% 19% 12%  
Australian  
   Median OS  910 2002 -2009  60% 
   13.3 m  17% 
   5.4 m  13% 
   7.2 m   
   6.2 m 
UK-Scotland  
   Median OS  114 2002 -2012  56% 
   13.5 m  12% 
   4.1 m  16% 
   11.0 m   
UK-England 
+Wales  
   Median OS  8740 * 2008 -2012  
 
 75% 
 
   13.1 m  14% 
 
   4 m 11% 
 
   8.4 m   
Canada  
   Median OS  245 1991 -2012  
 63% 
   12.5 m  14% 
   4.5 m  11% 
   8.1 m   
France  
   Median OS  5726  1998 -2016  91% 
   14 m  8% 
   4 m 1% 
   8 m  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 22 of 87  
 *histology % noted only for specified types (N=3319) 
 Thus, these recent studies confirm further the poorer prognosis of nonepithelioid MPM ranging from 4. 0 to 5.4 months for sarcomatoid and from 7.2 to 11.0 months for biphasic and are consistent 
with the 6.2 months for non- epithelio id histology noted in the Australian study ( Linton 2014
). The 
poor prognosis of sarcomatoid MPM has recently been reviewed ( Galetta 201 6).  
 
Indeed, poor outcome of patients with non- epithelioid histologies has led to their exclusion from 
recent clinical trials (e.g., the anti-mesothelin [amatuximab] study: A Randomized, Double-blind, Placebo -controlled Study of the Safety and Efficacy of Amatuximab in Combination With
 
Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma, [STUDY_ID_REMOVED]) ( Amatuximab 2015
). This underscores further the urgent need for development of 
effective therap y for non- epithelioid MPM.  
 The reason(s) for this poor prognosis for sarcomatoid histology has been attributed to expression of B7 homolog 1 (B7-H1; also known as programmed death ligand 1 [PD-L1]) which is expressed more frequently in sarcomatoid than epithelioid  histologies ( Mansfield & Roden 2014
). Also, 
sarcomatoid and biphasic more frequently are deficient in expression o f ASS1 , the rate limiting 
enzyme in the urea cycle to form arginine. ASS1 -deficiency is also asso ciated with a poor prognosis 
in MPM and a variety of other cancers ( Szlosarek 2006 & 2016, Delage 2008 ). The reason for this 
is not entirely clear, but appea rs due to rapidly expanding cancer cells preferentially using aspartate 
from the urea cycle to form nucleic acids and not arginine ( Rabinovich 2015 ). ASS1 deficiency 
typically occurs through epigenet ic modification ( Phillips 2013 ).  
 2.1.1.2 Mesothelioma: Chemotherapy for MPM 
 
The recommended treatment is dependent on both stage and histology. It is recommended that 
patients with operable clinical stage I -III epithelioid or mixed  histology disease undergo 
multimodality therapy including surgery (Ettinger 2016
). Current National Comprehensive Cancer 
Network (NCCN) guidelines ( Mesothelioma NCCN 2015 ) recommend chemotherap y alone for all 
patients who have sarcomatoid histology, as well as for inoperable or clinical stage IV patients. Similar recommendations come from the European Society of Medical Oncology (ESMO) (
Baas 2015 ). This underscores further the poor prognosis for sarcomatoid patients. 
 In MPM, both RR and PFS correlate with OS (Francart 2009, Blayney 2012, Hasan 2014
). Thus RR 
and PFS serve as surrogate endpoints for OS in MPM.  
 
Pemetrexed  + Cisplatin /Carboplatin 
 The standard first- line chemotherapy treatment for MPM and advanced peritoneal mesothelioma  is 
pemetrexed  + cisplatin ( Fennell 2008, Mirarabshahii 2012, Turner 2012, Kotova 2015
).  This is 
based on a phase 3 study for MPM comparing pemetrexed + cisplatin to cisplatin only (
Vogelzang 2003) and open access data for peritoneal mesothelioma ( Mirarabshahii 2012 , 
Turner 2012 ).  For MPM, m edian OS in the pemetrexed + cisplatin arm was 12.1 months 
(confidence interval [CI] : 10.0 to 14.4) vs. 9.3 in the control cisplatin arm, thus there was a 
2.8 months survival advantage.  Median time to progression ( TTP) was 5.7 months in the study arm 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 23 of 87  
 vs. 3.9 months in the control arm. Response ra tes, determined by investigator assessment, were 
41.3% (95% CI : 34.8 to 48.1) in the pemetrexed +cisplatin arm versus 16.7% in the control arm. The 
1-year survival rate was 50.3% for pemetrexed  + cisplatin arm . Change in disease was assessed by 
measuri ng the thickness of up to three involved areas of pleural rind at each of thre e separate levels 
at least 2 cm  apart on computed tomography scan, at base line, and every other cycle (at  least one 
measurement was > 1.5 cm). Although the overall RR (ORR) was 41.3%, it was onl y 4/18 (22.2%) 
for sarcomatoid ( Mansfield & Symanowski 2014 ), and this result was not noted in the primary 
publication ( Vogelzang 2003 ). Indeed, in that summary review on MPM clinical trials focusing on 
sarcomatoid , the ORR for all subjects in the 30 studies that recorded data on survival and ORR in 
sarcomatoid, the ORR for all MPM was 21.9% in 1475 patients and only 19/137 (13.9%) in those 
with sarcomatoi d disease (9.3% of total). As such, these results for sarcomatoid ORR to platinum 
based therapy may be an over estimate.  
 
Further data on pemetrexed + cisplatin comes from expanded access programs that occurred after enrollment of the pivotal trial. In an expanded access program in the USA before regulatory 
approval (2002 to 2004), 728 chemotherapy naïve patients with MPM were enrolled and treated with pemetrexed + cisplatin (Obasaju 2007
). The inclusion criteria were similar to the phase 3 study 
except that measurable lesions were not requir ed, and RR could be assessed using RECIST, 
Southwest O ncology Group or World Health Organization criteria . Response data was available on 
615 patients. Histologic subtype data was not reported. The ORR was 2 0.8% (95% CI: 17.7-24.3) , 
the median survival was 10.9 (95% CI: 9.8-12.3) months, and the one year survival was 45.9%. Likewise, an expanded access program was initiated internationally (
Santoro 2008 ). A total of 1704 
chemo naïve patients were enrolled  from 2002 to 2006, 843 received pemetrexed + cisplatin and 
861 received pemetrexed  + carboplatin (AUC of 5).  The inclusion criteria were similar to the phase 
3 study except that me asurable lesions were not requir ed, and the three different response criteria 
for assessment were allowed . The histologic breakdown for the pemetrexed + cisplatin group was as 
follows: epithelial 67.0%, sarcomatoid 6.3%, mixed 9.1%, and others 17.6%. Similar histologic breakdown occurred for the pemetrexed + carboplatin cohort. The ORR in 745 patients evaluable for resp onse in the pemetrexed + cisplatin group was 26.3% (95% CI: 23.2-29.6), and was 21.7% 
(95% CI: 18.1-24.8) in the pemetrexed  + carboplatin group. The median TTP was 7.0 months in the 
cisplatin cohort and 6.9 in the carboplatin cohort. The median survival was not estimated due to the high censoring rate. The 1-year survival rate was 63.1% in the cisplatin arm and 64% in the carboplatin arm. More grade 3/4 toxicity was noted in the carboplatin arm, as were more deaths.  
 The results of two phase 2 trials of pemetrexed +  carboplatin in 178 patients from 11 Italian centers 
treated between 2002 and 2005 also w ere reported ( Ceresoli 2008
). Epithelioid represented 77%, 
mixed biphasic 12% and sarcomatoid 5%. The ORR was 23.8% (95% CI: 16.8-32.1).  Therefore, 
these ORR results with  pemetrexed + carboplatin  in a heavily epithelioid population are similar to 
those observed in the international expanded access program with pemetrexed + cisplatin (
Santoro 2008 ). 
 Thus the ORR in the expanded access programs with pemetrexed + cisplatin (Obasaju 2007
, 
Santoro 2008 ) were approximately half of that observed in the phase 3 study of pemetrexed + 
cispl atin (20.8% and 26.3% vs. 41.3%) although measureable lesions were not required in the 
expanded access programs. Median TTP and median OS were only available for one expanded 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 24 of 87  
 access program, but these were similar to the phase 3 trial. The 1 -year survival rates were 45.9 and 
63.1% versus 50.3% in the phase 3 trial. 
 More recently, a randomized phase 2 study compared pemetrexed + cisplatin to that combination plus CBP501 in chemo naïve  MPM ( Krug 2014
). Of the 23 in the pemetrexed + cisplatin arm, the 
histology was 70% epithelioid , 22% sarcomatoid and 9% mixed. For pemetrexed + cisplatin, the 
ORR, by modified RECIST ( Byrne 2004 ), was 4/20 (20%) by investigator assessment and 2/20 
(10%) by independent radiology assessment. For the doublet, the median PFS was 4.6 months by investigator and 3.4 by independent assessment, and the median OS was 12.8 (95% CI: 6.5-16.1) months by independent assessment.  
 In Japan, a retrospective analysis compared t he results of 17 patients treated with pemetrexed + 
cisplatin to 13 with gemcitabine + cisplatin in MPM ( Shukuya 2014
). Overall, epithelioid accounted 
for 70%, sarcomatoid for 20% and not otherwise specified for 10%. The RR were 35% vs. 15%, the PFS were 215.5 days vs. 142.5 days and median OS was 597.5 days vs. 306.5 days, respectively, favoring the pemetrexed group.  Hematologic AEs were more common in the gemcitabine group.  
 A French consortium (French Group of Onco-Pneum ology) reported their data collected from 
medical files between 2005 and 2008 ( Raynaud 2015
). There were 406 patients from 37 sites, and 
75% of patients received chemotherapy, primarily platinum + pemetrexed (91%). The ORR w as 
17.2%. 
 More recently, a French consortium of 73 hospitals added the anti -vascular endothelial growth 
factor (VEGF) bevacizumab to first- line pemetrexed + cisplatin in a randomized , open-label, phase 
3 trial that enrolled 448 subjects aged 18-75 years ( Zalcman 2016
). Epithelio id accounted for 81% 
and sarcomatoid or mixed for 19%. ORR was not reported. The primary outcome measure was OS with an anticipated improvement of 33% (haz ard ratio [HR] 0.75). The trial did not meet its primary 
outcome measure with HR = 0.77; the trial was stopped early by the independent data monitoring committee after assessment at 342 of the planned 397 deaths. Median OS for the doublet was 16.1 (95% CI: 14.1-17.9) months. Furthermore, the predictive analysis based on VEGF assessed as a continuous variable showed that the VEGF interaction between treatment group and VEGF concentration was not significant with bevacizumab treatment and O S or PFS. In addition, there 
were more serious cardiovascular adverse events as well as study discontinuation associated with the triplet therapy. Survival related to specific histologic subtypes was not shown. Another concern with the study was the exclusion of potential subjects older than 75 years, as they account for a significant percentage of  MPM patients (
Zauderer 2016 ). Indeed, in a review of 9014 patients with 
MPM from Belgium, the Netherlands and England collected between 2007 and 2011, 59% were 70 years or older (
Damhuis 2015 ). Thus patients older than 75 years comprise a significant portion 
of MPM patients.  
 Cediranib or placebo was combined with cisplatin and pemetrexed in a randomized, phase 2 trial (Tsao 2019
). The triplet did not improve OS. There were 12 patients with biphasic or sarcomatoid 
histology randomized to the placebo plus cisplatin and pemetrexed arm. Their median OS on cisplatin plus pemetrexed was 6.3 months. The ORR for these 12 was 8.3% (1/12) by both RECIST 1.1 and mRECIST criteria.  
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 25 of 87  
 Other Chemotherapies  
 
Similar data  were obtained in MPM with another antifolate, raltirexed in combination with cisplatin  
vs. cisplatin monotherapy ( Van Meerbeeck 2005 ). Among 213 patients with measurable disease 
(125 for combination vs. 122 for cisplatin), ORR by RECIST by investigator assessment was 23.6% 
(95% CI: 15.7-31.6) vs. 13.6%, PFS was  5.3 vs. 4.0 months, and median OS was 11.4 (95% CI: 
11.1-15.0) vs.  8.8 months, respectively. For the combination arm, the histologies were: epithelioid 
75%, mixed 14% and sarcomatoid 4%. A double-blind, phase 2 study compared gemcitabine + 
cisplatin with or without bevacizumab ( Kindler 2012 ). Epithelioid  accounted for 70.4% and non-
epithelio id for 20.6%. The ORR was 24.5% in 53 patients treated with the 3 drug regimen vs. 
21.8% in 55 treated with the two drug regimen. The median PFS was 6.9 vs. 6.0 months, and the median OS were 15.6 and 14.7 (95% CI: 10.3-20.0) months , respectively .  
 
Summary  
 The prognosis for MPM is poor, with an overall median OS of ~ 1 year . The OS for epithelioid 
MPM is best followed by biphasic and then sarcomatoid. For th e non- epithelioid , the median 
survival appears to be ~ 6 months. Regarding ORR, a variety of studies enriched for the epithelial subset, with best survival and response rate,  more consistently show a rate of ~20-25% by 
investigator assessment in contrast to the 41% observed in the registration study, which also used investigator assessment ( Vogelzang 2003
). Thus it is also reasonable to believe the ORR assessed 
by BICR would be even lower, as was shown in a recent, albeit small study, where the ORR by BICR was half that compared to investigator assessment (
Krug 2014 ). 
 It is generally considered that conventional cytotoxic chemotherapy has reached a therapeutic 
plateau and novel approaches are urgently needed ( Fennell 2008, Mirarabshahii 2012, Turner 2012
, 
Kotova 2015 ). 
 
2.1.2 Amino Acid Deprivation Therapy  
 One established method for treating some malignancies is amino acid deprivation 
(Holcenberg 1977
).  This is based on the observation that some tumors are auxotrophic for 
otherwise non- essential amino acids.  The best known example is the use of asparaginase (in the 
form of a polyethylene glycol conjugate, peg- asparaginase) in acute lymphoblastic leukemia (ALL) 
(Pasut 2008 ).  Since most normal cells are able to synthesize asparagine, while the leuk emia cells 
cannot due to lack of the enzyme asparagine synthetase, there is a selective effect on the growth of leukemia cells.   Depletion of asparagine is relatively well tolerated and peg -asparaginase is part of 
standard therapeutic regimens for ALL (
Zeidan 2009, van den Berg 2011 ). 
 2.1.3 Arginine Auxotrophy in Cancer Cells  
 Arginine is a non- essential amino acid that is, by definition, not required for the growth of most 
cells.   The biochemical basis for this is synthesis of arginine from citrulline via the urea cycle 
(Husson 2003, Haines 2011
).  The ASS1  enzyme catalyzes the conversion of citrulline and aspartic 
acid into argininosuccinate, which is then converted into arginine and fumaric acid by 
argininosuccinate lyase (ASL).  It has long been known that some tumor cells are auxotrophic for 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 26 of 87  
 arginine, based on the observation that normal cells derived from liver, kidney and testes could 
grow in medium depleted of arginine but supplemented with citrulline, while tumor cells from these organs could not ( Tytell 1960
).  This implies that certain tumor cells could not re -synthesize 
arginine from citrulline.  Other investigators also reported that certain tumor cell lines could not be 
maintained in medium contaminated with Mycoplasma species and that the killing of tumor cells under these conditions was associated with arginine depletion (
Kenny 1963, Kraemer 1963  and 
1964 ).  Further studies showed that the depletion of arginine by Mycoplasma was due to the activity 
of the enzyme arginine deiminase (ADI),  which is not present in mammalian cells ( Schimke 1966 ).  
Thus, the understanding at that point was that some tumors were killed by arginine depletion mediated by Mycoplasma- produced ADI. 
 Depletion of available arginine however, should not lead to cell death in the presence of the ASS1 and ASL enzymes, which would replete arginine through conversion of citrulline. It was therefore hypothesized that cells auxotrophic for arginine might lack one of these enzymes and subsequent ly 
shown that certain cancer cell lines and human cancer tissue specimens lack significant expression of ASS1 ( Sugimura 1992 , Ensor 2002, Dillon 2004
).  The activ ity of ADI as an arginine -degrading 
drug is only apparent in cells that lack the ability to compensate by synthesizing endogenous arginine from citrulline.  
 In particular, methylation -dependent silencing of the ASS1 promoter has been identified as a 
mechanism of gene repression in a subset of ASS1 -deficient arginine auxotrophic solid and 
hematological tumors , including MPM ( Szlosarek 2 006, Nicholson 2009 , Delage 2012
).  
ASS1 -deficiency is associated with a poor prognosis in MPM ( Delage 2008 ) and a variety of other 
cancers including osteosarcoma ( Kobayashi 2010), myxofibrosarcoma ( Huang 2013 ), glioblastoma 
(Syed 2013), bladder cancer ( Allen 2014), breast cancer ( Qiu 2014 ) and pancreatic cancer 
(Liu 2014 ). The reason for this is not entirely clear, but may  due to rapidly expanding cancer cells 
preferentially using aspartate from the urea cycle to form nucleic acids and not arginine (
Rabinovich 2015 ). This ASS1 deficiency redirects aspartate to pyrimidine synthesis. In cont rast, 
expressing ASS1 decreases cell proliferation by decreasing nucleotide synthesis, resulting in a less malignant phenotype. Therefore, the urea cycle enzymes are metabolically linked to pyrimidine synthesis and regulation of neoplastic growth. Another group has also shown that ASS1 is a tumor suppressor in renal cell carcinoma by modulating both the urea cycle and glycolytic flux (
Simon  2015 ). Furthermore, they showed that re-expression of ASS1 retarded proliferation both in 
vitro and in vivo xenograft models.  
 2.1.4 Development of ADI -PEG 20  
 As a result of the above observations regarding the potential anti- cancer activity of arginine 
depletion, interest was focused on the development of ADI as a drug.  The enzyme was cloned fro m 
Mycoplasma hominis, expressed in E. coli  and subsequently conjugated to polyethylene glycol 
(PEG) ( Takaku 1992 and 1993, Holtsberg 2002
).  The PEG conjugates were prepared to enhance in 
vivo stability, to increase the circulating half-life and decrease the immunogenicity of the 
recombinant Mycoplasma enzyme.   It was determined that synthesis of ADI- PEG with PEG of 
20,000 mw via a succinimidyl succinate linker ( ADI-PEG 20) provided the optimal combination of 
enhanced half-life and diminished immunogenicity, as well as ease and yield of manufacture (
Holtsberg  2002 ).  Results of phase 1 and 2 ADI- PEG 20 treatment of subjects with H CC in the 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 27 of 87  
 USA, Italy and Taiwan have been reported ( Curley 2003, Izzo 2004 and 2007, Yang 2010 , 
Glazer  2010 ), as have similar phase 1 and 2 studies in metastatic melanoma ( Ascierto 2005 , 
Savaraj  2007, Feun 2008, 2012, Ott 2013 ).  These studies demonstrated medical benefit.  
 
2.1.5 Current ADI -PEG 20 Clinical Trials  
 The therapeutic applicability of targeting arginine deprivation therapy with ADI-PEG 20 in combination with systemic chemotherapy is only now being studied in the clinic.  Recent preclinical 
studies have revealed that arginine deprivation may be combined successfully with cisplatin, docetaxel, gemcitabine, chloroquine and PI3K inhibitors to enhance the pro- apoptotic effect of 
ADI-PEG 20 in various arginine-dependent cancer xenograft models, including prostate cancer, 
pancreatic cancer, osteosarcoma and melanoma ( Cheng 2007, Kim 2009, Daylami 201 4
, 
Tsai 2012 ).  Clinically, the first combination phase 1 trial to assess the role of docetaxel with 
ADI-PEG 20 commenced in the US in 2011 (Study Registry ID: [REMOVED]) and a 
second phase 1 is underway with cisplatin at the MD Anderson Cancer Center (Texas, US) (Study Registry ID: [REMOVED]).  Preliminary results show that the ADI-PEG  20-doublet chemotherapy regimens are well tolerated and have resulted in objective 
responses (Polaris -data on file).  ADI -PEG 20 is currently being investigated in multiple clinical 
trials. Further information is available on these trials at ClinicalTrials.gov . 
 2.1.6 Cisplatin  
 Cisplatin is a heavy metal compound containing platinum ( Rozencweig 1977, Prestayko  1979
).  Its 
mechanism of action involves covalent binding to purine DNA bases, this leads to cellular apoptosis (
Kelland 2007 ).  Side effects of cisplatin include nephrotoxicity, ototoxicity, gastrointestinal upset 
(including nausea and vomiting), neurotoxicity (especially peripheral neuropathy), electrolyte disturbances (hypomagnesaemia, hypokalemia and hypocalcaemia) and myelosuppression (
Cisplatin  1999 ).  The latter, depending on dosage regimen, typically has an onset of about 10 days 
with a nadir of about 14-23 days, with recovery by 39 days.  Fever and infection may occur in those with neutropenia.  Deaths due to inf ection, secondary to myelosuppression, may also occur. 
Myelosuppression appears to occur less frequently with lower doses (
Rozencweig 1977 ).  
 2.1.7 Pemetrexed  
 Pemetrexed is a folate analog metabolic inhibitor (Pemetrexed 2013
).  In clinical trials, the most 
common adverse reactions (incidence ≥ 20%) during therapy as a single agent were fatigue, nausea, and anorexia.  Additional common adverse reactions (incidence ≥ 20%) during t herapy when used 
in combination with cisplatin included vomiting, neutropenia, leukopenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation. 
 2.1.7.1 ADI-PEG 20 p lus Cisplatin in Melanoma: Preclinical Studies  
 Arginine is the substrate for nitric  oxide (NO) synthase ( Husson 2003, Haines 2011
).  Depletion of 
NO inhibited melanoma proliferation, and enhanced cisplatin -induced apoptosis in melanoma cells 
in tissue culture ( Tang 2004, Sikora 2010 ).  In addition, NO inhibition with the selective antagonist 
N6-(1-iminoethyl) – L lysine dihydrochloride (L- NIL) synergized with cisplatin in xenograft models 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 28 of 87  
 without added toxicity ( Sikora 2010 ).  Interestingly, although the mice only received 3 doses of 
cisplatin every 3 days, continued dosing of L- NIL was sufficient to suppress tumor growth 
(Sikora 2010 ).  These findings suggest that combination of NO inhibition with ADI- PEG  20 and 
cisplatin would be a reasonable approach to inhibiting melanoma, as ADI-PEG 20 has been shown 
to inhibit NO both in tissue culture, animals and humans with either melanoma or HCC (
Thomas 2002, Dillon 2002, Ascierto 2005, Izzo 2007 ). 
 
More recently, in vitro  data has confirmed enhanced melanoma cell apoptosis with the combinati on 
of ADI -PEG20 and cisplatin and with the combination in xenograft models ( Savaraj  2015 ).  
Treatment with ADI-PEG 20 and cisplatin combination showed significantly enhanced activity 
compared to either agent alone. The under lying mechanism is complex, but increased DNA damage 
upon arginine deprivation appears due to decreased DNA repair proteins which blunt the cancer cells’ ability to respond to cisplatin induced DNA damage.  
 Thus both laboratory and xenograft data show that the combination of ADI-PEG 20 and cisplatin results in enhanced anti-tumor activity in ASS1 -deficient melanoma cells, even when the cisplatin 
was administered over a limited period of time.  
 2.1.7.2 ADI-PEG 20 p lus Cisplatin in Melanoma: Clinical Study  
 As noted, a phase 1 is underway with cisplatin at the MD Anderson Cancer Center (Texas, US) (ClinicalT rials.gov Identifier: [STUDY_ID_REMOVED]).  Preliminary results show that this doublet 
chemotherapy regimen (cisplatin 35 mg/m
2 weekly x weeks 1  - 3 of every 4 weeks [105 mg/m2 
every 4 weeks] and ADI-PEG 20 36 mg/m2 weekly) is well tolerated and has resulted in objective 
responses ( Fu 2014).  This dose of ADI-PEG 20 is the same as that planned in this study, and the 
dose of cisplatin  planned in this study (75 mg/m2 every 3 weeks or 300 mg/m2 planned for every 
12 weeks [4 months]) is slightly less than that (315 mg/m2 every 12 weeks) in the ongoing 
melanoma study.  2.1.8 Phase 2 Study of ADI -PEG 20 M onotherapy in ASS1 -deficient MPM in the United 
Kingdom (ADAM Study)  
The benefit of ADI- PEG 20 treatment in ASS1 -deficient mesothelioma is supported strongly by a 
Phase 2 randomized study in ASS1- deficient MPM at 8 cancer centers in the United Kingdom (A 
Clinical Trial of ADI- PEG 20 in Patients with Malignant Pleural Mesothelioma [ADAM Study] 
[[STUDY_ID_REMOVED]]), led by the principal investigator of the current study. This study compared ADI-PEG 20 monotherapy with best supportive care (BSC) ( Szlosarek 2013, 2016
). When this trial 
started, pemetrexed and cisplatin were not the approved first-line chemotherapy in the UK. Potential 
subjects had to have inoperable MPM, an ECOG performance status of 0- 1, measurable disease by 
CT scan, and ASS1 deficiency (defined as ≤ 50% tumor cells with moderate and/or strong expression by IHC). ASS1 deficiency was found in 98 out of 214 subjects screened (46%). Sixty eight (68) patients were randomized 2:1 to ADI-PEG 20 (36 mg/m
2) + BSC (N=44) or BSC (N=24). 
CT scan was performed every 8 weeks. The primary endpoint was PFS, and the secondary 
endpoints were response rate, OS and toxicity. The study was powered for PFS with a target hazard 
ratio of 0.60. The study enrolled between March 2011 and May 2013. Epithelioid accounted for 96% of the enrolled subjects. Approximately half of the subjects were previously treated with a 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 29 of 87  
 platinum doublet. For ADI-PEG 20 + BSC, 17/44 (39%) were chemonaïve and 27/44 (61%) had 
been treated with prior chemotherapy.  
 
ADI-PEG 20 + BSC prolonged PFS (3.2 months) compared with BSC alone (2.0 months) 
(hazard ratio 0.56, 95% CI [0.33-0.96], p=0.03).  
 Furthermore, although the study was not powered for OS, there was also a trend to improvement in OS with ADI -PEG 20 treatment. A test for proportional hazards produced p=0.02 for OS. Thus OS 
violated the proportional hazards assumption, so the restricted mean survival time, a measure of life expectancy, was also estimated. The restricted mean survival times (life expectancy) for OS are 15.7 (ADI-PEG 20) vs. 12.1 (BSC) months, a difference of 3.6 months (95% CI -1.0 to 8.1, p=0.13) 
 Note that the restricted mean survival of ADI-PEG 20 monotherapy treated subjects of 15.7 months compares favorably with the 12.1 months OS observed with the pemetrexed + cisplatin doublet 
(Vogelzang 2003
). 
 There was no objective response on CT scan using modified RECIST criteria for MPM, although 18/39 (46%) of ADI- PEG 20 treated patients had a PR by FDG -PET.  
 ADI-PEG 20 was well tolerated as monotherapy in MPM patients, with no new adverse events 
compared with other ADI-PEG 20 monotherapy studies.  
Given that PFS is a well -established surrogate for OS in MPM, the extended median PFS supports 
further exploration of the role of ADI- PEG 20 treatment in providing survival benefit.   
 
ADI-PEG 20 wa s generally well tolerated and showed evidence of clinically significant activity in 
patients selected  for arginine -dependent MPM ( Szlosarek 2016 ).  Thus arginine deprivation with 
ADI-PEG 20 may have a role in the future management of MPM either alone or in combination 
with selected therapies.  One of the metabolically responding patients has already been reported 
(Szlosar ek 2013 ).  Furthermore, another patient with a prolonged response was on coexistent folate 
inhibition with methotrexate used to treat their rheumatoid arthritis.  This suggests further that 
combination treatment with ADI- PEG 20 may be beneficial in MPM (se e below). 
 
2.1.9 Phase 1 Study of ADI -PEG 20 Plus Pemetrexed and Cisplatin in MPM and Non -
squamous Non- Small Cell Lung Cancer (NSCLC)  (TRAP Study)  
 Based on the success of ADAM study, a phase 1 study in ASS1 -deficient patients with MPM or 
nonsquamous non- small cell lung carcinoma (NSCLC -nonsquamous) was undertaken (Phase 1 
Study in Subjects with Tumors Requiring Arginine to Assess ADI- PEG 20 With Peme trexed and 
Cisplatin [ADIPemCis] [TRAP Study];  [STUDY_ID_REMOVED]). The TRAP study examines the standard regimen of pemetrexed + cisplatin (500 mg/m
2 and 75 mg/m2 respectively, both given every 
3 weeks) with escalating doses of ADI -PEG 20 (18, 27 and 36 mg/m2).  Subjects may receive a 
maximum of 6, 3- week cycles of three-drug treatment for a total of 18 weeks of treatment.  Those 
subjects completing the three -drug regimen may continue on ADI-PEG 20 monotherapy if they 
have SD or better. Subjects must be chemotherapy naïve except for those with NSCLC and EGFR mutant or ALK positive disease, who must have had an EGFR tyrosine kinase inhibitor (TKI) or 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 30 of 87  
 ALK inhibitor (if available). Following the dose escalation portion, maximum tolerated dose 
(MTD) cohorts of up to 30 subjects each for MPM and NSCLC will be enrolled.  As of 20 March 2019, 36 MPM patients (12 epithelioid; 12 biphasic; and 12 sarcomatoid) were 
enrolled in the dose-escalation and dose expansion study at the MTD . The overall response rate was 
as follows: 15/36 (41.6%) PR and 19/36 (52.8%) SD for a DCR of 34/36 (94.4%);  the PR rate in 
non-epithelioid disease was 8/24 (33.3%). Notably, the overall median OS in the expansion cohort was 10.1 months and 8.2 months in the non- epithelioid patient population, comparing favorably 
with the 22.2% of the pemetrexed + cisplatin phase 3 benchmark trial ( Vogelzang  2003
-quoted in 
Mansfield  & Symanowski 2014 ) and known poorest prognosis of the MPM histologies 
(Mansfield  & Symanowski 2014, Galetta 2016 ). The reason(s) for the higher than anticipated non-
epithelioid enrollment are not clear, but appear due, at least in part, to enhanc ed referral of such 
patients to the lead investigator as this trial does not exclude such patients (see above) (Peter  Szlosarek -personal communication).  
 Thus, for MPM with a high percentage of non-epithelioid, the ORR achieved with ADI-PEG  20 + pemetrexed + cisplatin is significantly higher than would be expected for the 
standard pemetrexed + cisplatin doublet.  
 In view of the poorer outcome for non- epithelioid MPM, it is remarkable that the median PFS for 
the sarcomatoid and biphasic subjects  in th e dose expansion TRAP study (20/31 enrolled) was 5.0 
months, approach ing the level of 5.7 months in a population containing 68% epithelioid in the 
pemetrexed + cisplatin treated group ( Vogelzang 2003
). 
 Note that response rate i n the TRAP trial was determined using the modified RECIST  criteria 
(Byrne 2004 , Tsao 2011
). Modified RECIST takes into account disease only in the thorax. In 
contrast, RECIST 1.1 takes into account disease in the thorax as well as in other body areas, although it does not assess pleural disease as well as modified RECIST does (
Eisenhauer 2009 , 
Tsao 2011 ). In the TRAP trial, tumor measurements using modified RECIST or RECIST 1.1 
resulted in the same ORR (Peter Szlosarek, personal communication). However, as non -epithelioid 
tumors , especially sarcomatoid more frequently have more aggressive disease that may extend 
beyond the thorax ( Klebe 2010, Galetta 2016 ), we will use modified RECIST response criteria for 
MPM for intra -thoracic disease ( Appendix A ) and RECIST 1.1 response criteria for extra -thoracic 
disease (Appendix B ) for this current trial.   
 2.1.10 Rationale for C ombining ADI -PEG 20 w ith Pemetrexed and Cisplatin  
 
2.1.10.1 Rationale for C ombining ADI -PEG 20 w ith Pemetrexed  
 
ADI-PEG 20 inhibits intracellular levels of thymidine, and pemetrexed potentiates the anti -tumor 
activity of ADI-PEG 20. Treatment with ADI-PEG 20 was lethal in ASS1 negative bladder cancer cells and its exposure was associated with a marked reduction in intracellular levels of thymidine, 
due to suppression of both uptake and de novo synthesis ( Allen 2014
). Inhibition of de novo 
thymidine synthesis was linked to decreased expre ssion of folate -dependent nucleotide synthesizing 
enzymes thymidylate synthase and dihydrofolate reductase. Notably, inhibition of de novo synthesis was associated with potentiation of ADI-PEG 20’s anti- tumor activity by the antifolate drug 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 31 of 87  
 pemetrexed in a  xenograft model. Similar data on thymidine salvage and de novo synthesis 
pathways were obtained in a panel of ADI- PEG 20 treated ASS1 -negative mesothelioma cell lines. 
Taken together, these findings argue that arginine deprivation combined with antifolate s warrants 
clinical investigation in cancers such as MPM and nonsquamous NSCLC where pemetrexed + 
cisplatin are first- line chemotherapy.  
 As noted above, there is a biochemical rationale for combining ADI-PEG 20 with pemetrexed in those tumors where standard treatment includes pemetrexed. Furthermore, there are biochemical rationales for combining ADI-PEG 20 with cisplatin, too.   2.1.10.2 Rationale for Combining ADI-PEG 20 w ith C isplatin  
 Inhibition of nitric oxide synthesis by arginine depletion is enhanced by cis platin, and ADI -PEG 20 
inhibits synthesis of DNA repair enzymes required to repair cisplatin induced DNA damage.  Arginine is the substrate for nitric oxide (NO) synthase ( Husson 2003, Haines 2011
).  Depletion of 
NO inhibited melanoma proliferation, and enhanced cisplatin -induced apoptosis in melanoma cells 
in tissue culture ( Sikora 2010 ).  In addition, NO inhibition with the selective antagonist N6 
(1 iminoethyl) – L lysine dihydrochloride (L NIL) synergized with cisplatin in xenograft models 
without added toxicity ( Sikora 2010 ).  These findings suggest that combination of ADI-PEG 20 and 
cisplatin would be a reasonable approach to inhibiting melanoma, as ADI-PEG 20 has been shown 
to inhibit NO in tissue culture, animal models and humans with either melanoma or HCC (see Investigator’s Brochure ). 
 Pre-clinical data have also been obtained with combination of cisplatin and ADI PEG 20 in treating 
melanoma ( Savaraj 2015
).  Compared with either agent alone, treatment of ADI-PEG 20 + cisplatin 
caused significantly more growth inhibition as well as an increase in apoptosis in ASS1 -negative 
melanoma cells.  Tissue culture data shows that arginine deprivation with ADI -PEG 20 potentiates 
cisplatin sensitivity in ASS1 -deficient tumor cells, and this effect is mediated by increased DNA 
damage and increased apoptosis, partly due to decreased DNA repair proteins. Thus tumor cells have increased difficulty in attempting to repair DNA damage caused by cisplatin in the presence of ADI-PEG 20. In addition, treatment with ADI-PEG 20 and cisplatin combination sho wed 
significantly enha nced anti- tumor activity compared with either agent alone in a xenograft model.  
 ADI-PEG 20 has also been tested in combination with cisplatin in a phase 1 trial ([STUDY_ID_REMOVED]) 
(Fu 2014
). The combination has been shown to be well-tolerated with no added toxicity with 
ADI-PEG 20 compared with those reported for cisplatin alone, except for injection site reactions 
that are consistent with the intramuscular injection mode of administration for ADI-PEG 20. In addition, objective responses have been observed.  
 
 Description of Investigational Product  
 Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis , produced in E. coli , 
and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker.  Thus ADI -PEG 20 
is an arginine degrading enzyme, ADI, coupled to PEG. 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 32 of 87  
 
 Summary of Findings to Date  
 
2.3.1 Clinical Experience with Hepatocellular Carcinoma  
 ADI-PEG 20 has been found to be well tolerated and to result in apparent medical benefit in phase 1 
and phase 2 studies. Some patients have been on ADI-PEG 20 weekly therapy for over 3 years.  A global phase 3 trial has finished  enrolling.  For further information, see the  Investigator’s Brochure. 
 2.3.2 Clinical Experience with Metastatic Melanoma  
 ADI-PEG 20 has been found to be well tolerated and to result in apparent medical benefit in phase 1 
and phase 2 studies ( Phillips 2013
).  In particular, patients with metastatic uveal melanoma 
appeared to benefit with a significant prolongation of progression- free survival ( Ott 2013 ). For 
further information, see the  Investigator’s Brochure.  
 2.3.3 Clinical Experience in MPM 
 The results of the phase 2 and phase 1 studies have been noted above.  2.3.4 Adverse Events  
 The toxicities expected from the use of ADI-PEG 20 are relatively mild based on the clinical experience to date detailed above.  The most frequently reported physical symptom was mild, temporary tenderness at the injection site beginning 24 hours after the injection and lasting a total of 
1 to 2 days.  However, allergic reactions, including anaphylaxis have occurred.  The most common 
laboratory toxicities, even at doses higher than those proposed here, were mild (Grade 1 to 2) and 
asymptomatic elevations of  various serum chemistry values.  Neutropenia also has been observed 
and has responded to growth factor support.  
 Study Rationale  
 The above background information provides the biochemical rationale for the use of ADI- PEG 20 
in oncology studies. T issue for ASS1 testing was initially  required for study entry  to support an 
adaptive biomarker- driven trial design. However, this design was amended prior to the in terim 
analysis following objective responses in other clinical studies of ADI -PEG 20 combined with 
chemotherapeutic agents (FOLFOX and gemcitabine plus nab- paclitaxel; Harding 2018 and 
Lowery 
2017 ) that  did not correlate with ASS1 deficiency and were seen in both subjects w ith and without 
ASS deficiency. Pemetrexed and cisplatin are the first line chemotherapy in advanced MPM . Taken 
together, our preclinical and clinical data suggest that such a treatment combined with ADI -PEG 20 
would be even more efficacious than st andard pemetrexed plus cisplatin only.  
 In MPM, both RR and PFS correlate with OS (Francart 2009, Blayney 2012, Hasan  2014
). Thus RR 
and PFS serve as surrogate endpoints for OS in MPM. 
   
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 33 of 87  
 Clinical Experience  
 
As noted above, a phase 1 combination study of ADI-PEG 20 plus pemetrexed and cisplatin is currently enrolling. The combination has been safe and well tolerated, with no more toxicity than with pemetrexed and cisplatin alone, except for injection site reactions consistent with the IM 
method of ADI-PEG 20 administration.   3 STUDY OBJECTIVES  
 
 Primary Objectives  
 
The primary objective of this study is : 
• Determine  efficacy  as determined by RR, measured by modified RECIST  criteria for 
unresectable  MPM  and RECIST 1.1 criteria (phase 2 portion) and OS (phase 3 portion)  
 
 Secondary Objectives 
 
The key secondary objective of the phase 2 portion is: 
• Determine the duration of response (DOR)  
 
The key secondary objective of the phase 3 portion is : 
• Assess progression free survival (PFS) 
 
Other secondary objectives of this study are:  
 
• Assess safety and tolerability of ADI -PEG 20 in combination with pemetrexed and cisplatin  
• Determine the pharmacodynamics of ADI-PEG 20 in combination with pemetrexed and 
cisplatin  
• Determine the immunogenicity of ADI-PEG 20 in combination with pemetrexed and cisplatin  
• Determine the pharmacokinetics of ADI -PEG 20 in combination with pemetrexed and cisplatin  
 
Objectives will be assessed according to the overall MPM population and according to each of the 
MPM subtypes.  
The goal of the phase 2 portion of the trial is to provide data to support accelerated approval by the 
United States Food & Drug Administration, and the goal of the phase 3 portion of the trial is to provide a confirmatory study that would be ongoing at the time of the marketing application. 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 34 of 87  
 4 STUDY DESIGN 
 
 Design Summary  
 
This is a randomized, double- blind , multi -center,  phase 2 /3 trial of ADI-PEG 20 in combination 
with pemetrexed and cisplatin in subjects with unresectable MPM  of sarcomatoid or biphasic 
histologies .  
 
The starting dose represents 100% of the recommended dose of cisplatin and pemetrexed and ADI-PEG 20  as determined  in the phase 1 trial. 
 
4.1.1 Continued Treatment after 6 Weeks of Treatment of ADIPemCis  
 Tumor assessment imaging will be performed at baseline  (during screening) and at the end of week 
6 for tumor response using modified RECIST for MPM for local pleural disease (Byrne 2004, 
Tsao 
2011 ) and RECIST  1.1 for metastatic lesions ( Eisenhauer 2009 ). The same imaging modality is to 
be used throughout the triplet treatment duration .  
 In the event of disease progression , the triplet chemotherapy will be stopped and the patient offered 
an alternative treatment plan.   
 In the absence of disease progression requiring other therapeutic interventions, patients may receive additional cycles of ADI PemCis or PlaceboPemCis  treatment following the same procedures and 
schedule as week 7 and onward for up to 18 weeks.    
Subjects may continue to receive treatments unless, one of the following occurs at any time during 
the course of therapy: (1) unacceptable AEs, or (2) death, or (3) progressive disease, or (4) significant noncompliance on the part of the subject, or (5) refusal of the subject to continue treatment or observations, or (6) decision by the Investigator that termination is in the subject’s best medical interest, or (7) unrelated medical illness or complication, or (8) lost to follow -up.  Any 
patient with tumor and stable disease or partial response should continue treatment until progression, unless Investigator thinks a better option is available.  Thus, subjects completing ADIPemCis or PlaceboPemCis may continue to receive ADI -PEG 20 or placebo treatment.  Any 
patient with a complete response may receive 4 more weekly treatments  of ADI -PEG 20  or placebo.  
The maximum number of cycles of pemetrexed  + cisplatin is 6 (18  weeks at every 3  weeks cycle).   
 4.1.2 Blinded and Open- Label Extension at Study End  
 Subjects ongoing at study end (once the required number of events have been observed for the final analysis) may continue to receive weekly treatment on ADIPemCis or PlaceboPemCis (or ADI-PEG 20/placebo alone), depending on where the subjects are in the treatment schedule,  until 
the study is unblinded. Once the study treatment assignments are known, the subjects receiving ADI-PEG 20 may continue to receive ADIPemCis (or ADI -PEG 20 alone) until 1 of the following 
occurs: (1) unacceptable AEs, or (2) death,  (3) PD or (4) decision by the Sponsor. Subjects 
receiving placebo should be consulted regarding alternative treatment options.  A local laboratory may be used instead of a central laboratory for the extension phase of the study. 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 35 of 87  
  
Subjects wishing to conti nue study treatment will follow the Schedule of Assessments in 
Table  4.1.2.1  
 Blinded and Open- Label Extension Schedule of Assessments and Procedures  
 
 Table 4.1.2.1 Study Assessments and Procedures 
 
 Study Week  
Study Procedure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 E
O
T 
Vital Signsa X X X X X X X X X X X X X X X X X X  
AE assessmentb X   X   X     X     X     X     X 
Concomitant medications  X   X   X     X     X     X     X 
Study drug administrationc X X X X X X X X X X X X X X X X X X  
Note: All study evaluations and related procedures may occur ± 3 days of the planned date.  
Subjects who remain on treatment after 18 weeks will continue following the schedule in Table 4.1.2.1 .  For example, week 
19 would follow the schedule for week 1, week 20 would follow the schedule for week 2 and so on.  
a. Vital signs to be obtained before and 1 hour ± 15 minutes after ADI -PEG 20 or placebo treatment.  
b. Adverse events, including serious adverse events will be assessed at each of the indicated visits.  Ongoing adverse 
events will be followed until resolution or stabilization.  New AEs will be recorded until 30 days after last drug administration. Adverse events will be reported to Polaris monthly. SAEs will be reported within 24 hours of awareness to Polaris or designee.  
c. During blinded extension, visits will be reg istered in IWRS. During Open -Label Extension, Polaris will provide a list 
of vial numbers to be pulled from inventory and given to subjects at each visit.  ADI -PEG 20 will be administered 
weekly.  Cisplatin and pemetrexed will be administered every 3 weeks  up to the planned 18 weeks duration of these 
agents.  
 
Note:  CT/MRI scans during the extension will be standard of care in the opinion of the investigator.  
 4.1.3 Anticipated Number of Subjects and Target Accrual  
 See Section 11.  
 
 Criteria for Study Terminatio n 
 The study may be terminated at any time by Sponsor for the following reasons: 1) the Investigator does not adhere to the protocol, i.e. commits significant protocol violations, 2) in Sponsor’s judgment, there are no further benefits to be achieved from the study, or 3) the clinical development of the investigational product in this study is discontinued.  If this study is discontinued, Sponsor will inform all study investigators/institutions, the IRB/IEC  and regulatory authorities. 
 The Investigator and Sponsor have the right to close a study, at any time; however, this should occur only after consultation between the parties.  If the study is closed, the IRB/IEC must be 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 36 of 87  
 informed.  If the study is closed prematurely, all study materials, except documentation that has to 
remain stored at the center site, must be returned to Sponsor.  The Investigator will retain all other 
documents until notification given by the Sponsor for destruction.  Events that may trigger premature termination of a study or closure of a center i nclude, but are not limited to: 
 
• New toxicity finding 
• Non-compliance with the protocol 
• Change in development plans for the drug 
• Slow recruitment  
• Poor quality data 
• Regulatory authority mandate  
 
5 STUDY POPULATION 
 
 Inclusion Criteria  
 A subject will be eligible for study participation if they meet the following criteria  prior to the first 
dose:   
1. Histologically proven unresectable MPM of biphasic or sarcomatoid histology. Biphasic 
MPM is defined using the World Health Organization’s international histological classification of tumors as containing an epithelial and a sarcomatoid component with each component comprising at least 10% of the tumor ( Corson 2004, Allen 2005
). 
2. Naïve to  prior chemotherapy or immunotherapy (i.e., this is a first- line systemic therapy 
study). 
3. Measurable disease as assessed by modified RECIST for MPM local pleural disease 
(Appendix A ) and R ECIST 1.1 for metastatic lesions  (Appendix B ).  
4. ECOG performance status of 0 – 1 (Appendix C ). 
5. Predicted life expectancy of at least 12 weeks.  
6. Age ≥ 18 years (there is no upper age limit).  
7. Fully recovered from any prior surgery and no major surgery within 4 weeks. Surgery for placement of vascular access devices is acceptable.  
8. Subjects and their partners must be asked to use appropriate contraception.  They must agree 
to use two forms of contraception or agree to refrain from intercourse for the duration of the study and for 35 days after last dose of ADI -PEG 20 or for at least six months after treatment 
with pemetrexed and c isplatin  whichever is the longer  duration. Females must not be 
pregnant at the start of the study, and a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study. If positive HCG pregnancy test, further evaluation to rule out pregnancy must be performed according to GCP before this patient is claimed eligible.  
9. Informed consent must be obtained prior to study initiation.  
10. Hemoglobin (HB) > 9.0 g/dL. 
11. Absolute neutrophil count (ANC) > 1,500/µL.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 37 of 87  
 12. Platelets > 75,000/µL. 
13. Either: (i)  serum b ilirubin ≤ 1.5 x upper limit of normal (ULN) or 
(ii) alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or alkaline 
phosphatase (ALP) ≤ 3 x (ULN) unless raised due to tumor in which case up to 5 x ULN is 
permissible  
14. Serum uric acid ≤ 10 mg/dL (595 µmol/L) (with or without medication control).  
15. Creatinine clearance ≥ 45 mL/min (estimated, using Cockcroft and Gault formula).  Cisplatin 
dose adjustment is recommended for subjects with a creatinine clearance between 4 5 and 59 
mL/min (Bennis 2014) as follows: reduce cisplatin dose by 25% for clearance between 50-59.9 mL/min and by 50% for clearance between 45 – 49.9 mL/min. 
 
 Exclusion Criteria   
 
A subject will not be eligible for study participation if s/he meets any of the exclusion criteria  
before first dose : 
1. Radiotherapy (except for palliative reasons)  the previous two weeks before.  
2. Ongoing toxic manifestations of previous treatments.  
3. Symptomatic brain or spin al cord metastases (patients must be stable for > 1 month post 
radiotherapy or surgery).  
4. Major thoracic or abdominal surgery from which the patient has not yet recovered. 
5. Serious infection requiring treatment with intravenous antibiotics at the time of study 
entrance, or an infection requiring intravenous therapy within 7 days prior. 
6. Known to be serologically positive for human immunodeficiency virus (HIV). Testing to determine possible infection status is not required.  
7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, 
symptomatic congestive heart failure (New York Heart Association Class III or IV), symptomatic cardiac arrhythmia, previous history of myocardial infarction (unless stable and 
good e jection fraction on echocardiogram ) or psychiatric illness and social situations that 
would limit compliance with study requirements. 
8. Is a participant of, or plans to participate in , another interventional clinical study whilst 
taking part in this study.  Participation in an observational or biomarker study would be 
acceptable, with prior Sponsor approval. 
9. Subjects with history of another primary cancer, including co- existent second malignancy, 
with the exception of: a) curatively resected non- melanoma skin cancer; b) cu ratively treated 
cervical carcinoma in situ; or c) other primary malignancy  with no known active disease 
present in the opinion of the Investigator will not affect patient outcome.   
10. Allergy to cisplatin or other platinum -containing compounds.  
11. Pregnancy o r lactation.  
12. Expected non- compliance.  
13. Subjects who had been treated with ADI-PEG 20 previously. 
14. History of uncontrolled seizure disorder not related to underlying cancer. 
15. ECOG performance status > 2. 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 38 of 87  
 16. Allergy to pegylated compounds.  
17. Allergy to E. coli drug  products (such as GMCSF).  
18. Allergy to pemetrexed or to any other ingredient used in the formulation.  
 
 Criteria for Subject Withdrawal 
 
Subjects are free to discontinue the study  treatment at any time, for any reason, and without 
prejudice to further treatment.   
 A subject experiencing any of the following will be withdrawn from the study treatment: 
1. Significant noncompliance on the part of the subject. 
2. Refusal of the subject to continue tr eatment or observations.  
3. Adverse Event. Laboratory abnormalities that can be corrected with interventions (e.g., hyperuricemia with allopurinol and/or urate oxidase, and neutropenia with growth factor support) do not require subject withdrawal.  
4. Decision by the Investigator that termination is  in the subject’s best medical interest.  
5. Unrelated medical illness or complication.  
6. Death.  
7. Lost to follow -up. 
8. Progressive Disease according to modified RECIST or RECIST 1.1 as appropriate for the 
disease under study , or clinical progression in the opinion of the Investigator. BICR results 
will be used for decisions on the di scontinuation of or continued treatment during the phase 2 
portion.   
 
 Withdrawal Procedures  
 In the event of a subject’s withdrawal, the investigator will promptly notify the study monitor and will make every effort to complete the EOT  assessments (see  Table  1.4.2
).  
 Subjects withdrawn from treatment for reasons other than PD may continue to receive scans every 8 
weeks until PD.  
 After discontinuation/withdrawal from treatment, a subject must be entered into the follow -up 
period, and contacted regularly (every 3 months) for survival status until  study closure.  If a subject 
decides not to continue to receive study drug, they will be removed from the study treatment portion and the investigator will request the subject to provide follow up information on the study.  If a subject withdraws from the study  treatment, every effort will be made to complete  EOT , Follow- Up 
Visit, and End of Study eCRFs . 
 If a subject should die during treatment or within 30 days of stopping treatment, the investigator will inform Sponsor’s representative.  The cause of death should be reported in detail, within 24 
hours, on an SAE form and reported to Sponsor’s representative /designee (see Sectio n 9
). 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 39 of 87  
 Subjects that have signed informed consent for treatment, and undergo at least some of the 
screening procedures, but fail to meet eligibility criteria will be considered s creening failures. The 
reason for failure will be recorded on the screening log provided by Polaris.  A record of such subjects will be maintained in the Trial Master File (TMF) at the study site and will be retained for the required period of time in comp liance with the Code of Federal Regulations (CFR) 21, 
Sec.312.57, part (c) and Good Clinical Practice (GCP). Subjects that are “screen failures” may be rescreened  at the discretion of the investigator.   
 All withdrawn subjects will be followed until resolution of any ADI- PEG  20 related AEs, or until 
these unresolved AEs are judged by the investigator to have stabilized. 
 6 STUDY PROCEDURES  
 The procedures for each visit are listed in Section 1.4
 SCHEDULE OF ASSESSMENTS AND 
PROCEDURES.  
 Results of all assessments will be recorded on the appropriate eCRF.  
 
 Screening Procedures  
 The investigator will inform each prospective subject of the nature of the study, explain the 
potential risks, and obtain written informed consent from the subject prior to performing any study -
related procedures and prior to the administration of study drug.    The results of the screening evaluation must meet the inclusi on/exclusion criteria for the subject to 
be entered into the study.  Thus the investigator must review the results of histology determination, 
diagnostic testing (CT scan or MRI, serum pregnancy test [if appropriate], and clinical laboratory tests), and th e results of that screening testing must meet the inclusion/exclusion criteria for the 
subject to be enrolled into the study. BICR results will be used for eligibility determination  in the 
phase 2 portion.  
Study Informed Consent Form 
 There will be one ma in consent form for this study .   
 6.1.1 ASS1 Expression Screening  
 
ASS1 expression testing was initially required but the protocol was amended  to remove this 
requirement.  
 
6.1.2 Study Screening  
 6.1.2.1 Screening Procedures within 4 weeks (28 days)  of Start of Treatment 
 
The following must be performed/ obtained within the four weeks before  the patient receives the 
first dose of ADI- PEG 20:  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 40 of 87  
 • Upon determination  that a patient has a biphasic or sarcomatoid  tumor, the patient will then 
undergo further screening procedures, as follows  
• Demographic details  
• Medical History including prior diagnosis, prior treatment, concomitant diseases, 
concomitant treatment and baseline signs and symptoms  
• Disease Assessments: Radiological measurements (chest, abdominal and pelvis 
computerized tomography (CT) scan, as appropriate), ideally within 2 weeks of study drug administration  but 28 days is acceptable. 
 
6.1.2.2 Screening Procedures within 1 week (7 days) of Start of Treatment  
 
The following mus t be performed within one week before  the patient receiving the first dose of 
ADI-PEG 20 : 
• ECOG performance status  
• Complete physical examination  
• Height, weight, temperature, blood pressure (BP) , respiratory rate  and heart rate  
• Laboratory Tests: Samples to be obtained for clinical laboratory tests as outlined in 
Table  9.2.  Serum human chorionic gonadotropin (HCG) test to rule out pregnancy at study 
entry; results must be obtained and reviewed before the first dose of ADI -PEG 20 is 
administered, if applicable (i.e., females).  
• Creatinine clearance ≥ 45 mL/min (estimated, using Cockcroft and Gault formula). 
Creatinine clearance = {(l 40 –age[yr]) x weight[kg])/(72xS erum creatinine[mg/dL])}x 0.85 
(if female).  
• 12 lead electrocardiogram (ECG) 
 
 Clinic Visits  
 
There are no fasting or food restrictions for the clinic visits.  The visit frequency is described in Section 1.4
 SCHEDULE OF ASSESSMENTS AND PROCEDURES.   Selected weekly clinic visits 
may be conducted in the home setting by home cancer care staff rather than in the clinic. If home 
care is to be used the process must be documented and approved by the Sponsor. 
 6.2.1 End of Treatment  
 At the time of discontinuation of treatment for any reason, subjects will be asked to report to the study site for EOT  assessments. This assessment is to be completed 7 -30 days after last dose 
administered (preferably 30 days after last dose administration but may  be performed earlie r if 
necessary).  
 6.2.2 Follow- up Period  
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 41 of 87  
 The subject will be contacted every 3 months post EOT  assessment  until  study closure to determine 
survival status. In addition, a current survival status is required prior to the interim and final 
analysis.  Any ongoing AE s related to ADI -PEG 20 when subject stops the study treatment will be 
followed by the Investigator until the event resolves, stabilizes, or returns to baseline status (see Follow-up Period Table, Table  1.4.3
). 
 7 STUDY DRUG S 
 
 Identity of Investigational Product and Standard, Background Chemotherapies  
 7.1.1 Drug Name(s)  
 7.1.1.1 ADI-PEG 20  - Investigational Product  
 For further information, see the Investigator’s Brochure. Arginine deiminase (ADI) is a 
recombinant protein cloned from M. hominis , produced in E. coli , and conjugated with polyethylene 
glycol (PEG) of 20,000 mw.  Thus, ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG. ADI-PEG 20 is the invest igational product in the study. 
 7.1.1.2 Pemetrexed  – Standard, Background Chemotherapy  
 This is an approved medication that is considered in the study as background therapy to be provided through the local pharmacy. The brand name Alimta ® (Lilly -name used in the USA) should be used 
for this study unless use of an alternative generic version has been approved in advance by the 
Sponsor. 
 
7.1.1.3 Cisplatin  – Standard, Background Chemotherapy  
 
This is an approved medication that is considered in the study as background therapy to be provided 
through the local pharmacy. 
 
7.1.2 Storage Conditions 
 The investigator will ensure that all the study drugs are stored and dispensed in accordance with US Food and Drug Administration (FDA) regulations and other country specific health authority regulations concerning the storage and administration of investigational drugs. 
 ADI-PEG 20  and placebo will be stored frozen at the temperature indicated on the product label.   
The drug product is stable for 24 hours once it is thawed after taking it out fro m frozen storage.  
 Pemetrexed and cisplatin are to be stored per institutional standards.  
 
 Blinding of Investigational Product 
 Subjects will be randomly assigned to receive ADI -PEG 20 drug product or matching placebo in a 
double-blind fashion. Thus, neither the investigator, nor the subject will know which study 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 42 of 87  
 treatment is being administered. The randomization number will be assigned based on information 
obtained from an IWRS. ADI-PEG 20 drug product and placebo will be identical in appearance in order to preserve the blinding. In order to maintain this blind, study medication (ADI-PEG 20 or placebo) will be labeled with a unique “medication number”, which will be assigned to a subject by an IWRS. Note that SAS programming may occur as study data accumulate in order to have analysis programs ready at the time the study finishes. In such an event, arbitrary treatment group assignments must be randomly linked to subjects, effectively rendering any output of programs meaningless. The complete random lists wi ll be archived with the IWRS. Should a medical 
emergency arise that requires identification of the study medication administered, in order to manage the acute situation of the subject, the blind can be broken. The investigator should treat the subject as i f the subject were on the active drug product . The study medication can be unblinded by 
the investigator via the IWRS  if needed.  
 
Unblinding may occur for emergency purposes only. Investigators should note that the occurrence 
of an SAE should not routinely precipitate the immediate unblinding of the label. If unblinding is necessary for the treatment of a subject for an SAE, the investigator should promptly document and 
explain any unblinding to Polaris, or their designee within 24 hours of unblinding. The medical 
monitor must also be promptly notified that the blind has been broken. If unblinding occurs, the study medication (ADI-PEG 20 or placebo) must be discontinued. Subjects that have discontinued study drug/placebo may not re -start treatment.   
 
 Study Treatment  
 7.3.1 Dose and Administration 
 
ADI-PEG 20  or placebo will be administered by intramuscular (IM) injection to subjects once 
weekly.  Subjects will remain in the treatment area for 1 hour ± 15 minutes after the injection.  At 
the end of this post injection period, subjects will be assessed for safety and tolerability, including obtaining vital signs.  ADI- PEG 20 or placebo is to be administered before pemetrexed + cisplatin. 
Peme trexed + cisplatin administration is to begin  at least  60 minutes after  ADI -PEG 20  or placebo 
administration  on the same day, except during cycle 1 when the chemotherapy is administered on 
Day 3 .   
 Pemetrexed + cisplatin are to be administered per institu tional standards (this may include capping 
of BSA for dosing, banding, rounding, prefilled products, or logistical requirements for prehydration, etc.).  
 7.3.2 Rationale and Dose Selection  
 7.3.2.1 ADI-PEG 20  
 ADI-PEG 20  (at dose of  36 mg/m
2) or placebo is to be given via the IM route of administration. 
This is the dose that has been used successfully in the current phase 1 study of ADI -PEG 20 plus 
pemetrexed plus cisplatin in MPM and NSCLC. Subjects will receive one injection of ADI- PEG 20 
or placebo intramuscularly into the deltoid, gluteal or quadriceps muscles (Note: this will total approximately 6 mL for a larger subject, if this volume is a problem from an institutional nursing 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 43 of 87  
 perspective, it may be given as 2 injections in different body locations) weekly.  To limit the 
volume administered for a larger subject there will be dose capping at 74.8 mg which is the equivalent of 6.5 mL.  The injections may be given ± 3 days from the scheduled weekly dosing, 
except for the first dose, which is fixed.  Subjects will be observed in the clinic for 1 hour ± 15 minutes following each ADI- PEG 20  or placebo injection.  ADI-PEG 20 or placebo is to be 
administered before pemetrexed and cisplatin. Pemetrexed and cisplatin administration is to begin at least 60 minutes after  ADI -PEG 20 or placebo administration  on the same day, except for the first 
cycle where the doublet chemotherapy will be administered on day 3.  Treatments shall not be 
interrupted due to either scheduling for CT (or MRI) scans or delays in the assessment of scan results.  
 7.3.2.2 Pemetrexed and Cisplatin  
 Treatment with pemetrexed and cisplatin is as per institutional guidelines , including infusion 
protocols.  The dosages of pemetrexed and cisplatin are those used to treat unresectable MPM .  The dose of 
pemetrexed is 500 mg/m
2 every 3 weeks given by IV.  The dose of cisplatin is 75 mg/m2 every 3 
weeks given by IV.  7.3.3 Dose Adjustments  
 Treatment may be withheld for up to 2 weeks in any subject that demonstrates Grade 3 
non-hematologic toxicity or hematologic toxicity, as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE version 4.0 3, or approved version ).  If the toxicity is no longer 
Grade 3, treatment may be resumed; treatment does not have to wait for the next scheduled dose visit.   Use of hematopoietic growth factors is allowed to treat hematologic toxicity at the discretion 
of the investigator. Grade 3 or 4 laboratory abnormalities (e.g., hyperuricemia) that can be corrected with interventions do not require cessation of therapy.  If treatment is withheld for more than 2 weeks (or more than 2 missed doses of ADI-PEG 20/placebo), the subject should be discontinued 
from treatment, unless it is approved by Polaris in certain situations for the subject to continue.   
 
ADI-PEG 20  or Placebo  
 
ADI-PEG 20  or placebo will be given on days 1 (week 1), 8 (week 2), and 15 (week 3) of a cycle.  
Toxicity which is attributable to either cisplatin or pemetrexed will not mandate withholding the dose of ADI -PEG 20  or placebo for that cycle.   Dose reduction of ADI-PEG 20 or placebo is not 
allowed . 
 Investigators retain the discretion to withhold ADI-PEG 20  or placebo dose on the grounds of 
patient safety.  
 For patients to receive Day 15 ADI -PEG 20  or placebo the following parameter is required  during 
the chemotherapy treatment period (Cycles 1 -6): 
1. Platelets ≥ 50  x 10
9/L – on day 8 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 44 of 87  
 Patients who do not meet this  criteri on should have the dose of ADI -PEG 20  or placebo withheld.  
Specific toxicity resulting from ADI-PEG 20  or placebo administration should be managed as 
follows:  
• Local injection site reactions to date have been self -limiting and typically resolve within 
48 hrs.  
• Anaphylaxis should be managed in line with local policy for anaphylaxis.  In the event of 
Grade 2 or lower anaphylaxis re- challenge with ADI -PEG 20 or placebo may be considered 
and pre-medication with hydrocortisone and cholorpheniramine may  be used.  Grade 3 or 
greater anaphylaxis will result in the patient being withdrawn from study  treatment. 
• Hyperuricemia is to be monitored . Any clinically relevant elevation should be treated with 
allopurinol or urate oxidase, or sites may choose appropriate substitutions according to local 
policy.  
• Epilepsy/fits should be managed according to local policy and with benzodiazepines as 
necessary.  Once stabilized and dependent on the type and severity of reaction re- challenge 
with ADI -PEG 20 or placebo may be considered.  If further seizures occur, desp ite 
prophylactic measures, the patient should be withdrawn from study treatment . 
 
Pemetrexed and Cisplatin:  
 Cisplatin dose adjustment is recommended for subjects with a creatinine clearance between 45 and 
59 mL/min  (e.g., Bennis 201
5).  
 
Dose adjustments at the start of a subsequent cycle should be based on nadir hematologic counts or maximum non -hematologic toxicity from the preceding cycle of therapy.  Treatment may be 
delayed to allow suffici ent time for recovery .  Upon recovery, patients should be re- treated using 
the guidelines in Table 7.3.3 : 
 Table 7.3.3: Management of Drug Related Toxicity 
 
Cisplatin  Pemetrexed  
Hematological:  
Nadir ANC <500/mm3 & nadir platelets 
≥50,000/mm3 75% previous dose  75% previous dose  
Nadir platelets <50,000/mm3 regardless of 
nadir ANC  75% previous dose  75% previous dose  
Nadir platelets <50,000/mm3 with bleeding 
regardless of nadir ANC  50% previous dose  50% previous dose  
Non-Haematological:  
Any Grade 3 or 4 toxicities except mucositis  75% previous dose  75% previous dose  
Any diarrhea requiring hospitalisation 
(irrespective of grade) or Grade 3 or 4 
diarrhoea  75% previous dose  75% previous dose  
Grade 3 or 4 mucositis  100% previous dose  50% previous dose  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 45 of 87  
  Cisplatin  Pemetrexed  
Neurotoxicity Grade 1  100% previous dose  100% previous dose  
Neurotoxicity Grade 2 50% previous dose  100% previous dose  
Creatinine clearance 50 -59.9 mL/min  75% previous dose  Not applicable 
Creatinine clearance 4 5-49.9 mL/min  50% previous dose  Not applicable 
 
If a subject develops non-hematologic toxicities ≥ Grade 3 (excluding neurotoxicity), pemetrexed should be withheld until resolution to less than or equal to the subject's pre-therapy value.  Treatment should be resumed according to the guidelines in Table  7.3.3
.   
 Treatment with pemetrexed and cisplatin should be discontinued if a patient experiences any hematologic or non-hematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.  The first occurrence of toxicity which leads to a dose reduction of pemetrexed and / or cisplatin will not mandate a dose reduction in ADI -PEG 20  or placebo so long as the toxicity is attributable to the 
cytotoxic agent(s).  
 Either pemetrexed and / or cisplatin may be discontinued due to toxicity, and the continued single 
chemotherapy agent may be given with ADI-PEG 20 or placebo.   7.3.4 Switching from Cisplatin to  Carboplatin  
 Cisplatin is the recommended chemotherapy for use in the initial and subsequent cycles. However, subjects who do not tolerate cisplatin or who would not be expected to tolerate cisplatin may have carboplatin substituted for cisplatin at any cycle including the initial cycle at the discretion of the investigator.   The dose of carbop latin is area under the plasma concentration –time curve (AUC) 5 
mg per ml per minute. This may be modified at investigator discretion.  
 7.3.5 Missed Doses 
 An ADI -PEG 20 or placebo dose that is administered within the +3 days from the projected day will 
be considered delayed but not a deviation.  Beyond the +3 days, the dose would be considered missed  for that week .  Missed doses of ADI -PEG 20 or placebo will not be made up. 
 A pemetrexed and/or cisplatin /carboplatin  (or carboplatin) dose that is not adminis tered on Cycle 
X/Day 1 will be considered delayed if given within 2 weeks of that cycle.  Subsequent dosing schedule would need to be adjusted so that the chemotherapy is given in 3 weeks’ time.  Beyond this, the doses would be considered missed.     7.3.6 Subje ct Replacement  
 Only screening failure subjects will be replaced. All patients who receive any dose of study drug 
will be evaluable for safety.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 46 of 87  
  
7.3.7 Optional Single Agent Treatment  
 Subjects that have completed 18 weekly treatments (ADI -PEG 20 or placebo plus pemetrexed and 
cisplatin /carboplatin) may continue ADI- PEG 20  or placebo if they have stable disease or better  for 
up to 2 years.   7.3.8 Data Safety and Monitoring Board (DSMB)  
 A DSMB will be instituted for this study to ensure the safety of the subjects. Recommendations for 
continuation of the study will be guided by safety evaluations at safety data reviews. The committee will include two (2) independent oncologists with experience in thoracic oncology and an independent statistician. Safety meetings will be held as per the DSMB charter, approximately every 6 months and more often if deemed necessary. Decisions on study termination, amendment, or cessation of subject recruitment, based on safety or outcome findings, will be made after recommendations from the DSMB have been assessed by Polaris.  The DSMB will not be expected 
to conduct the key efficacy analyses  at the interim or final analysis .  
 7.3.9 Duration of the Study  
 Anticipated Duration of Treatment: 18 weeks - with possible extension for responding or stable disease, and stopping for progressive disease  
 Anticipated Enrollment Period: Approximately 24 months 
 
Anticipated Follow -up Period: Approximately 12  months. Thus the study is anticipated to take 
36 months to complete.  
 
7.3.10 Estimated Study  Drug Requirements  
 Study drug is as follows: ADI- PEG 20 , in the histidine -buffered formulation, will be provided as a 
sterile solution in single -dose glass vials.  
 Placebo is as follows: Placebo will be provided as a sterile solution in single -dose glass vials. Each 
vial delivers 3.5 mL of solution containing low viscosity sodium carboxymethylcellulose, PEG 3350, propylene glycol, and Tween 80. The placebo will not contain ADI, PEG 20 or succinimidyl linker.  
 It is assumed that each subject will be treate d with approximately 18 doses of either study drug or 
placebo. Some subjects will be treated for shorter duration and some for longer duration.  Thus the approximate number of vials required  for the phase 2 portion of the study is: 88 subjects 
per study arm x 2 vials per week x 18 weeks = 3168 vials of ADI-PEG 20 and an equivalent number of vials of placebo.   
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 47 of 87  
 7.3.11 Study Drug Dispensing  
 
To prepare the test article for intramuscular use, first allow the frozen vial to warm to room temperatu re and then gently swirl the solution. Remove flip-off cap and using clean  technique, 
withdraw an appropriate volume of solution into a syringe. Vials are designed for single-use only. Any test material remaining in an opened vial must not be used.  
Clinical trial material  Preparation  Administration  
Test Article  Once the agent has been thawed and 
warmed to room temperature, the appropriate amount of agent for the individual subject is to be drawn into a 
syringe and injected intramuscularly.   
Inject 
intramuscularly  
 7.3.12 Packaging and Labeling  
 Label text will be approved according to Polaris or their designee’s procedures. The drug product and placebo labels will comply with local legal and regulatory requirements and will be multi-language where appropriate. The proper storage conditions of the study drug and placebo will also be described on the medication labels.  
 The following clinical trial materials (CTM) will be used:  
• ADI-PEG 20 for IM injection  
• Placebo for IM injection  
 ADI-PEG 20 is produced by DesigneRx Pharmaceuticals, Inc. (DesigneRx), a subsidiary of Polaris. 
Placebo will be identical in appearance to the active study drug. Placebo will also be supplied by DesigneRx. The CTM is blinded.  Pemetrexed , cisplatin , and carboplatin are available through the study site pharmacy. 
 7.3.13 Study Drug Handling  
 Participating countries and sites will be provided with the CTM according to the number of patients assigned, and labeled according to local law. Once the CTM has been received, it should be kept in a safe place as directed on label . Study drug supplies must be used only for the investigation 
specified in this protocol, and study drug supplies must be accessible only to authorized staff. The investigator, or responsible person or pharmacist, as appropriate at each site must confirm the receipt of the drug supplies by signing the order form. Study drug supplies may only be administered by the investigator or the investigator’s designate. Study drug accountability must be performed every day study drug is dispensed. Used or partially used vials should be retained until use has been verified by Polaris or their designee. Documented destruction of partially used drugs and disposal of drug containers must be performed by each site. One copy of the destruction certificate must be kept by the investigator, or responsible person or pharmacist, as appropriate at 
each site, and the other copy must be sent to the Polaris representative.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 48 of 87  
 7.3.14 Study Drug Storage  
 
CTM  will be stored until use at conditions described on the label. 
 7.3.15 Study Drug Accountability and Return 
 The investigator must ensure that all drug supplies are kept in a secure locked area with access limited to those authorized by the investigator.  The investigators or appropriate designee will 
maintain a record of all study medications received and dispensed.  Records must include but not be limited to the date received, lot number, expiration date, amount received, and the disposition of all study drug.  Current dispensing records will also be maintained including the date and amount of 
drug dispensed and the subject receiving the drug.  All remaining drug not required by regulations to be held by the clinical facility must be returned to Sponsor or its representative immediately after the study is completed.  Study drug shipments will be add ressed to the Investigator’s authorized 
designee, preferably, the site’s pharmacy.  The recipient will verify the amount and condition of the 
drug and will return a signed Acknowledgment of Receipt and the temperature profile from the temperature monitor to the Sponsor.  A drug dispensing log (inventory) will be kept by the study 
site, containing at least the following:  
 
• The subject’s identification (subject number and initials) 
• Date and quantity of drug dispensed 
• Date and quantity of drug returned to the i nvestigator/pharmacy (if applicable)  
• Date and quantity of accidental loss of drug (if any) 
 
These inventories must be made available for inspection by the study monitor.  The Investigator should have access to the study drug dispensing record.  At the end of the study, the study monitor will also collect the original study drug dispensing records.  At the end of the study or as directed by Sponsor, all used and unused supplies, including partially used or empty containers, will be disposed of or transferred as instructed by Polaris, and in accordance with local written procedures, if applicable.   Any disposal or transfer of investigational 
agent shall be noted on the investigational drug disposition log and signed-off by a second person.  At the end of the study, the monitor will collect the original drug disposition logs.  7.3.16 Cross-Over 
 No crossover will be permitted.  
 7.3.17 Compliance  
 This study will be conducted in accordance with the provisions of the Declaration of Helsinki, the FDA Code of Federal Regulations, the ICH Guidelines on GCP, and local regulations as applicable. 
Before initiating the trial, the Investigator/institution should have written and dated approval from the Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) for the trial protocol, 
written informed consent  documents, and any written information to be provided to subjects.  The 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 49 of 87  
 investigator or appropriate designee will maintain a record of all study medications received and 
dispensed and also source documents for each subject in the study, consisting of case and visit notes.  
 Prior and Concomitant Therapy  
 A concomitant therapy is any drug or substance administered from administration of first dose of study drug until the last dose of study drug administered.   A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) or diagnostic assessment performed from administration of first dose of study drug until the last dose of study drug administered . No 
new concomitant therapies or procedures will be collected after the administration of last dose of study drug. If the subject is being followed for study drug related toxicity the corresponding concomitant therapy or procedure will be followed until the event is re solved or stabilized.  
 The use of concomitant therapies or procedures defined above must be recorded on the subject’s eCRF, according to instructions for e CRF completion.  AEs related to administration of these 
therapies or procedures must be documented on the appropriate e CRF.  
 All medications (prescription and non-prescription ), vitamin and mineral supplements, and/or herbs 
taken by the participant will be documented on the concomitant medication e CRF and will include 
generic (preferably) or brand name, start and stop date, dose and route of administration, and indication. Medications taken for a procedure should also be included. All non- drug therapies must 
be recorded in the respective sections of the eCRF.  
 Subject s who require oral anticoagulation with warfarin  (or other substitutions) may continue 
provided there is increased vigilance with local INR monitoring. 
 7.4.1 Non-Permitted Concomitant Therapies  
 Subjects may not  receive chemotherapy, radiation therapy (palliative radiation therapy to sites not 
repre senting PD is acceptable), or immunotherapy during the study.  Subjects may not receive 
interferon  or the vaccine for yellow fever.  
 7.4.2 Permitted Concomitant Therapies  
 At the discretion of the investigator, any drug or non-drug therapy necessary to treat any condition arising during the study, except another systemic therapy (chemotherapy) and/or radiation therapy, and/or immunotherapy.  
 Non-steroidal anti -inflammatory drugs (NSAIDs) will be avoided where possible.  Patients with 
mild to moderate renal insufficiency (creatinine clearance from 45 to 79  mL/min) should avoid 
taking, medications such as ibuprofen and aspirin (>1.3 g daily), where possible.  If necessary, they should be omitted for 2 days before, on the day of, and 2 days following pemetrexed and cisplatin administration . 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 50 of 87  
 7.4.2.1 ADI-PEG 20  
 
Routine treatment with antihistamines or corticosteroids is not recommended before ADI- PEG 20 
treatment, but may be instituted at the discretion of the treating physician if clinically necessary in  a 
patient that has experienced an allergic reaction while on ADI -PEG 20 treatment. Investigators may 
prescribe all other concomitant medications or treatments deemed necessary to provide adequate patient care. Thus corticosteroid may be given prior to pem etrexed administration (see below).  
 For management of Grade 3 or greater hyperuricemia, allopurinol therapy will be administered to subjects until serum uric acid levels have normalized and symptoms have resolved.   If the 
hyperuricemia does not respond to allopurinol therapy, uricase (rasburicase) therapy may be administered.  
 7.4.2.2 Pemetrexed and Cisplatin  
 To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration.  The corticosteroid should be 
equivalent to 4 mg of dexamethasone administered orally twice a day.  To reduce toxicity, patients treated with pemetrexed must also receive vitamin supplementation.  Patients must take oral folic acid or a multivitamin containing folic acid (350 to 1,000 micrograms) on a daily basis.  At least five doses of folic acid must be taken during the seven days preceding the first dose of pemetrexed, and dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.  Patients must also receive an IM injection of vitamin B
12 
(1,000 micrograms) in the week preceding the first dose of pemetrexed and once every three cycles 
thereafter.  Subsequent vitamin B 12 injections may be given on the same day as pemetrexed. 
 
Supportive and pre -medications to include  the following (or equivalent substitutions) or as per local 
policy: 
• Folic acid 400 mcg daily, oral 
• Hydroxycobalamin 1000 mcg IM injection  
• Dexamethasone 4 mg bd (3 doses) preceding hospital visit. Dexamethasone may also be 
administered i.v. and at a dose per local policy. 
• Anti-emetic e.g. 5HT3 antagonist, domperidone and dexamethasone 8 mg 
• Furosemide 40 mg oral once 
 8 EFFICACY ASSESSMENTS  
 
 Efficacy Parameters  
 See Section 3
.  
 8.1.1 Timing and Methods of Efficacy Assessments  
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 51 of 87  
 Overall survival will be assessed by the time from randomization until death or censoring. PFS will 
be assessed as the time from randomization until objective tumor progression or death. 
 
The Schedule of Assessments ( Section 1.4 ) lists the timing of imaging studies.  
 Subjects that miss a scheduled efficacy assessment, whether a laboratory test, clinic visit procedure or CT/MRI, should be contacted by study site personnel with the request that the subject have the missed assessment performed.  
 If clinical progression  is suspected , an efficacy assessment  (i.e. CT/MRI scan) should be performed 
at that time  and results obtained prior to removing a subject from study treatment.   
 A blinded independent central review (BICR) of the CT/MRI scans will  be established , and details 
will be provided in a separate d ocument to describe the imaging requirements and BICR process. 
 
 Appropriateness of Efficacy Assessments  
 The measures of efficacy to be used in this study reflect accepted standard of care, i.e., should be widely used and generally recognized as reliable, accurate, relevant and able to discriminate between effective and ineffective treatment agents.  
 9 SAFETY ASSESSMENTS  
 Laboratory tests, vital sign measurements, physical examinations and subject medical history will be performed to detect new abnormalities and any deterioration in pre -existing conditions.  All 
clinically significant abnormalities and deteriorations should be recorded in the eCRFs as AEs and 
graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.  Safety monitoring will be performed by the Sponsor and the CRO, if applicable, on a regular basis.  
 Vital Signs  
 
• Systolic and diastolic blood pressure using an appropriate cuff size  
• Respiration rate  
• Heart rate  
• Body temperature 
Note that any clinically significant abnormalities should  be noted in the eCRFs as AEs.  
 
 Laboratory Tests 
 Samples will be obtained for the clinical laboratory tests outlined in Table 9.2 and as per Section  1.4
 
SCHEDULE OF ASSESSMEN TS AND PROCEDURES .  
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 52 of 87  
 A central laboratory will be utilized to process and provide results for the clinical laboratory tests.  
The baseline laboratory test results for clinical assessment for a particular test will be defined as the 
last measurement prior t o the initial dose of study drug.  
 However, a local laboratory may be used as well on days of chemotherapy  administration to 
determine whether or not to give the chemotherapy .  Central laboratory samples are to be collected 
at the same time as local samples and sent in for testing.  
 Hematology and Chemistry sampling from Cycle X/Day 1 should follow the chemotherapy administration day in case of a chemotherapy dosing delay.  Clinically significant local laboratory findings that directly inform a dosing  decision will be recorded as an adverse event.  
 A central laboratory will be utilized to proce ss and provide results of blood sampling for special 
tests (pharmacodynamics [peripheral blood arginine and citrulline levels], immunogenicity [anti-ADI-PEG 20 antibodies], and pharmacokinetics [peripheral blood ADI- PEG 20 levels] ).     
  Table  9.2 Clinical Laboratory Tests  
Hematology (CBC) Serum Chemistry  
Hematocrit  
Hemoglobin Red blood cell (RBC) count White blood cell (WBC) count Absolute Neutrophil Count (ANC)  
Lymphocytes ( Absolute values ) 
Monocytes ( Absolute values) 
Basophils (Absolute values) Eosinophils ( Absolute values) 
Platelet count (estimate not acceptable)   
 Albumin  
Alkaline phosphatase Blood urea nitrogen (BUN) Calcium  
Chloride  Creatinine  
Glucose (nonfasting) 
  HCG (at screening only)  
Potassium  
Serum glutamic -oxaloacetic transaminase 
(SGOT/AST)  
Serum glutamic -pyruvic transaminase 
(SGPT/ALT)  
Sodium Total bilirubin  
Total protein  
Uric acid  
 For any laboratory test value outside the reference range that the investigator considers clinically significant:  
• The investigator may repeat the test to verify the out-of-range value. 
• The investigator will follow the out- of-range value to a satisfactory clinical resolution or 
stabili zation.  
• A laboratory test value that requires a subject to be discontinued from the study or requires a 
subject to receive treatment will be recorded as an AE.  
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 53 of 87  
 Special Blood Sampling  
 
Arginine, citrulline , anti -ADI-PEG 20 antibody, and ADI -PEG 20  levels, as well as future research 
will be obtained at the times (before  ADI-PEG 20 injection) noted in Section 1.4 . 
 Special blood sampling should follow calendar days; do not adjust for changes in dosing schedule.  
 ECG  
 ECG and QTcF collection will also be determined.  If the week 4 or week 12 ECG collection 
timepoint is missed due to dosing being delayed or withheld, the ECG should be collected at the 
next visit. 
 
 Physical Examination  
 
A comprehensive physical examination, including height and weight, will be performed at the screening visit.  Physical examination will be performed on Day 1 of every cycle and at other times 
as clinically indicated.  If weight varies by >10%, the BSA and dose s should be recalculated.  Any 
clinically significant findings or absence of findings relative to each subject’s physical examination 
will be carefully documented in the subject’s AE eCRF.  Symptom directed examinations may be 
performed more frequently  at the discretion of the investigator.  
 
 Adverse Events  
 An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product and that does not necessarily have a causal relationship with 
the treatment.  An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.  
 Note: The definition above, provided for in the GCP -ICH Guideline E6, is being extended for the 
purpose of Polaris studies to include any events, intercurrent diseases and accidents observed while the subject is on study, i.e., during the actual treatment period, as well as during drug- free, pre  and 
post- treatment periods.    
 Subjects will be monitored throughout the study for AEs and every effort must be made to remain alert to possible AEs.  At the signing of the ICF, each subject should be given the names and contact information of appropriate  study site staff for the reporting of AEs and medical emergencies.  
 For description of a Serious Adverse Event (SAE), see Section 9.5.7
. 
 9.5.1 Assessment of Adverse Events – Relationship to Study Drug  
 The relationship of all serious and non- serious adverse events to the investigational agent(s) will be 
determined by the Investigator on the basis of their clinical judgment, using 1 of the following terms 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 54 of 87  
 (in accordance with FDA Guidance for Industry and Investigators, “ Safety Reporting 
Requirements for INDs and BA/BE Studies” released December 2012 ): 
 
• Definitely related (There is clear evidence to suggest a causal relationship and other possible 
contributing factors can be ruled out.) 
• Probably related (There is evidence to suggest a causal relationship and the influence of other 
factors is unlikely.)  
• Possibly related (There is some evidence to suggest a causal relationship (e.g. because the event 
occurs within a reasonable time after administration of the trial medication).   However, the 
influence of other factors may have contributed to the event (e.g. the patient’s clinical condition, other concomitant treatments).) 
• Unlikely related (There is little evidence to suggest there is a causal relationship (e.g.  the event 
did not occur within a reasonable time after administration of the trial medication).   There is 
another reasonable explanation for the event (e.g. the patient’s clinical condition, other concomitant treatment).)  
• Unrelated (There is no evidence of any causal relationship)  
 The Investigator must assess the causality of all serious adverse events/reactions to ADI -PEG 20, or 
to pemetrexed or to cisplatin, or to a combination of any or all three in relation to the trial treatment 
according to the definition given.  Note: Information provided in the Investigator’s Brochure may support these evaluations.  9.5.2 Recording of Adverse Events 
 Any medical sign or symptom a subject may experience post ICF and before first administration of study treatment should be recorded as part of patient medical history . Assessment of progressive 
disease is an endpoint of the study and would not typically be recorded as an AE.  Adverse events are to be recorded on the AE page of the e CRF. Severity of all AEs will be graded 
according to the CTCAE scale (Version 4.0 3).  Disease progression is to be recorded on specific 
tumor assessment pages rather than the AE page of the eCRF.  
 Adverse events will be recorded from administration of first dose of study drug  until 30 days after 
last study drug administration.  If any toxicity or medical sign or symptom a subject may experience post signing of ICF meets the definition of Serious Adverse Event (SAE) per S ection  9.5.7
 they 
must be reported as an SAE per Section 9.5.8  
 Action taken with study treatment (study drugs) as a result of the AE will be categorized as dose 
increased, dose not changed, dose reduced, drug interrupted, and drug withdrawn, not applicable, and unknown.  Action taken to treat the event will be categorized as none, medication, surgical/diagnostic procedure, hospitalization, other, and withdrawal from study.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 55 of 87  
 Event outcome at resolution or time of last follow -up will be recorded as event resolved , resolved 
with sequelae, resolving, not resolved, fatal, and unknown. 
 9.5.3 Following Adverse Events  
 Adverse events related to ADI -PEG 20  that were still ongoing at End-of- Treatment visit should be 
followed up until resol ution or stabilization or until all attempts to determine resolution of the event 
are exhausted.  
 The investigator should use his/her discretion in ordering additional tests as necessary to monitor the resolution of such events.   Note: All follow -up information pertaining to SAEs must be forwarded to Polaris designee within 
24 hours of receipt.  9.5.4 Discontinuation due to Adverse Events  
 Subjects may be withdrawn from the study at any time.  Subjects withdrawn from the study due to an AE, whether serious or non- serious, must be followed by the Investigator until the clinical 
outcome from the AE is determined.  Any subject who experiences an AE may be withdrawn at any 
time from the study at the  discretion of the Investigator.   The AE(s) should be noted on the 
appropriate eCRFs and the subject’s progress should be followed until the AE is resolved.  The Polaris medical monitor must be notified.  If the AE may relate to overdose of study treatment, the 
Investigator Brochure should be consulted for details of any specific actions to be taken.  
9.5.5 Pregnancy  
 
Although pregnancy itself is not considered an adverse event or a serious adverse event, pregnancy should be reported as “Information” (not as an “Adverse Event” or “Other Problem or Event”).  
 Pregnancy does not have to be reported if the subject has entered study  follow-up period and 
conception occurred 30 days after the final dose of study drug administration .   
 Pregnancy Notification and Outcome Form will be provided to the investigational site to assist in reporting of the pregnancy and follow-up information to Polaris.  A subject that becomes pregnant will be discontinued from the study.    The pregnant subject or the partner of a male subject should be followed until termination or to 
partum to ensure absence of congenital anomaly or birth defect that may have resulted from maternal exposure or transmission of the study drug via semen following paternal exposure.  A congenital anomaly or birth defect should be promptly reported as a SAE  per Sections 9. 5.7
 and 
9.5.8 . 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 56 of 87  
 Investigators should advise all subjects to use a highly effective method of birth control to protect 
the health and safety of the mother and/or child .  Investigators should repor t the pregnancy of a 
subject or a subject’s partner to their IRB/IEC per IRB/IEC  guidelines.   In addition, Investigators 
should follow IRB/IEC  guidelines for consenting pregnant partners of study subjects in order to 
obtain pregnancy follow up information. 
 9.5.6 Post-treatment  Adverse Events 
 Adverse events that are identified at the last assessment visit (or the early termination visit) must be recorded on the  AE eCRF with the status of the AE noted. AEs that are related to ADI -PEG 20  
should be followed until resolution or deemed stable by the investigator.  All events that are 
ongoing at this time will be recorded as ongoing on the e CRF. Serious adverse events  will follow 
the SAE procedures specified.  
 9.5.7 Serious Adverse Events 
 Subjects will be monitored throughout the study for SAEs.  An SAE is any untoward medical occurrence that at any dose: 
1. Results in death,  
2. Is life -threatening*, 
3. Requires inpatient hospitalization or prolongation of existing hospitalization**, 
4. Results in persistent or significant disability or incapacity,  
5. Is a congenital anomaly/birth defect,  
6. Is another medically important condition***.  
*The term “ life-threatening ” in the definition of “ serious” refers to an event in which the subject is 
at risk of death at the time of the event; it does not refer to an event, which hypothetically might 
have caused death if it were more severe.  
 **The following are not considered SAEs in this Polaris sponsored clinical study:  
• A visit to the emergency room or other hospital department < 24 hours that does not result in 
admission (unless considered “important medical event” or event life -threatening).  
• Elective surgery, planned prior to signing study consent. 
• Medical/surgical hospital admission for purpose other than remedying an ill health state and 
was planned prior to entry into the study.  Appropriate documentation is required in these 
cases.  
• Routine health assessment requiring hos pital admission for baseline/trending of health status 
(e.g., routine colonoscopy). 
• Hospital a dmission encountered for another life circumstance that carries no bearing on health 
status and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, care -giver respite, family circumstances, administrative).  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 57 of 87  
 • Hospital a dmission  or other medical occurrences (such as prolonged hospitalization or death) 
for adverse events due to the malignant disease under study (including associated signs and 
symptoms of disease progression) . Changes in disease are reported separately.  
• Hospital a dmission for study biopsies. 
 
***Medically important conditions that may not result in death, be immediately life-threatening or require hospitalization may be considered as SAE when, based upon appropriate medical judgment, they may jeopardize the subject or may require intervention to prevent one of the outcomes listed in the definition above.  Examples of such events are intensive treatment in an emergency ro om or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization; or development of drug dependency or drug abuse. 
 Note: The term “severe” is often used to describe the intensity (severity) of an event (such as: mild, 
moderate, or severe, e.g., pain).  The event itself may be of relatively minor medical significance (such as severe headache).  This is not the same as “serious”, which is based on subject/event 
outcome or action criteria usually associated with events that pose a threat to subject’s life or vital functions.  Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  A suspected unexpected serious adverse reaction (SUSAR) is defined as an untoward and unintended response to a study drug, which is not listed is the applicable product information, and meets one of the above listed serious criteria.  
 9.5.8 Reporting Serious Adverse Events  
 Any Serious Event that is reported or observed that occurs from the time that the subject has signed informed consent form until 30  days after the final dose of study treatment regardless of the severity 
of the event or its relationship to study treatment must be reported to the  Polaris designee within 
24 hours of the study site staff becoming aware of the event.   Thereafter, serious events should only 
be reported if the Investigator considers it possibly related or related to study treatment.  
 A report mus t be submitted to the Polaris designee regardless of the following:
 
• whether or not the subject has undergone study- related procedures  
• whether or not subject has received study treatment  
• the severity of the event  
• the relationship of the event to study treatment  
 A serious pre- treatment event is any event that occurs post ICF and prior to first administration of 
study treatment that meets the criteria for SAE.  A serious pre -treatment event should be recorded as 
medical history and the study site needs to con tact Polaris designee within 24 hours of site study 
becoming aware of serious pre- treatment event.  
 All initial and follow -up information pertaining to SAEs must be forwarded to Polaris  designee 
within 24 hours of study site staff  becoming aware of serious adverse event .  SAE s will be reported 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 58 of 87  
 using either paper or electronic forms and the sites will be provided with instructions at the time of 
study initiation.  
 
SAE Report ing guidelines will be provided to the investigational site to assist in collecting, 
organizing, and reporting SAEs and follow- up information.  
 All SAEs should be followed to their resolution, with all SAE related documentation such as 
doctor’s notes, hospital discharge  summary, etc. provided to Polaris  designee in a timely manner.   
 SAEs will be reported to all applicable Regulatory Authorities as noted in 21 CFR 312.32(c).  The Sponsor will also comply with  responsibilities and requirements concerning SAE/ SUSAR 
reporting established in  the European Directive 2001/20/EC. 
 
 Appropriateness of Safety Assessments  
 Safety evaluations selected for this study are typical of those for this subject population and utilize widely accepted measures.  
 10 PHARMACODYNAMIC, PHARMACOKINETIC, IMMUNOGENICITY AND OTHER ASSESSMENTS  
 
 Pharmacodynamic P arameters 
 Approximately 10 mL  of peripheral blood will be collected as plasma prior to ADI- PEG 20  or 
placebo  dosing and used for pharmacodynamics , pharmacokinetics  and immunogenicity studies.   
 Pharmacodynamics will be assessed by measurement of peripheral blood levels of arginine and citrulline by LCMS.  
 
 Immunogenicity Parameters  
 Immunogenicity will be assessed for all patients from the ADIPemCis arm by measureme nt of 
perip heral blood antibodies to ADI-PEG 20. Blood will also be available for testing for anti- PEG 
antibodies.  
 Pharmacokinetics  
 Pharmacok inetics will also be determined for all patients from the ADIPemCis arm.   
 
 Exploratory Research  
 
Additional translational research, including pharmacogenomics and profiling the inflammatory and 
metabolomic effects of ADI -PEG 20 in combination with pemetrexed and cisplatin is now planned. 
This research will be conducted on existing plasma samples from subjects in the US and UK who 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 59 of 87  
 have consented to their blood samples being used in future research. Also, research will be 
conducted on archival tissue from subjects at selected sites in the UK who have consented to their tissue samples being used in future research.  
 11 STATISTICAL CONSIDERATIONS  
 Detailed procedures for statistical analyses to be performed for this study will be provided in a separate Statistical Analysis Plan that will be finalized prior to the final database lock.  Any changes 
to the protocol- specified or SAP -specified planned ana lyses that are made after the database lock 
will be described in the clinical study report.  
 This study will employ an adaptive design with two interim analys es to be conducted at the end of 
the Phase 2 portion and when  50% of planned OS events for phase 3 have occur red.  These two 
interim analyses will be performed by an Independent Analysis Group.  The decision rules  and 
analysis strategies that will be applied at the interim and final analyses are described in the SAP .   
   
 Statistics  and Sample Size Considerations  
 
The sample size calculation for the efficacy  endpoint RR assumed that the objective response rate in 
the PlaceboPemCis arm was 15%.  A total sample size of 176 subjects ( 88 per arm)  in the phase 2 
portion of the study will provide appro ximately  87% power to detect an improvement in the RR 
from 15% to 35% at the interim analysis . 
 
The sample size calculation for the phase-3 primary endpoint (OS) assumed that the median OS was 6 months in the PlaceboPemCis arm.  Assuming a median OS of 8.4 months in the ADIPemCis arm 
(corresponding to a HR of 0.714), 338 OS events will provide power of approximately 87% for the 
OS analysis.  Assuming uniform accrual over a 24-month period and a total study duration of 36 
months, the planned total sample size in the study was 386 subjects. The target number of events may be increased at the second interim analysis, which will affect the total nu mber of patients.  
 
 Analysis Populations  
 The following patient populations will be used in the analysis of efficacy and safety data:  The Intent- to-Treat (ITT) population will contain all randomized patients.  All analyses using the 
ITT population will group patients according to the randomized treatment, regardless of the treatment received during the course of the study. The ITT population will be used in the analysis of the efficacy endpoints.  
 The Per -Protocol (PP) population will include all ITT subj ects who have no major protocol 
violations that may potentially affect the primary and secondary efficacy measures (e.g., no MPM, no measurable disease).  Subjects to be excluded fr om the PP Population will be determined prior to 
database lock and prior to breaking the blind of the treatment group assignments.  The major protocol deviation criteria will be specified in the SAP and finalized as part of the blinded data review prior to the final database lock.  Assignment of subjects to treatment group is bas ed on the 
randomized treatment assignment.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 60 of 87  
  
The Safety Analysis (SA) population will contain all patients who received at least one dose of the study medication . All analyses using the SA population will group patients according to the 
treatment actually received. All safety analyses will be based on this population.   
 
 Demographics and Baseline Characteristics  
 The number of patients who have been randomized, have received at least one dose of the study medication and have completed the clinical trial according to the protocol will be summarized.  The 
number of patients that discontinue the treatment or the study, as well as the reasons for discontinuation, will be summarized.  In addition, summary tables with descriptive statistics will be generated fo r demographics, baseline characteristics and relevant disease characteristics and history 
by the treatment arm in the ITT population. 
 
 Safety Analysis  
 
11.4.1 Adverse Events  
 Adverse events will be graded using the NCI CTCAE (version 4.03), which provides a mechanism for grading the severity of the adverse event.  Treatment Emergent Adverse Events (TEAEs) include all adverse events that start on or after the first dose of study medication, or adverse events that are present prior to the first dose of study medication, but their severity or relationship increases after the first dose of study medication up to and including 30 days after the final study medication dosing date.  
The number and percent of subjects with any TEAEs will be displayed by system organ class and 
preferred term for each treatment group.  Within each preferred term, subjects will be counted only once if they had more than one event reported during the treatment period.  The same summary will be performed for all serious TEAEs and all TEAE s causing discontinuation of study drug.  
 TEAEs will also be summarized by greatest reported severity grade (Grades 1 -5) for each event 
preferred term.  Counts indicate subjects reporting one or more TEAEs that map to the severity grade classification for  each preferred term.  At each level of summarization (system organ class or 
event preferred term) subjects are only counted once.  TEAEs will be summarized by greatest reported relationship in a similar manner.  
 A listing will be produced for all subjects  who reported serious TEAEs or who discontinued study 
medication due to TEAEs.  All TEAEs will be listed individually by subject.   
 Formal toxicity monitoring will occur, as described in Section 9
, Safety Assessments . Laboratory 
tests, ECGs, vital sign measurements, physical exams and patient interviews will be performed to 
detect new abnormalities and deteriorations of any pre -existing conditions.  All clinically significant 
abnormalities and deteriorations should be recorded in the Case Report Forms as Adverse Events and graded according to the NCI CTCAE v4.03.  All subjects who received at least one dose of 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 61 of 87  
 ADI-PEG 20 will be evaluated for safety and tolerability.  Appropriate summaries of AEs, and 
laboratory data.  AEs will be listed individually per patient according to CTCAE version 4.03, and 
the number of patients experiencing each AE will be summarized using descriptive statistics.  
 
 Efficacy Analysis  
 11.5.1 Primary Efficacy Endpoint s 
 The number and percent of patients responding, measured by modified RECIST for MPM and RECIST 1.1 criteria, as applicable, will be summariz ed by treatment group.  The analysis of RR 
will be conduct ed at the end of the phase 2 portion, after adequate response assessment  of the 
first176 subjects enrolled .  The treatment groups will be compared using the Cochran- Mantel -
Haenszel (CMH)  test, stratified by tumor histology  (biphasic versus sarcomatoid) . The significance 
level and coverage probability to be used in the RR analysis will be base d on alpha=0.05 (two -
sided).   The primary analysis of OS will be performed at the final analysis.  The treatment effect on OS will 
be evaluated  using the stratified log -rank test (stratified by tumor histology ). The significance levels 
to be used in the OS analysis at the final analyses will be based on α=0.05 (two- sided) . 
 11.5.2 Key Secondary Efficacy Endpoints  
 The key secondary objective of the phase 2 portion ( DOR) will be analyzed at the end of the phase 
2 portion.   
The key secondary endpoint for the phase 3 portion is PFS, which  will be analyzed only if the 
analysis of OS is statistically significant at the final analysis , with alpha level of 0.05 (two- sided) 
using the same statistical methodologies as applied to OS.     
 
 Multiplicity Adjustment 
 
Details are described in the SAP.   
 
 Interim A nalysis 
 This study will include two separate interim analyses:  
• The first interim analysis will be conducted at th e end of the phase 2 portion, after adequate 
response assessment  of the first 176 subjects enrolled.  This interim analysis will evaluate 
the treatment effect on RR in the ITT population.  
• The second interim analysis will be performed once 50% of the planned OS e vents for phase 
3 have occurred (ie, 169 of the 338 planned OS events). This interim analysis will evaluate OS in the ITT population in an unblinded manner.  
 The RR data will be analyzed at the end of phase 2 portion to support accelerated approval.  The OS 
data at the second interim analysis will be analyzed to support the following decisions: 
• Futility stopping: Terminate the study due to futility  at the interim analysis. 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 62 of 87  
 • Sample size re- estimation: Increase the target number of OS events after the second interim 
analysis. 
 
The decision -making rules associated with these decisions are described in the SAP.  
 A DSMB will be instituted for this study to ensure the safety of the subjects. Recommendations for continuation of the study will be guided by safety evaluations at safety data reviews. The committee will include two independent oncologists with experience in thoracic oncology and an independent statistician. Safety meetings will be held as per the DSMB charter, approximately every 6 mon ths 
and more often if deemed necessary. Decisions on study termination, amendment, or cessation of subject recruitment, based on safety or outcome findings, will be made after recommendations from the DSMB have been assessed by Polaris. The DSMB will not be expected to conduct the efficacy analyses at the interim or final analyses.  
 In addition to the explicit adjustment of the target number of OS events based on an unblinded interim analysis described above, the number of enrolled patients may be adjusted in a blinded manner to achieve the desired number of OS events.  This will be accomplished using standard event forecasting methods (see, for example, Anisimov 2011).  
 Pharmacodynamics 
 Blood levels of arginine and citrulline will be summarized descriptive ly for each group and for all 
subjects by time point for the observed value.   
 Immunogenicity  
 Blood levels of antibodies to ADI- PEG 20 will be summarized descriptively for each treatment 
group and for all subjects by time point for the observed value as w ell as for the change from 
baseline value.   
 
  Pharmacokinetics  
 Pharmacokinetics will also be summarized descriptively for each group and for all subjects by time by time point for the observed value.  
 
12 ETHICS  
 
 Institutional Review Board  / Independent Ethics Committee  
 
The investigator will ensure that the protocol and consent form are reviewed and approved by the appropriate Institutional Review Board/Independent Ethics Committee (IRB/IEC) prior to the start of any study procedures.  The  IRB/IEC will be appropriately constituted and will perform its 
functions in accordance with Food and Drug Administration (FDA) regulations, International 
Conference on Harmonisation (ICH) good clinical practice (GCP) guidelines, and applicable local 
regulatory requirements as applicable.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 63 of 87  
 In addition, the IRB/IEC will approve all protocol amendments (except for logistical or 
administrative changes), written informed consent documents and document updates, subject recruitment procedures, written information  to be provided to the subjects, available safety 
information, information about payment and compensation available to subjects, the investigator’s curriculum vitae and/or other evidence of qualifications, and any other documents requested by the IRB/IEC a nd regulatory authority as applicable.  
 
 Ethical Conduct of the Study  
 This study will be conducted in accordance with the Declaration of Helsinki and GCP according to ICH guidelines. Specifically, this study is based on adequately performed laboratory and animal experimentation; the study will be conducted under a protocol reviewed by an IRB or IEC; the study will be conducted by scientifically and medically qualified persons; the benefits of the study are in proportion to the risks; the rights and welfare of the subjects will be respected; the physicians 
conducting the study do not find the hazards to outweigh the potential benefits; and each subject will give his or her written, informed consent before any protocol- driven tests or evaluations are 
performed . 
 
 Informed Consent  
 The nature and purpose of the study will be fully explained to each subject.  Written informed consent must be obtained from each subject prior to any study procedures being performed.  The consent documents to be used for the study will include all the required elements of informed consent per regulatory requirements and will be reviewed and approved by the appropriate IRB/IEC before use. 
 
 Changes to Protocol 
 
Only Polaris may modify the protocol.  Amendments to the protocol will be made only after 
consultation and agreement between Polaris and the investigator.  The only exception is when the investigator assesses a subject’s safety will be compromised without immediate action.   In these 
circumstances, immediate approval of the chairman of the IRB/IEC must be sought, and the investigator should inform Polaris and the full IRB/IEC within 5 working days after the emergency occurred.  All amendments that have a significant impact on subject risk or the study objectives, or require revision of the informed consent forms , must receive approval from the IRB/IEC prior to 
their implementatio n. 
 13 STUDY MONITORING  
 
 Data Reporting and Electronic Case Report Forms  
 The investigator will permit the site monitor to review study data as frequently as is deemed necessary to ensure data is being recorded in an adequate manner and protocol adherence is satisfactory. The investigator will access medical records for the monitor to verify eCRF entries. The investigator, as part of his or her responsibilities, is expected to cooperate with the Sponsor/designee in ensuring the study adheres to GCP requirement s. The investigator may not 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 64 of 87  
 recruit subjects into the study until an initial visit, or, with the agreement of Sponsor, attendance at a 
site initiation visit has been made by the Sponsor/designee to conduct a detailed review of the protocol and eCRFs.    13.1.1 Pre-Study Requirements  
 
The following is required before study drug can be shipped to the study site: 
• Signed Statement of Investigator  
• Regulatory Approval (e.g., active IND or IMPD) 
• Ethics Committee approval of Protocol and Informed Consent Forms 
• Executed Clinical Trial Agreement (if applicable) 
 
13.1.2 Study Master Files  
 The Investigator must retain a Sponsor-specified comprehensive and centralized filing system (“Study Master File”) of all study -related documentation that is suitable for inspection by Polaris 
and regulatory authorities.  Upon completion of the study, the Investigator is required to submit a summary report to Sponsor at the discretion of the Sponsor.  The Investigator must arrange for the retention of the Study Master File for a period of time determined by Sponsor.  No part of the Study Master File shall be destroyed or relocated without 
prior written agreement between Sponsor and the Investigator.  13.1.3 Study Records  
 The study documents must be maintained as specified in the ICH guidelines for GCP and as required by the applicable regulatory requirements.  The investigator/institution should take measures to prevent accidental or premature destruction of these documents.  
 Essential documents should be retained until at least 2 years after the last ap proval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product.  These documents should be retained for a longer period, however, if required by the applicable regulatory requirements or by an agreement with Sponsor.  It is the responsibility of Sponsor to inform the investigator/institution as to when these documents no longer need to be retained.  13.1.4 Electronic Case Report Forms ( eCRFs)  
 An electronic data capture system will be used for this trial. Instructional materials will be provided to the sites as appropriate. The investigator and site staff will ensure all data from subject visits are promptly entered into the electronic Case Repo rt Forms (eCRFs) in accordance with study specific 
eCRF completion guidelines. The investigator must approve the eCRFs within the electronic system to verify the integrity of the data recorded.  
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 65 of 87  
 A list of the normal ranges for all laboratory tests to be u ndertaken forms part of the documentation 
to be collated prior to trial start. If a central laboratory has been selected to conduct any or all tests, 
it is essential all samples be analyzed at that laboratory. The investigator must maintain source documents such as laboratory reports and complete history and physical examination reports.   
 Access to Source Data/Documents  
 The investigator will provide direct access to source data and documents to individuals conducting study-related monitoring, audits, IRB/IEC review, and regulatory review.  The investigator must inform the study subject that his/her study- related records m ay be reviewed by the above 
individuals without violating the subject’s privacy of personal health information.  
 
 Confidentiality  
 Attention is drawn to the regulations promulgated by the FDA under the Freedom of Information Act providing, in part, that information furnished to clinical investigators and IRBs/IECs will be kept confidential by the FDA only if maintained in confidence by the clinical investigator and IRB/IEC.  By signing this protocol, the investigator affirms to Sponsor that the investigator will 
maintain, in confidence, information furnished to him by Sponsor and will divulge such information to the IRB/IEC under an appropriate understanding of confidentiality with such board.  
 Retention of Data  
 All records and documents pertaining to the study will be maintained by the investigator for a period of: (a) 2 years after approval of the drug; (b) 5 years after non-approval of the NDA or 
ANDA; or (c) 2 years after withdrawal of the IND under which this study was conducted.  In order to avoid any possible errors, the investigator will contact Sponsor prior to the destruction of any study records.  The investigator will promptly notify Sponsor in the event of accidental loss or destruction of any study records.  
 Quality Control and Quality Assurance  
 Sponsor/designee will implement and maintain quality control and quality assurance procedures with written standard operating procedures to ensure the study is conducted and data are generated, 
documented, and reported in compliance with the protocol, GCP, and applicable regulatory requirements.  This study will be conducted in accordance with the provisions of the Declaration of 
Helsinki and all revisions thereof (Tokyo 2004), and in accordance with the FDA Code of Federal Regulations (CFR §312.50 and §312.56) and the ICH (E6) Guidelines on GCP (CPMP/ICH/135/95and the provisions of the EU Clinical Trial Directives 2001/20/EC and 2002/20/EC.   14 ADMINISTRATIVE INFORMATION 
 
 Financing and Insurance  
 These issues will be addressed in a separate agreement between Sponsor and the investigator. 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 66 of 87  
  
 Publication Policy  
 
Sponsor will retain ownership of all data.  All proposed publications based on this study will be subject to Polaris’s approval requirements.  
 Any and all data and results and intellectual property rights in the data and results derived from this study are the property of Sponsor.  Sponsor may utilize the data in a variety of ways, including but not limited to submission to government regulatory agencies/authorities or disclosure to other investigators.  An investigator in this study, while free to utilize data derived from the study for scientific purposes, must discuss any publication with Sponsor prior to release and obtain written consent of Sponsor on and for the intended publication.  Sponsor recognizes the right of the investigators to publish the results upon the completion of the study.  However, the investigator(s) must send a draft manuscript of the intended publication or abstract to Sponsor thirty (30) days in advance of submiss ion in order to obtain the approval of Sponsor prior to submission of the final 
version for intended publication.  This draft will be reviewed promptly and approval will not be withheld unreasonably.  In case of a difference of opinion between Sponsor and the investigator(s), the contents of the draft will be discussed in order to find a solution which satisfies both parties.  
 Protocol A mendments  
 Protocol amendments may be implemented only after approval by the Investigator, Sponsor, IRB/IEC and, if requir ed, the regulatory authorities.  Amendments that are intended to eliminate an 
apparent immediate hazard to subjects may be implemented prior to such approvals.  However, in 
this case, approval must be obtained as soon as possible after implementation.  Implementation of 
administrative amendments that do not affect the safety of the subjects do usually not require prior IRB/IEC approval, just notification, unless otherwise required by local ethics committees.   
 
 Premature Trial T ermination  
 Sponsor and Investigator have the right to prematurely terminate the study.  In such case, one party 
must notify the other in advance in writing about the intent of and the reasons for the termination.  The investigator must also notify the appropriate IRB/IEC accordingly.  
 Language 
 The protocol is written in English.  All correspondence between the study site and Sponsor should be maintained in English.  Case Report Forms must be completed in English.  All written material to be used by subjects and para- clinical staff must use vocabulary that is clearly understood, and be 
in the language appropriate for the study site.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 67 of 87  
 15 REFERENCES  
 
Allen M, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Joel S, Chmielewska- Kassasir M,  Tomlinson I, Roylance R, Whitaker HC, Warren 
AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crooke T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW. 2014. Prognostic and therapeut ic impact of argininosuccinate synthetase 1 control in bladder cancer as 
monitored longitudinally by PET imaging. Cancer Res74:896-907.  Amatuximab -Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed 
and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS). [STUDY_ID_REMOVED].ClinicalTrials.gov accessed 19 July 2015.  Allen TC. 2005. Rec ognition of histopathologic patterns of diffuse malignant mesothelioma in 
differential diagnosis of pleural biopsies. Arch Pathol Lab Med 129:1415-1420.  Anisimov V. 2011. Predictive event modelling in multicentre clinical trials with waiting time to response. Pharmaceutical Statistics 10:517 -522. 
 Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottiano A, Izzo F, Melucci MT, Beneduce G, De Rosa V, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF. 2005. Pegy lated arginine deiminase treatment of patients with 
metastatic melanoma: results from phase I and II stud ies. J Clin Oncol 23:7660-7668. 
 Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines Committee. 
2015. Malignant pleural mesoth elioma: ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow-up. Ann Oncol 26 Suppl 5:v31-v39. 
 Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD. 2015. Demographics, management and survival of patients with malignant pleural mesothelioma  in the National Lung 
Cancer Audit in England and Wales. Lung Cancer 88:344-3448.   Benn is Y1, Savry A, Rocca M, Gauthier-Villano L, Pisano P, Pourroy B. 2014. Cisplatin dose 
adjustment in patients with renal impairment, which recommendations should we follow?  Int J Clin 
Pharm 36:420-429.  Blayney JK, Ceresoli GL, Castagneto  B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, 
Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA. 2012. Response to chemotherapy is predictive in relation to longer overall survival in an 
individual patient combined -analysis with pleural mesothelioma. Eur J Cancer 48:2983 -2992. 
 Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA,  
Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S. 2016. Comprehensive genomic 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 68 of 87  
 analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing 
alterations.  Nat Genet 48 :407-416. 
 
Byrne MJ, Nowak AK. 2004. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.  Ann Oncol15:257–260.  Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del 
Conte G, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A. 2008. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.  Br J Cancer 99 :51-56. 
 Cheng PNM, Lam TL, Lam WM, Tsui SM, Cheng AWM, Lo WH, Leung YC. 2007. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma thro ugh arginine depletion. Cancer Res 67:309–317.  
 Cisplatin - Product Label. 1999. Bristol- Myers -Squib. 
  Corson JM. 2004. Pathology of mesothelioma. Thorac Surg Clin 14:447-460.  Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA. 2003. Regression of hepatocellular carcinoma in a patient treated with arginine deiminase.  Hepato -Gastroenterology 50:1208-1211. 
 Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. 2015. Treatment patterns and survival analysis in 9014 patients w ith malignant pleural mesothelioma from 
Belgium, the Netherlands and England. Lung Cancer 89:212-217. 
 
Daylami R, Muilenburg DJ, Virudachalam  S, Bold RJ. 2014. Pegylated arginine deiminase 
synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. J Exp Clin Cancer Res 33(1):102.  
 Delage B, Luong P, Maharaj L, O’Riain C, Syed N, Crook T, Hatzimichael E, Papoudou- Bai A, 
Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, Szlosarek PW. 2012. Promoter methylation of argininosuccinate synthetase -1 sensitises 
lymphomas to arginine deiminase treatment, autophagy and ca spase-dependent apoptosis. Cell 
Death Dis; Jul 5;3:e342. doi: 10.1038/cddis.2012.83.  Delage B, Sheaff M, López-Ríos F, Cawkwell L, Lind M, Fennell D, Crook T, Lemoine N, Szlosarek P. 2008. Argininosuccinate synthetase expression and survival outcome in pa tients with 
malignant mesothelioma: molecular analysis and therapeutic implications. Abstract 124. Presented at the International Mesothelioma Interest Group Meeting, Amsterdam, Netherlands.  
 Dillon BJ, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA. 2002. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med Sci Monit 8:BR248-253.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 69 of 87  
 Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. 2004. 
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100: 826-833.  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuch S, 
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. 2009. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247.  Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. 2002. Pegylated arginine deiminase (ADI- SS 
PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.  Cancer Res 62:5443-5440.  Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. 2016. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw 14 :825-836. 
 Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, van Meerbeeck J. 2008.  Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5:136 -147. 
 Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rogers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N. 2012.  Negative argininosuccinate 
synthetase expression in melanoma tumours may predict clinical benefit from arginine -depleting 
therapy with pegylated arginine deiminase. Br J Cancer 106:1481-1485. 
 Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. 2008. Arginine deprivation as a targeted therapy cancer. Curr Pharm Des 14:1049-1057.  Francart J, Vaes E, Henrard S, Legrand C, Baas P, Gaafar R, van Meerbeeck JP, Sylvester R, Robert A.  2009. A prognostic index for progression- free survival in malignant mesothelioma with 
application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 
45:2304-2311.  
 Fu S, Nguyen E, Janku F, Subbiah V, Patel SP, Falchook GS, Zinner R, Tsimberidou AM, Hong DS, Piha -Paul SA, Wheler JJ, Shi N, Bomalaski JS, Hwu P, Meric -Bernstam F. 2014. Targeting 
argininosuccinate synthetase -deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus 
cisplatin. J Clin Oncol 32 (suppl; abstr 2563) presented at the Annual Meeting of the American Society of Clinical Oncology.  Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 70 of 87  
 Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, 
Girard N. 2018. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference 
Center.  J Thorac Oncol  13:1189-1203. 
 Galetta D, Catino A, Misino A, Logroscino A, Fico M. 2016. 
Sarcomatoid mesothelioma: future 
advances in diagnosis, biomolecular assessment, and therapeutic options in a poor -outcome disease. 
Tumori. 2016 Mar- Apr; 102(2):127-30.  
 Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F. 2010. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28:2220 -2226. 
 Haines RJ, Pendleton LC, Eichler DC. 2011. Argininos uccinate synthase: at the center of arginine 
metabolism. Int J Biochem Mol Biol 2:8 -23. 
 Hasan B, Greillier L, Pallis A, Menis J, Gaafar R, Sylvester R, Fennell DA, Baas P, Surmont V, Van Meerbeeck JP, O'brien ME. 2014. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and  an independent study validation. Eur J Cancer 50:2771-2782. 
 Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK. 2018. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other 
gastrointestinal malignancies. Cancer Chemother Pharmacol 82:429 -440. 
 
Holcenberg JS. Enzymes as drugs. 1977. Ann Rev Pharmacol Toxicol 17:97-116.  Holtsberg  FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA.  2002. Poly(ethylene glycol) 
(PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.  J Control Release 80:259-271.  Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, Li SH, Hung HC, Yu SC, Lan J, Shiue YL, Hsing CH, Chen LT, Li CF. 2013. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therape utic relevance. Clin Cancer Res 19:2861-2872. 
 Husson A, Brasse-Lagne C, Fairand A, Renouf S, Lavoinne A. 2003. Argininosuccinate synthetase from the urea cycle to the citrulline –NO cycle. Eur J Biochem 270:1887-1899. 
 Izzo F, Marra P, Beneduce G, Castello  G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg 
FW, Bomalaski JS, Clark MA, Ng C, Curley SA.  2004.  Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma:  results from phase I/II studies.  J Clin Oncol 22:1815-1822.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 71 of 87  
 Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, 
Holtsberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F, Korba BE. 2007. Pegylated arginine deiminase lowers hepatitis C viral titers and inhib its nitric oxide synthesis. J 
Gastroenterol Hepatol 22:86-91.  Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. 2010. Malignant mesothelioma. Intern Med J 40:742-750.  Kelland L. 2007. The resurgence of platinum- based cancer chemotherapy. Nat Rev Cancer 7:573-
584.  Kenny GE, Pollock ME. 1963. Mammalian cell cultures contaminated with pleuropneumonia- like 
organisms. I. Effect of pleuropneumonia- like organisms on growth of established cell strains. J 
Infect Dis 112:7 -16. 
 Kim RH, Coates JM, Bowles TL , McNerney GP, Sutcliffe J, Jung JE, Gandour-Edwards R, Chuang 
FYS, Bold RJ, Kung HJ. 2009. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69:700-708.  Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. 2012. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509-2515.  
Klebe S, Brownlee NA, Mahar A, Burchette JL, Sporn TA, Vollmer RT, Roggli VL. 2010. 
Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol 23:470-479. 
 Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama H, Hirohashi S, Kawai A, Yamada T. 2010. Reduced arginin osuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis 
in patients with osteosarcoma. Mol Cancer Ther 9:535-544.  Kotova S, Wong RM, Cameron RB. 2015. New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res 7:51 -63. 
 Kraemer PM, Defendi V, Hayflick L, Manson LA. 1963. Mycoplasma (PPLO) strains with lytic 
activity for murine lymphoma cells in vitro. Proc Soc Exp Biol Med 112:381-387. 
 Kraemer PM. 1964. Mycoplasma (PPLO) from covertly contaminated tissue cultures: differences in arginine degradation between strains. Proc Soc Exp Biol Med 117:910-918.  Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S. 2014. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer 85:429-434. 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 72 of 87  
  
Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. 2014. Factors associated with survival in a large series of patients with malignant pleural meso thelioma in 
New South Wales. Br J Cancer 111:1860-1869.  Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Wu E, Ma Q. 2014. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase- deficient pancreatic 
cancer cells to gem citabine via inhibition of NF -κB signaling. BMC Cancer Sep 20;14:686. 
 Lowery MA, Yu KH, Kelsen DP , Harding JJ, Bomalaski JS,  Glassman DC,  Covington 
CM, Brenner R,  Hollywood E, Barba A , Johnston A, Liu KC , Feng X, Capanu M, Abou- Alfa 
GK, O'Reilly EM . 2017. A phase 1/1B trial of ADI-PEG 20 plus nab- paclitaxel and gemcitabine in 
patients with advanced pancreatic adenocarcinoma. Cancer 123: 4556-4565. 
 Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. 2014. B7- H1 ex pression in malignant pleural mesothelioma is associated with sarcomatoid 
histology and poor prognosis. J Thorac Oncol 9:1036-1040.  Mansfield AS, Symanowski JT, Peikert T. 2014. Systematic review of response rates of 
sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer 86:133 -136. 
 Marshall AD, Bayes HK, Bardgett J, Wedderburn S, Kerr KM, Currie GP. 2015. Survival from malignant mesothelioma: where are we now? J R Coll Physicians Edinb 45:123-126.  McDonald JC. 2010. Epidemiology of malignant mesothelioma --an outline. Ann Occup Hyg 
54:851-857.  Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D'Amico TA, Harpole DH, Berry MF. 2015. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 196:23-32.  Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. 2012. Diffuse malignant peritoneal mesothelioma --an update on treatment. Cancer Treat Rev 38:605-612. 
 Moolgavkar SH, Meza R, Turim J. 2009. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 20:935-944.   NCCN Guidelines. Mesothelioma. 2015.  Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A, 
Schmid P, Crook T 2009. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer; 125: 1454-1463.  Obasaju  CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, 
Monberg MJ, Jänne PA; Pemetrexed Expanded Access Program Investigators. 2007. Single- arm, 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 73 of 87  
 open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural 
mesothelioma: outcomes of an expanded access program. Lung Cancer 55:187-194. 
Ott PA, Carvajal D, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, 
Venhaus R, Pan L, Old L, Pavlick AC, Wolchok JD. 2013.  Phase I/II study of pegyl ated arginine 
deiminase (ADI -PEG 20) in patients with advanced melanoma. Invest New Drugs 31:425-434. 
 Pasut G, Sergi M, Veronese FM. 2008. Anti- cancer PEG -enzymes: 30 years old, but still a current 
approach. Adv Drug Deliv Rev 60:69-78. 
 
Pemetrexed Produc t Label 2013 
 Phillips MM, Sheaff MT, Szlosarek PW. 2013. Targeting arginine- dependent cancers with arginine-
degrading enzymes: opportunities and challenges. Cancer Res Treat 45:251-262.  Prestayko AW, D’Aoust JC, Issell BF, Crooke ST. 1979. Cisplatin ( cis-diamminedichloroplatinum 
II). Cancer Treat Rev 6:17 -39. 
 Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu J, Gaur S, Forman HJ, Zhang H, Zheng S, Yen Y, Huang J, Kung HJ, Ann DK. 2014. Arginine starvation impairs mitochondrial respiratory function in ASS1 -defic ient breast cancer cells. Sci Signal Apr 1;7(319):ra31.  
 Rabinovich S, Adler L, Yizhak K, Sarver A, Silberman A, Agron S, Stettner N, Sun Q, Brandis A, Helbling D, Korman S, Itzkovitz S, Dimmock D, Ulitsky I, Nagamani SC, Ruppin E, Erez A. 2015. Diversion of aspartate in ASS1 -deficient tumours fosters de novo pyrimidine synthesis. Nature 
527:379-383.  Raynaud C, Greillier L, Mazieres J, Monnet I, Mastroianni B, Robinet G, Fraboulet G, Dixmier A, Berard H, Lamy R, Letreut J, Lena H, Oliviero G, Botta S, Vergnenegre A, Borget I, Chouaid C. 2015. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BM C Cancer Nov 6;15:857.  
 Rozencweig M, Von Hoff DD, Slavik M, Muggia FM. 1977. C is-diamminedichloroplatinum (I I): a 
new anticancer drug. Ann Intern Med 86:803-812.  Saint -Pierre MD, Pease C, Mithoowani  H, Zhang T, Nicholas GA, Laurie SA, Wheatley- Price P. 
2015. Malignant pleural mesothelioma outcomes in the era of combined platinum and folate antimetabolite c hemotherapy. Lung Cancer Int 2015:590148. 
 Santoro A , O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz- Ares L, 
Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C. 2008. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3:756-763. 
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 74 of 87  
 Savaraj N, Wu C, Tien Kuo M, You M, Wangpaichitr M, Robles C, Spector S, Feun L. 2007. The 
relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights 2:119-128.  Savaraj N , Wu C , Li YY, Wangpaichitr M , You M , Bomalaski J, He W , Kuo MT , Feun LG . 2015. 
Targeting argininosuccinate synthetase negative melanomas using combination of arginine 
degrading enzyme and cisplatin. Oncotarget 6:6295-6309.  
Schimke RT, Berlin CM, Sweeney EW, Carroll WR. 1966. The generation of energy by the 
arginine dihydrolase pathway in Mycoplasma hominis 07. J Biol Chem 241:2228-2236.  Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N. 2014. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. Respir Investig 52:101-106.  Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JF, Grimm EA, Overwijk WW. 2010. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16:1834-1844.  Simon MC. 2015. Hypoxia, metabolism and tumor progression. Presented at the AACR Meeting on Cancer Metabolism, Bellvue, WA.  
 Sugimura K, Ohno T, Kusuyama T, Azuma I. 1992. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro.  Melanoma Res 2:191-196.  Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O'Neil K, Roncaroli F, Crook T. 2013. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis Jan 17;4:e458.  Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, 
Rudd RM, Balkwill FR, Fennell DA. In vivo loss of expression of argininosuccinate synthetase in 
malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006; 12: 7126-7131.  Szlosarek PW, Luong P, Phillips MM, Baccarini M, S Ellis, Szyszko T, Sheaff MT , Avril N. 2013. 
Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol 31(7):e111-113.  Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson JA, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemo ine NL, Sheaff MT, Rudd RM, Fennell DA, Hackshaw A. 2016. Randomized trial of arginine 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 75 of 87  
 deprivation with pegylated arginine deiminase in patients with ASS1 -deficient malignant pleural 
mesothelioma. JAMA Oncology -in press.   
 
Takaku H, Takase M, Abe S -i, Hayashi H, Miyazaki K. 1992. In vivo anti- tumor activity of 
arginine deiminase purified from Mycoplasma arginini.  Int J Cancer 51:244 -249. 
 Takaku H, Misawa S, Hayashi H, Miyazaki K. 1993. Chemical modification by polyethylene glycol of the anti -tumor e nzyme arginine deiminase from Mycoplasma arginini.  Jpn J Cancer Res 
84:1195-1200.  Tang CH, Grimm EA. 2004. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 279:288- 298. 
 Thomas JB, Holtsberg FW, Ensor CM, Bomalaski JS, Clark MA. 2002. Enzymatic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin. Bioc hem J 363:581-587. 
 Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, Kuo MT. 2012. Activation of Ras/PI3K/ERK pathway induces c- Myc stabilization to upregulate argininosuccinate synthetase, 
leading to arginine deiminase resistance in melanoma cells. Cancer Res 72: 2622-2633. 
 Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. 2011. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Onco l 6:598-601. 
 
Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box -
Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. 2019. Phase II Trial of 
Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy- Naïve Patients With 
Unresectable Malignant Pleural  Mesothelioma (SWOG S0905). J Clin Oncol  37:2537-2547. 
 
Turner K, Varghese S, Alexander HR Jr. 2012. Current concepts in the evaluation and treatment of 
patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 10:49 -57. 
 Tytell AA, Neuman RE. 1960. Growth response of stable and primary ce ll culture to L -ornithine, L-
citrulline, and L-arginine. Exp Cell Res 20:84-91.  Van den Berg H. 2011. Asparaginase revisited. Leukemia Lymphoma 52:168-178.  Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Botto mley A, Debruyne C, Giaccone G; European Organisation for Research and Treatment of 
Cancer Lung Cancer Group; National Cancer Institute of Canada. 2005. Randomized phase III 
study of cisplatin with or without raltitrexed  in patients with malignant pleural mesothelioma : an 
intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881-6889.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 76 of 87  
 Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer 
M, Emri S, Manegold C, Niyikiza C, Paoletti P. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleura l mesothelioma. J Clin Oncol 
21:2636-2644.  Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang -Peng J, Chen PJ,
 Chen LT. 2010. A randomized phase II study of pegylated arginine 
deiminase (ADI -PEG 20) in Asian advanced hepatocellular carcinoma (HCC) patients. Br J Cancer 
103:954-960.  Zalcman G, Mazieres J, Margery J, Greillier L, Audigier -Valette C, Moro -Sibilot D, Molinier O, 
Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). 2016. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a ran domised, controlled, open- label,  
phase 3 trial. Lancet 387:1405-1414.  Zauderer MG. 2016. A new standard for malignant pleural mesothelioma. Lancet 387:1352-1354. 
 Zeidan A, Wang ES, Wetzler M. 2009. Pegasparaginase: where do we stand? Expert Opin Biol Ther 9:111-119.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 77 of 87  
 16 APPENDIX A: MODIFIED RECIST  CRITERIA FOR MALIGNANT PLEURAL 
MESOTHELIOMA 
 
Tumour thickness perpendicular to the chest wall or mediastinum was measured in two positions at three separate levels on transverse cuts of CT scan. The sum of the six measurements defined a pleural unidimensional measure. Transverse cuts at least 1 cm apart and related to anatomical landmarks in the thorax were chosen to allow reproducible assessment at later time points. If measureable tumour was present, transverse cuts in the upper thorax, above the level of division of the main bronchi were preferred. At reassessment, pleural thickness was measured at the same position at the same level and by the same observer. This was not necessarily the greatest tumour thickness at that level. Nodal, subcutaneous and other bidimensionally measurable lesions were measured unidimensionally as per the RECIST criteria. Unidimensional measurements were added to obtain the total tumour measurement.  
 
Response Criteria  Definition  
CR disappearance of all target lesions with no evidence of tumour elsewhere  
PR at least a 30% reduction from baseline in the total tumour measurement  
PD an increase of at least 20% in the total tumour measurement over the nadir measurement, or the appearance of one or more new lesions 
SD those who fulfilled the criteria for neither PR nor PD  
 A confirmed response required a repeat observation on two occasions 4 weeks apart.  
Byrne MJ, Nowak AK.  2004
. Modified RECIST criteria for assessment of response in malignant 
pleural mesothelioma.  Ann Oncol15:257–260. 
 
A practical guide to modified RECIST for MPM also has been published: Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM.  2011
. A practical guide of the Southwest 
Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 6 :598-601. 
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 78 of 87  
 17 APPENDIX B: RECIST 1.1 CRITERIA  
 
Category  RECIST 1.1  
Minimum size 
measurable lesions  • CT 10 mm; delete reference to spiral scan  
• Clinical:  
 10 mm (must be measurable with calipers)  
Lymph Node 
• CT: 
      > 15 mm short axis for target  
      >10–<15 mm for non -target  
      <10 mm is non -pathological  
Special 
considerations on 
lesion measurability  Notes included on bone lesions, cystic lesions  
Overall tumor 
burden  5 lesions (2 per organ)  
Response criteria 
target disease  • CR lymph nodes must be <10 mm short axis  
• PR at least a 30%  decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters  
• PD 20% increase over smallest sum on study (including 
baseline if that is smallest) and at least 5 mm increase or 
new lesions  
Response criteria 
non-target disease  
 More detailed description of ‘unequivocal progression’ to 
indicate that it should not normally trump target disease status. It must be representative of overall disease status change, not a 
single lesion incre ase 
New lesions  New section on New lesions  
Overall response  • Two tables: one integrating target and non -target and the 
other of non- target only  
• Special notes:  
-How to assess and measure lymph nodes -CR in face of residual tissue  
-Discussion of ‘equivocal’ progression  
Confirmatory 
measure  Retain this requirement ONLY for non -randomized trials with  
primary endpoint of response  
Progression -free 
survival -More specific comments on use of PFS (or proportion 
progression-free) as phase II endpoint 
-Greater detail on PFS assessment in phase III trials  
Reporting of 
response results  -Divided into phase II and phase III  
-9 categories collapsed into 5 
-In phase III, guidance given about reporting response  
Response in phase 
III trials  This section removed and referenced in section above: no need 
to have different criteria for phase II and III  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 79 of 87  
 Imaging appendix  - Appendix II: updated with detailed guidance on use of MRI, 
PET/CT (Note that for this study,  non-CT/MRI scanning are not 
required and but may be completed as standard of care) 
- Other practical guidance included  
New appendices  - Appendix I: comparison of RECIST 1.0 and 1.1  
- Appendix III: frequently asked questions  
Appendix I. Summary of major changes RECIST 1.0 to RECIST 1.1 in E.A. Eisenhauer, P. 
Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). EUROPEAN JOURNAL OF CANCER 45 ( 2009
) 228-247. 
 Response Evaluation Criteria in Solid Tumors - Quick Reference  
 
Eligibility  
 Only patients with measurable disease at baseline should be included in protocols where objective tumor response is the primary endpoint.   Measurable disease is defined by the presence of at least one measurable lesion.  
 In studies where the primary endpoint is tumor progression (either time to progression or proportion with progression at a fixed date), the protocol must specify if entry is restricted to those with measurable disease or whether patients having non -measurable disease only are eligible.  
 
Measurement of Tumors at Baseline: Measurable vs. Non -Measurable Lesions  
 At baseline, tumor lesions/lymph nodes will be categorized measurable or non -measurable as 
follows:  
 
Measurable  
  Tumor lesions: measure at least longest diameter with a minimum size o f: 
  10 mm using CT scan (CT scan thickness no greater than 5 mm), or   10 mm caliper measurements on clinical exam (lesions which cannot be     accurately  measured with calipers should be recorded as non- measurable, or  
   20 mm by chest x- ray 
 
Malignant lymph nodes: measure at short axis with a minimum size of ≥ 15 mm 
 Non-measurable lesions - all other lesions, including small lesions (longest diameter <10  mm) or 
pathological lymph nodes with ≥ 10 to ≤ 15 mm (short axis).  Lesions considered tr uly non -
measureable: leptomeningeal disease, pleural/pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, and also abdominal masses/organomegaly identified by physical exam that is not measurable by reproducible imaging techniques  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 80 of 87  
  
Special considerations  
 
Bone lesions 
 
Bone sc an, PET scan  or plain films are not considered adequate imaging techniques, however, these 
lesions can be used to confirm t he presence or disappearance of  bone lesions 
 
Cystic lesions 
 Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions  
 “Cystic lesions” thought to represent cystic metastases can be considered as measurable lesions, if they met the definition of measurability described above  
 
Lesions with prior local treatment  
 Lesions in a previously irradiated area or in an area subject to other loco -regional therapy are 
usually not considered measurable unless there has been demonstrated progression in the area  
 
Measurement of Lesions 
• All measurements should be taken and recorded in metric notation, using calipers if clinically assessed.  
• All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
• The same method of assessment and the same techniqu e should be used to 
characterize each identified and reported lesion at baseline and during follow -
up.   
 
Methods of Measurement  
 Clinical lesions - will only be considered measurable when they are superficial and ≥ 10 mm 
diameter as assessed using caliper s (e.g., skin nodules and palpable lymph nodes).  For the case of 
skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended.  
  CT and MRI – CT is the best currently available and reproducible me thods to measure target lesions 
selected for response assessment. CT should be performed with cuts of 5  mm or less in slice 
thickness contiguously.  When CT scans have slice thickness greater than 5 mm, the minimum size 
for a measurable lesion should be tw ice the slice thickness. MR I is also acceptable in certain 
situations.   Chest x -ray – chest CT is preferred over chest x -ray. However, lesions on chest x- ray may be 
considered measurable if they are clearly defined and surrounded by aerated lung. 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 81 of 87  
  
Ultraso und – is not useful in assessment of lesion size and should not be used as a method of 
measurement.  
 Endoscopy, laparoscopy – utilization of these techniques for objective tumor evaluation is not advised.  However, they can be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete response or surgical resection is an endpoint.  
 Tumor markers – alone  cannot be used to assess objective tumor response. If markers are initially 
above the upper limit of normal, however, they must normalize for a patient to be considered in complete response.   Cytology, histology – can be used to differentiate between PR and CR in rare cases if required by protocol (for example, residual lesions in tumor types such as germ cell tumors where know residual benign disease can remain).  When effusions are known to be potential adverse effect of 
treatment (e.g., with certain taxanes or angiogenesis inhibitors), the cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment can be considered if the measurable tumor has met criteria for response or stable disease in order to differentiate between response or stable disease and progressive disease.  
 
Baseline Documentation of “Target” and “Non- Target” Lesions  
 When more than one measurable lesion is pre sent at baseline, all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all involved organs should 
be identified as target lesions and will be recorded and measured at baseline (this means in instances 
where patients have only one or two organ sites involved, a maximum of two and four lesions respectively will be recorded).  
 Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involv ed organs, and lend themselves to reproducible repeated measurements.  
 Lymph nodes are normal anatomic structures which may be visible by imaging even if not involved by tumor.  As noted above, pathological nodes are defined as measurable and may be identified as target lesions if the short axis is ≥ 15 mm.  A sum of the diameters (longest diameter [LD] for non -nodal lesions, short axis for nodal lesions) 
for all target lesions will be calculated and reported as the baseline sum diameters.  The baseline sum diameters will be used as reference by which to characterize any objective tumor regression.  
 
All other lesions (or sites of disease) including pathological lymph nodes should be identified as non-target lesions and should also be recorded at baseline.  Measurements of these lesions are not 
required, but the presence or absence of each should be noted throughout follow-up.  
 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 82 of 87  
 Response Criteria  
 
Evaluation of target lesions: 
Complete Response 
(CR):  Disappearance of all target lesions. Any pathological lymph  nodes 
(whether target or non- target) must have reduction in short axis to 
< 10 mm.  
Partial Response 
(PR):  At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters.  
Progressive Disease 
(PD):  At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance 
of one or more new lesions is also considered progression.  
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference t he smallest sum 
diameters on study.  
 Special notes on assessment of target lesions:  
• Lymph nodes 
• The short axis should be measured. Thus, the “sum” of lesions may not be zero even if CR response criteria are met, since a normal lymph node is defined as having a short axis < 10 
mm. 
• Target lesions that have become “too small to measure”  
• A number should be recorded.  If, in the opinion of the radiologist, that the lesion has 
disappeared, the measurement should be recorded as 0 mm.  If the lesion is believed  to be 
present and is faintly seen but too small to measure, a default value of 5 mm should be 
assigned (5 mm is derived from the 5 mm CT slice thickness).  
• Lesions that split or coalesce  
• The longest diameters of the fragmented portions should be added toge ther to calculate the 
target lesion sum.  If the lesions have truly coalesced, the vector of the longest diameter 
should be the maximal longest diameter for the “coalesced lesion.”  
 Evaluation of non- target lesions:  
Complete Response 
(CR):  Disappearance of  all non -target lesions and normalization of 
tumor marker level. All lymph nodes must be non -pathological 
in size (< 10 mm short axis).  
Incomplete Response/  
Stable Disease (SD):  Persistence of one or more non -target lesion(s) or/and 
maintenance of tumor marker level above the normal limits.  
Progressive Disease 
(PD):  Appearance of one or more new lesions and/or unequivocal 
progression  of existing non -target lesions.  
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 83 of 87  
 • When the patient also has measurable disease, to achieve “unequivocal progression” on the 
basis of the non- target disease, there must be an overall level of substantial worsening in 
non-target disease such that, even in presence of SD or PR in target disease, the overall 
tumor burden has increased sufficiently to merit disco ntinuation of therapy. A modest 
“increase” in the size of one or more non -target lesions is usually not sufficient to qualify for 
unequivocal progression. 
• When the patient has only non- measureable disease, the same general concepts apply.  
 
New Lesions  
 
The appearance of new malignant lesions denotes progression.  There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal: i.e. not attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumor (for example, some “new” bone lesions may be simply healing or flare of pre -existing lesions). 
 If a new lesion is equivocal, for example because of its small size, continued therapy and follow-up evaluation will clarify if it represents truly new disease.  
 It is sometimes reasonable to incorporate the use of FDG -PET scanning to complement CT 
scanning in assessment of progression (particularly possible “new” disease).  FDG- PET scanning is 
not specifically required by the protocol but may be considered as part of standard of care.  New lesions on the basis of FDG -PET imaging can be identified according to the following algorithm: 
 
a. Negative FDG -PET at baseline with a positive (“positive” FDG -PET scan lesion means one 
which is FDG avid with an uptake greater than twice that of the surrounding tissue on the attenuation corrected image) FDG -PET at follow -up is a sign of PD based on a new lesion. 
b. No FDG- PET at baseline and a positive FDG-PET at follow up: 
i) If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed 
by CT, this is PD. 
ii) If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG- PET).  
iii) If the positive FDG -PET at follow -up corresponds to a pre- existing site of disease on 
CT that is  not progressing on the basis of the anatomic images, this is not PD. 
 Evaluation of Best Overall Response  
• The best overall response is the best response recorded from the start of the treatment until the end of treatment taking into account any requireme nt for confirmation.  
• When no imaging/measurement is done at a particular time point, the patient is not evaluable 
(NE) at that time point. If only a subset of lesion measurements are made at an assessment, 
usually the case is considered NE at that time po int, unless a convincing argument can be 
made that the contribution of the missing lesion(s) would not change the assigned time point response.  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 84 of 87  
  
Target 
lesions  Non-Target lesions  New Lesions  Overall response 
CR CR No CR 
CR Non-CR/non -PR No PR 
CR Not evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all 
evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
 
Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be classified as having “symptomatic deterioration”.  Every effort should be made to document the objective progression even after 
discontinuation of treatment.   In some circumstances it may be difficult to distinguish residual disease from normal tissue.  When 
the evaluation of complete response depends on this determination, it is recommended t hat the 
residual lesion be investigated (fine needle aspirate/biopsy) to confirm the complete response status. FDG- PET may be used to upgrade a lesion to a CR in a manner similar to a biopsy in cases where a 
residual radiographic abnormality is thought to represent fibrosis or scarring.  
 For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes or necrosis in existing lesions), treatment may continue until the next scheduled assessment.  If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.  
 
Confirmation 
 In non- randomized studies where response is the primary end -point, confirmation of PR and CR is 
required to ensure responses identified are not the result of measurement error. In randomized trials (phase II or III) or studies where stable disease or progression are the primary endpoints, confirmation of response is not required since it will not add value to the interpretation of trial 
results.  
 Frequency of tumor re -evaluation while on treatment should be protocol specific and adapted to the 
type and schedule of treatment. However, in the context of phase II studies where the beneficial therapy is not known, follow-up every 6-8 weeks (timed to coincide with the end of a cycle) is 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 85 of 87  
 reasonable. Smaller or greater time intervals than  these could be justified in specific regimens or 
circumstances.  
 
At the end of treatment, the need for repetitive tumor evaluations depends on whether the trial has a 
goal the response rate or the time to an event (progression/death).   If “time to an event” (e.g., time 
to progression, disease- free survival, progression -free survival) is the main endpoint, then routine 
scheduled re -evaluation of protocol  specified sites of disease is warranted.  
 
Duration of Overall Response 
 The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded on study.  
 The duration of overall complete response is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented. 
 
Duration of Stable Disease 
 Stable disease is measured from the start of the treatment (in randomized trials, from date of randomization) until the criteria for disease progression are met, taking as reference the smallest sum on s tudy measurements recorded since the treatment started.  
 The clinical relevance of the duration of SD varies in different studies and diseases. If the proportion of patients achieving SD for a minimum period of time is an endpoint of importance in a 
particular trial, the protocol should specify the minimal time interval requited between two 
measurements for determination of SD.  
 
Progression -Free Survival/Proportion Progression -Free  
 Phase II trials  
 
• In some circumstances, “response rate” may not be the optimal method to assess the potential 
anticancer activity of new agents/regimens.   In such cases “progression -free survival” (PFS) or 
the “proportion progression-free” at landmark time points, might be considered appropriate 
alternatives to provide an ini tial signal of biologic effect of new agents.  It is clear, however, 
that in an uncontrolled trial, these measures are subject to criticism since an apparently promising observation may be related to biological factors such as patient selection and not the impact of the intervention.  Thus, phase II screening trials utilizing these endpoints are best 
designed with randomized control.  
 Phase III trials  
 
• Assessment of progression is relatively straightforward if the protocol requires all patients to have measurable disease.  However, restricting entry to this subset of patients is subject to 
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 86 of 87  
 criticism: it may result in a trial where the results are less likely to be generalizable if, in the 
disease under study, a substantial proportion of patients would be excluded. 
 
Response Review  
 For trials were objective response (CR + PR) is the primary endpoint, and in particular where key drug development decisions are based on the observation of a minimum number of responders, it is recommended that all claimed respon ses be reviewed by an expert(s) independent of the study.  If 
the study is a randomized trial, ideally reviewers should be blinded to treatment assignment. Simultaneous review of the patients’ files and radiographical images is the best approach.  
 
Reportin g of Results  
 Phase II Trials  
 
• When response is the primary endpoint, and thus all patients must have measurable disease to enter the trial, all patients included in the study must be accounted for in the report of the results, even if there are major protocol treatment deviations or th ey are not evaluable.  Each 
patient will be assigned one of the following categories: 1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) unevaluable for response: specify reasons 
(for example: early death, malignant di sease; early death, toxicity; tumor assessments not 
repeated/incomplete; other [specify]).  Normally, all eligible patients should be included in the 
denominator for the calculation of the response rate for phase ii trials (in some protocols it will be appropriate to include all treated patients).  It is generally preferred that 95% two -sided 
confidence limits are given for the calculated response rate.  
• Trial conclusions should be based on the response rate for all eligible (or all treated) patients and should not be based on a selected “evaluable” subset.  
 Phase III trials  
• Response evaluation in phase III trials may be an indicator of the relative anti -tumor activity 
of the treatments evaluated and is almost always a secondary endpoint.  Observed differences in response rate may not predict the clinically relevant therapeutic benefit for the population studied.  
  
Polaris Group   
Protocol Number: POLARIS2015 -003, Phase 2 /3 MPM ADI-PEG 20 + Pemetrexed + Cisplatin   
 
Date : 21 September  2021 - Version 6 CONFIDENTIAL  
Page 87 of 87  
 18 APPENDIX C : PERFORMANCE STATUS  PERFORMANCE SCALES  (KARNOFSKY, 
ECOG -WHO -ZUBROD) 
 
These scales are used by practicing oncologists and researchers to assess how a patient's disease is 
progressing, to assess how the disease affects the daily life, and to determine appropriate treatment and prognosis. 
Status  Karnofsky  Grade  ECOG  
Normal, no complaints  100 0 Fully active, able to carry on 
all pre -disease performance 
without restriction  
Able to carry on normal activities. 
Minor signs or symptoms of disease  90 
1 Restricted in physically 
strenuous activity but 
ambulatory and able to carry 
out work of a light or 
sedentary nature, e.g., light 
housework , office work  Normal activity with effort  80 
Care for self. Unable to carry on 
normal activity or to do active work  70 
2 Ambulatory and capable of all 
selfcare but unable to carry 
out any work activities. Up 
and about more than 50% of 
waking hours  Requires occasional assistance, but 
able to care for most of his needs  60 
Requires considerable assistance and 
frequent medical care  50 
3 Capable of only limited self-
care, confined to bed or chair 
more than 50% of waking 
hours Disabled. Requires special care and 
assistance  40 
Severely disabled. Hospitalization 
indicated though death nonimminent  30 
4 Completely disabled. Cannot 
carry on any selfcare. Totally 
confined to bed or chair  Very sick. Hospitalization necessary. 
Active supportive treatment necessary  20 
Moribund  10 
Dead  0 5 Dead  
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And  
Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649- 655, 1982.The Eastern 
Cooperative Oncology Group, R obert Comis M.D., Group Chair.  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 1 of 39   
 
 
 
STATISTICAL ANALYSIS PLAN 
Polaris Group 
POLARIS2015- 003 
 
   
Protocol Title : 
Randomized, Double-Blind, Phase 2/3 Study in Subjects with 
Malignant Pleural Mesothelioma to Assess ADI -PEG 20 with 
Pemetrexed and Cisplatin (ATOMIC -Meso Phase 2/3 Study)  
Protocol Version 
and Date : Version 6; 21 September 2021 
 
Sponsor:  Polaris Group  
10675 Sorrento Valley Road, Suite 200 
San Diego, CA 92121 USA  
Prepared By:  Brian Beus  
Precision for Medicine  
6005 Hidden Valley Road, Suite 170 
Carlsbad, CA 92011  
Document Version 
and Date:  Version  4.0; 4 January 2022 
 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 2 of 39  1 STATISTICAL ANALYSIS  PLAN APPROVAL  
Sponsor:  Polaris Group  
Clinical Protocol Number:  POLARIS2015 -003 
Protocol Title:  Randomized, Double -Blind, Phase 2/3 Study in Subjects 
with Malignant Pleural Mesothelioma to Assess ADI -PEG 
20 with Pemetrexed and Cisplatin (ATOMIC -Meso Phase 
2/3 Study)  
Document File Name:  Polaris_POLARIS2015 -003_SAP_ V4.0_04JAN2022 .pdf 
Document Version and 
Effective Date:  Version 4.0; 4 January 2022  
Approved By:   
 
   
John S. Bomalaski, M.D.  
Exec. VP, Medical Affairs  
Polaris Pharmaceuticals, Inc.   Date  
   
   
Amanda Johnston, Ph.D.  
SVP, Clinical Affairs  
Polaris Pharmaceuticals, Inc.   Date  
   
   
Brian Beus  
Principal Statistician  
Precision for Medicine   Date  
   
   
Kun He  
Consultant, Statistics   Date  
05-Jan-2022
05-Jan-2022
05-Jan-2022
05-Jan-2022

Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003 Version 4.0; 4 January 2022 
Confidential  Page 3 of 39  2 TABLE OF CONTENTS  
1 Statistical Analysis Plan Approval ............................................................................2  
2 Table of Contents  ........................................................................................................3  
3 List of Abbreviations  ..................................................................................................6  
4 Introduction .................................................................................................................8  
5 Study Objectives  .........................................................................................................9  
5.1 Primary Study Objective  .......................................................................................9  
5.2 Secondary Study Objectives ..................................................................................9  
6 Investigational Plan  ..................................................................................................10  
6.1 Overall Study Design ...........................................................................................10  
6.2 Schedule of Assessments  ......................................................................................11  
6.3 Treatments  ............................................................................................................11  
6.3.1  Treatments A dministered  .............................................................................11  
6.3.2  Method of Assigning Subjects to Treatment Groups .................................12  
6.4 Efficacy and Safety Variables  .............................................................................12  
6.4.1  Efficacy Variables  ..........................................................................................12  
6.4.2  Description of Safety Variables  ....................................................................14  
6.4.3  Description of Pharmacodynamic, Immunogenicity, and 
Pharmacokinetic Variables  ...........................................................................16  
6.5 Data Quality Assurance .......................................................................................16  
7 Statistical Methods  ....................................................................................................17  
7.1 General Methodology ..........................................................................................17  
7.1.1  Reporting Conventions  ..................................................................................17  
7.1.2  Summarization by Visit .................................................................................18  
7.1.3  Standard Calculations  ...................................................................................18  
7.2 Analysis Populations  ............................................................................................18  
7.3 Study Subjects  ......................................................................................................19  
7.3.1  Disposition of Subjects  ...................................................................................19  
7.3.2  Protocol Deviations ........................................................................................19  
7.4 Efficacy ..................................................................................................................20  
7.4.1  Datasets Analyzed  ..........................................................................................20  
7.4.2  Demo graphic and Other Baseline Characteristics ......................................20  
7.4.3  Primary Efficacy Endpoint Analysis Methods  ............................................20  
7.4.4  Secondary Efficacy Endpoint Analysis Methods  ........................................21  
7.4.5  Statistical/Analytical Issues  ...........................................................................22  
7.4.6  Pharmacodynamics ........................................................................................24  
7.4.7  Immunogenicity ..............................................................................................24  
7.4.8  Pharmacokinetics  ...........................................................................................24  
7.5 Safety Analysis .....................................................................................................25  
7.5.1  Extent of Exposure and Treatment Compliance .........................................25  
7.5.2  Adverse Events  ...............................................................................................25  
7.5.3  Deaths , Other Serious Adverse Events, and Other Significant 
Adverse Events  ...............................................................................................26  
7.5.4  Clinical Laboratory Evaluation ....................................................................27  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 4 of 39  7.5.5  Vital Signs, Physical Findings, and Other Observations Related to 
Safety  ...............................................................................................................27  
7.6 Determination of Sample Size  .............................................................................28  
7.7 Changes in the Conduct of the Study or Planned Analyses  .............................29  
8 Reference List  ............................................................................................................29  
Appendix A: List of Tables, Figures and Data Listings  ...............................................31  
 
  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 5 of 39  TABLE OF TABLES  
Table 1  List of Abbreviations  .................................................................................6  
Table 2  Clinical Laboratory Tests ........................................................................15  
 
 
 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 6 of 39  3 LIST OF ABBREVIATI ONS  
Table 1 List of Abbreviations  
Abbreviation  Definition  
ADI Arginine deiminase  
ADIPem Platinum Combination therapy of ADI-PEG 20 , pemetrexed and cisplatin  
(or carboplatin)  
AE Adverse event  
ALT  Alanine transaminase (also known as SGPT)  
ANC  Absolute neutrophil count  
ASS1  Argininosuccinate synthetase (also known as ASS)  
AST  Aspartate transaminase (also known as SGOT)  
BICR  Blinded independent central review  
BMI  Body mass index  
BSA  Body surface area 
BUN  Blood urea nitrogen  
CBC  Complete blood count  
CI Confidence interval  
CMH  Cochran -Mantel -Haenszel  
CP Conditional power  
CR Complete response  
CSR  Clinical study report  
CT Computed tomography  
CTCAE  Common terminology criteria for adverse events  
DCR  Disease Control Rate  
DOR  Duration of response  
DSMB  Data Safety Monitoring Board  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EOT  End-of-treatment  
FDA  US Food and Drug Administration  
GCP  Good Clinical Practice  
ICH International Conference on Harmoni zation  
IM Intramuscular  
ITT Intent - to-treat 
IWRS  Interactive Web Response System  
LCMS  Liquid chromatography mass spectrometry  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 7 of 39  Abbreviation  Definition  
MedDRA  Medical Dictionary for Regulatory Activities  
MPM  Malignant pleural mesothelioma  
MRI  Magnetic Resonance Imaging  
NE Not evaluable  
OS Overall survival  
PD Progressive disease  
PEG  Polyethylene glycol  
PFS Progression free survival  
PlaceboPem Platinum  Combination therapy of placebo,  pemetrexed and cisplatin  (or 
carboplatin)  
PP Per-Protocol  
PR Partial response  
QTcF  Corrected QT interval using Fridericia’s correction  
RBC  Red blood cell count  
RECIST  Response Evaluation Criteria in Solid Tumors  
RR Response rate  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SD Standard deviation  or stable disease depending on context  
SE Standard error  
SGOT  Serum glutamic -oxaloacetic transaminase  
SGPT  Serum glutamic -pyruvic transaminase  
SI Système International  
TEAE  Treatment -emergent adverse event  
WBC  White blood cell count  
WHO  World Health Organization  
 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003 Version 4.0; 4 January 2022 
Confidential  Page 8 of 39  4 INTRODUCTION  
The purpose of this statistical analysis plan (SAP) is to provide comprehensive and 
detailed descriptions of the methods and presentation of data analyses proposed for 
Polaris Group,  Protocol POLARIS2015 -003 ( Randomized, Double -Blind, Phase 2/3 
Study in Subjects with Malignant Pleural Mesothelioma to Assess ADI -PEG 20 with 
Pemetrexed and Cisplatin (ATOMIC -Meso Phase 2/3 Study) ). Descriptions of planned 
analyses are provided in order to avoid post hoc decisions that may affect the 
interpretation of the statistical analysis.  The statistical methods  applied in the design and 
planned analyses of this study are consistent with the International Conference on 
Harmonization (ICH) guideline Statistical Principals for Clinical Trials (E9) (1998).   
This SAP will be finalized prior to data analysis and before treatment unblinding  and 
database lock  at the interim analysis  to provide full details, including templates for tables, 
listings, and figures, to be presented in the clinical study report (CSR). Any changes between the statistical methods provided in the clinical study protocol and this SAP will 
be explained herein; any changes or deviations from this SAP relative to  the final analysis 
will be fully documented in the CSR. Minor changes or deviations from the templates for 
tables, figures, and listings need not be documented in the CSR. 
Notable changes from version 1.0 to version 2.0 of this SAP correspond to similar 
changes from version 4 to version 5 of the protocol and include: 
•Removal of secondary endpoints of objective response rate and duration of
response in phase 3. Both endpoints will remain as endpoints for pha se 2.
•Removal of disease control rate as a secondary endpoint in phase 3.
•The timing of the interim analysis to assess futility and potential sample size
increase was modified from occurring at the end phase 2 to be performed  at a
separate time from the en d of phase 2 analysis when 50% of planned overall
survival events have occurred in order to obtain more reliable sample sizeestimates for phase 3 .
•Removal of the subject population selection rule at the interim analysis. Interimanalysis methods and options were updated and simplified accordingly.
•The cap for percent increase in sample size at the interim analysis was modified
from 50% to 30%.
•Methods for addressing multiplicity were modified based on the removal of
secondary endpoints and the remova l of the subject population selection rule at
the interim analysis.
Changes from version 2.0 to version 4.0 of this SAP are based on DSMB recommendations and other minor clarifications  as follows:  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 9 of 39  • The original planned sample size will be changed from 386 subjects to all 
enrolled up to August 15, 2021 (249 subjects) ; and the deaths for the original 
planned final analysis of OS will be changed from 338 to the actual number of deaths occurred on August 14, 2022. Also, an administrative penalty of α=0.00001 wil l be paid for second interim analysis, and the allocated α=0.04999 
will be used for the final analysis.  
5 STUDY OBJECTIVES  
5.1 Primary Study Objective  
The primary objective of this study is : 
• Determine efficacy as determined by the objective response rate ( RR), m easured 
by modified Response Evaluation Criteria in Solid Tumors  (RECIST) criteria for 
local pleural disease and RECIST 1.1 criteria for metastatic lesions  (phase 2 
portion) and overall survival (OS ) (phase 3 portion)  
5.2 Secondary Study Objectives  
The secondary objective of the phase 2 portion is: 
• Determine the duration of response (DOR)  
The secondary objective of the phase 3 portion is: 
• Assess progression free survival (PFS)  
Other objectives of this study are :  
• Assess safety and tolerability of ADI -PEG 20 in combination with pemetrexed 
and cisplatin   
• Determine the pharmacodynamics of ADI-PEG 20 in combination with pemetrexed and cisplatin  
• Determine the immunogenicity of ADI-PEG 20 in combination with pemetrexed and cisplatin  
• Determine the pharmacokinetics of ADI -PEG 20 in combination with pemetrexed 
and cisplatin  
The goal of the phase 2 portion of the trial is to provide data to support accelerated approval by the  United States Food & Drug Administration  (FDA) , and the goal of the 
phase 3 portion of the trial is to provide a confirmatory study that would be ongoing at the time of the marketing application.  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 10 of 39  6 INVESTIGATIONAL PLAN  
6.1 Overall Study Design 
This is a randomized, double- blind , multi -center,  phase 2 /3 trial of ADI -PEG 20 in 
combination with pemetrexed and cisplatin in subjects with unresectable m alignant 
pleural mesothelioma (MPM ) of sarcomatoid or biphasic histologies. 
Weekly ADI -PEG 20 at 36 mg/m2 (or placebo) will be combined with pemetrexed 500 
mg/m2 and cisplatin 75 mg/m2 both given every 3 weeks as first-line chemotherapy to 
non-epithelioid (biphasic and sarcomatoid) MPM. Eligible subjects will be randomized in 
a 1:1 ratio to ADI-PEG 20 with pe metrexed and cisplatin (ADIPem Platinum) or Placebo 
with pemetrexed and cisplatin ( PlaceboPem Platinum). The randomization will be 
stratified by  tumor histology (biphasic or sarcomatoid). Subjects may receive a maximum 
of 6, 3- week cycles of ADIPem Platinum  or PlaceboPem Platinum for a total of 18 weeks 
of treatment. Those subjects completing ADIPem Platinum or PlaceboPem Platinum 
treatment may continue on ADI- PEG  20 or placebo monotherapy if they have stable 
disease ( SD) or better. Subjects who do not tolerate cisplatin may be switched to 
carboplatin. 
Approximately 176 subjects (88 per arm) will be enrolled in the phase 2 portion of the 
trial and 386 subjects (193 per arm) in the whole phase 2/3 trial. At the end of the phase 2 
portion of the trial an interim ana lysis will be con ducted to evaluate RR in the first 176 
subjects (phase-2 subjects). A second  interim analysis will be conducted once 50% of the 
estimated OS events for phase 3 have occurred to determine whether to terminate the 
study for futility or for possible sample size re -estimation for the phase 3 portion of the 
trial.  
Based on DSMB recommendations, the original planned sample size will be changed from 386 subjects to all  enrolled up to August 15, 2021 (249 subjects). Radiological 
(CT/MRI) scans for assessing tumor response will be performed at baseline, every 6 weeks during ADIPemPlatinum or PlaceboPemPlatinum dosing, and every 8 weeks 
during ADI-PEG 20 or placebo only dosing. Tumor re sponse will be assessed using 
modified RECIST for MPM for intra -thoracic pleural disease and RECIST 1.1 for extra -
pleural metastatic disease as applicable. In case of tumor response ( complete or partial 
response ) repeat imaging will be performed  4 weeks la ter to confirm response.   The same 
imaging modality is to be used throughout the triplet treatment duration.  
Efficacy endpoints include RR , DOR, OS, and PFS; RR and DOR will be derived based 
on the tumor response assessments by a blinded independent central review  (BICR) for 
phase 2 and PFS will be derived based on the tumor response assessments by the 
investigator for phase 3. Safety assessments include adverse events (AEs) , laboratory 
tests, vital signs, electrocardiograms ( ECGs ) and physical examinations.  Efficacy and 
safety endpoints are described in Section 6.4 and will be measured according to the Schedule of Assessments described in Section  6.2. 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 11 of 39  6.2 Schedule of Assessments  
For the complete schedule of assessments, refer to  Section 1.4 of the clinical study 
protocol. Schedule of assessments for the blinded and open -label extension at study end 
is presented in Section 4.1.2 of the clinical study protocol. 
6.3 Treatments  
6.3.1 Treatments Administered  
ADI-PEG 20 at 36 mg/m2 (or placebo) will be administered weekly by intramuscular 
(IM) injection.  Pemetrexed 500 mg/m2 and c isplatin 75 mg/m2 will be  administered 
intravenously every 3 weeks.  For each cycle, day 1 administration of ADI-PEG 20 (or 
placebo) will be administered 60 -90 minutes prior to pemetrexed and c isplatin, except for 
the first cycle where the doublet chemotherapy will be administered o n day 3.  
The starting dose represents 100% of the recommended dose of c isplatin and pemetrexed 
and ADI -PEG 20 as determined in the phase 1 trial.  Criteria for withholding treatment, 
dose adjustments, or switching from cisplatin to carboplatin based on tox icity are 
described in Section 7.3.4 of the clinical study protocol. 
Tumor response will be evaluated at the end of week 6. In the event of disease 
progression, the triplet chemotherapy will be stopped, and the subject offered an 
alternative treatment plan.  In the absence of disease progression requiring other 
therapeutic interventions, subjects may receive additional cycles of ADIPem Platinum or 
PlaceboPem Platinum treatment following the same procedures and schedule as week 7 
and onward for up to 18 weeks.   
Subjects may continue to receive treatments unless, one of the following occurs at any 
time during the course of therapy: (1) unacceptable AEs, or (2) death, or (3) progressive disease, or (4) significant noncomplia nce on the part of the subject, or (5) refusal of the 
subject to continue treatment or observations, or (6) decision by the Investigator that 
termination is in the subject’s best medical interest, or (7) unrelated medical illness or 
complication, or (8) lo st to follow-up.  Any subject  with tumor and stable disease or 
partial response should continue treatment until progression, unless the investigator 
thinks a better option is available.  Thus, subjects completing ADIPem Platinum or 
PlaceboPem Platinum may co ntinue to receive ADI-PEG 20 or placebo treatment, 
following the schema of week 13 and onward or week 19 and onward if 12 or 18 weeks of triple therapy is completed.  Any subject with a complete response may receive 4 more weekly treatments of ADI-PEG 20  or placebo.  The maximum number of cycles of 
pemetrexed  + cisplatin is 6 (18 weeks at every 3  weeks cycle).  
Subjects ongoing at study end (once the required number of events have been observed for the final analysis) may continue to receive treatment on ADIPem Platinum  or 
PlaceboPem Platinum (or ADI -PEG 20/placebo alone), depending on where the subjects 
are in the  treatment schedule, until the study is unblinded. Once the study treatment 
assignments are known, the subjects receiving ADI-PEG 20 may continue to receive ADIPem Platinum (or ADI -PEG 20 alone) until 1 of the following occurs: (1) 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 12 of 39  unacceptable AEs, or (2) death, (3) progressive disease ( PD) or (4) decision by the 
Sponsor. Subjects receiving placebo should be consulted regarding alternative treatment 
options. 
6.3.2 Method of Assigning Subjects  to Treatment Groups 
Subjects will be randomly assigned in a 1:1 ratio to receive ADI -PEG 20 drug product or 
matching placebo in a double- blind fashion via a centralized Interactive Web Response 
System ( IWRS ) system . ADI -PEG 20 drug product and placebo will be identical in 
appearance in order to preserve the blinding. The randomization will be stratified by 
tumor histology (biphasic or sarcomatoid).  
6.4 Efficacy and Safety Variables  
6.4.1 Efficacy Variables  
6.4.1.1 Primary Efficacy Variables  
The primary efficacy endpoint of the phase 2 portion of the study is : 
• Objective response rate (RR) : calculated as the proportion of subjects whose best 
tumor response from all post- baseline tumor assessments is complete response 
(CR) or partial response (PR) 
Tumor response at each time point where CT/MRI scan s are performed will be assigned 
by the BICR as complete response (CR), partial response (PR), progressive disease (PD), 
or stable disease (SD).  In case of CR or PR, repeat imaging will be performed  4 weeks 
later to confirm response.  If the response is not confirmed by the repeat assessment, the 
response of CR or PR will be treated as SD for that time point.  
For subjects with intra -thoracic pleural disease, modified RECIST for MPM 
(Byrn e 2004 ) will be used to determine response at each post -baseline time point as 
follows:  
 Modified RECIST Criteria for MPM 
Response Definition  
CR disappearance of all target lesions with no evidence of tumor elsewhere  
PR at least a 30% reduction in the total tumor measurement  
PD an increase of at least 20% in the total tumor measurement over the nadir measurement, or the appearance of one or more new lesions  
SD those who fulfilled the criteria for neither PR nor PD  
For subject with ex tra-pleural metastatic disease , RECIST 1.1 (Eisenhauer 2009) will be 
used to determine response at each post -baseline time point. Assessment of target lesions, 
non-target lesions, new lesions, and overall response will be assigned  as follows:  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 13 of 39  RECIST 1.1 e valuation of target lesions: 
Response  Definition  
CR Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non- target) must have reduction in short axis to < 10 
mm. 
PR At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum diameters.  
PD At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline 
sum if that is the smallest on study). In addition to the relative increase of 
20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered 
progression.  
SD Neither sufficient shrinkage to qualify for  PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters on study.  
 RECIST 1.1 e valuation of non- target lesions:  
Response  Definition  
CR Disappearance of all non -target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (< 10 mm 
short axis).  
SD  Persistence of one or more non -target lesion(s) or/and maintenance of 
tumor marker level above the normal limits.  
PD Appearance of one or more new lesions and/or unequivocal progression  
of existing non -target lesions.  
 RECIST 1.1 overall response: 
Target lesions  Non-Target lesions  New Lesions  Overall response  
CR CR No CR 
CR Non-CR/non -PR No PR 
CR Not evaluated  No PR 
PR Non-PD or not all evaluated  No PR 
SD Non-PD or not all evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
The primary efficacy endpoint of the phase 3 portion of the study is: 
• Overall survival (O S): calculated as the time from randomization until death. In 
the event that no death is documented prior to study termination or analysis 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 14 of 39  cutoff, OS will be censored at the last known date the subject is known to be 
alive, either through completion of on-study visits or through survival follow-up 
contact. 
6.4.1.2 Secondary Efficacy Variables 
The s econdary efficacy endpoint of the phase 2 portion of the study is: 
• Duration of response  (DOR) : calculated for subjects who have a best tumor 
response of CR or PR as the time from date of initial response of CR or PR until 
date of tumor progression or death . Subjects without tumor progression or death 
at the end of treatment will be censored using the date of the last tumor 
assessment demonstrating no tumor progression. 
The s econdary efficacy endpoint of the phase 3 portion of the study is :  
• Progression- free survival (PFS): calculated as the time from randomization until 
date of tumor progression or death. In the event that no tumor progression or 
death is documented prior to end of treatment, analysis cutoff, or the start of confounding anticancer therapy, PFS will be censored at the date of the last 
tumor assessment demonstrating no tumor progression . 
6.4.2 Description of Safety Variables  
6.4.2.1 Adverse Events  
An AE is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.  
Note: The definition above, provided for in the GCP-ICH Guideline E6, is being extended for the purpose of Polaris studies to include any events, intercurrent diseases and accidents observed while the subject is on study, i.e., during the actual treatment period, as well as during drug- free, pre- and post- treatment periods.  
Adverse events will be recorded from administration of first dose of study drug  until 30 
days after last study drug administration.  Adverse events related to ADI -PEG 20  that 
were still ongoing at end of t reatment  (EOT)  visit should be followed up until resolution 
or stabilization or until all attempts to determine resolution of the event are exhausted.  
6.4.2.2 Laboratory Parameters  
Clinical laboratory tests listed in Table 2 will be obtained as per the schedule of events. 
Blood samples will be collected before ADI-PEG 20  or placebo  administration. A 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 15 of 39  certified laboratory will be utilized to process and provide results for the clinical 
laboratory tests.  
Table 2 Clinical Laboratory Tests   
Hematology (CBC)  Serum Chemistry  
Hematocrit  
Hemoglobin Red blood cell (RBC) count White blood cell (WBC) count 
Absolute Neutrophil Count (ANC) 
Lymphocytes (Absolute values)  
Monocytes (Absolute values)  
Basophils (Absolute values) Eosinophils (Absolute values)  
Platelet count (estimate not acceptable)  
 Albumin  
Alkaline phosphatase Blood urea nitrogen (BUN) Calcium  
Chloride Creatinine  
Glucose (non- fasting)  
HCG (at screening only) Potassium  
Serum glutamic -oxaloacetic transaminase  
(SGOT/AST)  
Serum glutamic -pyruvic transaminase 
(SGPT/ALT)  
Sodium Total bilirubin  
Total protein  
Uric acid  
6.4.2.3 Vital Signs  
Vital signs (blood pressure, respirat ory rate, heart rate, and temperature) will be obtained 
at screenin g, weekly during ADI -PEG 20 /placebo  treatment, and at the EOT  visit. On 
days of ADI -PEG 20 /placebo administration, vital signs will be obtained before and 1 
hour (± 15 minutes) after ADI -PEG 20  or placebo  treatment.  
6.4.2.4 Electrocardiograms 
ECG will be performed at screening, day 1 of cycle 2, day 15 of cycle 4, and during cycle 6 and beyond only as clinically indicated. On days of ADI -PEG  20/placebo  
administration, ECGs will be performed 1 hour (± 15 minutes) after ADI -PEG 20  or 
placebo  treatment.  
The results will include ventricular rate, P -R interval, R -R interval, QRS duration, QT 
interval, QTcF interval, and overall interpretation (normal, abnormal and not clinically significant, abnormal and clinically significant).  
The corrected QT interval will be corrected for respiratory rate using Fridericia’s 
correction : QTcF = QT/R -R
0.33. 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 16 of 39  6.4.2.5 Physical Examination 
A comprehensive physical examination, including height and weight, will be performed 
at the screening visit. Weight and body surface area (BSA) will be captured  on day 1 of 
each cycle. Symptom directed examinations may be performed as clinically indi cated .  
6.4.3 Description of Pharmacodynamic, Immunogenicity, and Pharmacokinetic 
Variables 
Approximately 10 mL of peripheral blood will be colle cted as plasma prior to 
ADI-PEG  20 or placebo dosing and used for pharmacodynamics, pharmacokinetics and 
immunogenicity studies. A central laboratory will be utilized to proce ss and provide 
results of blood sampling. 
Pharmacodynamics will be assessed by measurement of peripheral blood levels of 
argin ine and citrulline by liquid chromatography mass spectrometry ( LCMS ).  Subjects 
will also be assessed to determine if they experience arginine depletion and /or citrulline 
increase. Arginine depletion will be defined as blood levels ≤10 µ M and citrulline 
increase will be defined as increase from baseline ≥50%.  
Immunogenicity will be assessed by measurement of peripheral blood antibodies to ADI-PEG 20.  Blood will also be available for testing for anti-PEG antibodies.   
Pharmacokinetics will be assessed by measurement of peripheral blood ADI- PEG 20 
levels.  
Arginine, citrulline , anti -ADI-PEG 20 antibody, and ADI -PEG 20  levels will be obtained 
on day 1 and day 8 of cycle 1, day 1 of each subsequent cycle during combination 
therapy, and at weeks 19, 22, and 25 of ADI -PEG 20 or placebo only treatment. 
6.5 Data Quality Assurance 
Report summaries will be  generated using validated Base SAS
 software, version 9.4 or 
higher, on a PC or server -based platform.  Additional validated software may be used to 
generate analyses, as needed.  
All SAS programs that create outputs or supporting analysis datasets will be validated by 
a second statistical programmer or biostatistici an. At a minimum, validation of programs 
will consist of a review of the program log, review of output or dataset format and 
structure, and independent confirmatory programming to verify output results or dataset content. Additionally, all outputs will undergo a review by a senior level team membe r 
before finalization.  
The content of the source data will be reviewed on an ongoing basis by project statistical 
programmers and statisticians. Data will be checked for missing values, invalid records, and extreme outliers through defensive programming ap plications, analysis- based edit 
checks, and other programmatic testing procedures . All findings will be forwarded to the 
project data manager for appropriate action and resolution.  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 17 of 39  7 STATISTICAL METHODS  
7.1 General Methodology 
Data will be analyzed by Precision  for Medicine  biostatistics personnel. Statistical 
analyses will be reported with tables, fi gures, and listings, presented in rich text format, 
and using recommended ICH numbering. Output specifications for all tables, figures, and 
listings  will be in conformance with guidelines specified by the ICH in Appendix 7 of the 
Electronic Common Technical Document Specification (Apr 2003) .  
7.1.1 Reporting Conventions 
Tables and figures will be summarized by treatment group. Tables summarizing 
demographics and other baseline characteristics will also include a column for all 
subjects combined. In general, all data collected and any derived data will be presented in 
subject data listings, for all enrolled subjects. Listings will be ordered by site, subject 
number, treatment group, and assessment or event date. The treatment group presented in listings will be based on the planned assignment, unless otherwise noted. 
In general, continuous variables will be summarized to indicate the population sample 
size (N), number of subjects with available data (n), mean, standard deviation ( SD), 
median, minimum, and maximum values. Categorical  variables will be summarized by 
the N, n, num ber of subjects in each category, and the percentage of subjects in each 
category. Unless otherwise noted, the denominator to determine the percentage of subjects in each category will be based on the number of subjects with available data.  
Select ordinal data may be summarized using both descriptive statistics and counts and 
percentages of subjects in each category, as appropriate.  
Non-zero percentages will be rounded to one decimal place. Rounding conventions for 
presentation of summary statistics will be based on the precision of the variable of summarization, as it is collected in its rawest form (i.e., on the electronic case report form 
[eCRF] or as provi ded within an external file) and are outlined as follows:  
• The mean and median will be rounded to one more decimal place than the precision of the variable of summarization;  
• Measures of variability ( e.g., SD, SE) will be rounded to two more decimal places 
than the precision of the variable of summarization; and  
• Minimum and maximum values will be presented using the same precision as the 
variable of summarization.  
Other statistics ( e.g., CIs) will be presented using the same general rules outlined above, 
or assessed for the most appropriate presentation based on the underlying data.  
P-values will b e reported for all statistical tests , rounded to four decimal places. P- values 
less than 0.0001 will be displayed as “<0.0001”; p-values greater than 0.9999 will be displayed as “>0.9999”.  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 18 of 39  7.1.2 Summarization by Visit  
Data summarized by study visit (e.g., laboratory and vital signs) will be based on the 
nominal, scheduled visit label as reported on the e CRF includ ing the EOT  assessment  
where applicable.  
7.1.3 Standard Calculations 
Where appropriate, the calculated study day of each assessment or event will be 
present ed with the assessment or event date on subject data listings, where study day will 
be determined as:  
• The assessment/event date minus the date of first dose, if the assessment/event date is prior to the date of first dose; and  
• The assessment/event date min us the date of first dose, plus one, if the 
assessment/event date is on or after the date of first dose.  
Other variables requiring calculations will be derived using the following formulas:  
• Days:  A duration between two dates expressed in days will be calculated using 
the following conventions: 
o Later date – (earlier date + 1), if the earlier date is on or after the date of 
first dose of study drug; or 
o Later date – earlier date, if the earlier date is prior to the date of first dose 
of study drug. 
• Months:  A duration expressed in months will be calculated by dividing the 
duration in days by (365.25 / 12); 
• Years: A duration expressed in years will be calculated by dividing the duration 
in days by 365.25;  
• Change from Baseline: Change from baseline will be calcula ted as the 
post- baseline value minus the baseline value ; 
• Percentage Change from Baseline: Percentage change from baseline will be 
calculated as the change from baseline divided by the baseline value, multiplied by 100. 
7.2 Analysis Populations  
The analysis populations are defined as follows:  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 19 of 39  • Safety Population: Includes all randomized subjects who received at least one 
dose of the study medication . Assignment of subjects to treatment group is based 
on the treatment actually received. 
• Intent- to-Treat (ITT) Population: Includes all randomized subjects. Assignment of 
subjects to treatment group is based on the randomized  treatment assignment . 
• Per-Protocol (PP)  Population: Includes all ITT subjects who have no major 
protocol violations tha t may potentially affect the primary and secondary efficacy 
measures (e.g., no MPM, no measurable disease) . Subjects to be excluded from 
the PP Population will be determined prior to database lock and prior to breaking 
the blind of the treatment group assignments. Assignment of subjects to treatment 
group is based on the randomized treatment assignment.  
Data summaries to b e presented on both the Safety Population and the ITT Population 
will only be produced on both analysis sets if there is a difference in the population 
groups (e.g., at least one subject receives a different treatment than they were originally assigned).   
7.3 Study Subjects  
7.3.1 Disposition of Subjects  
Subject disposition will be summarized for all randomized subjects by treatment group and over al l subjects combined. Summaries will include the number and percentage of 
subjects in each analysis population, the primary reason for discontinu ing ADI -PEG 20 
or Placebo, and the primary reason for study termination. Subject disposition will also be summarized separately for each study center.  
7.3.2 Protocol Deviations 
Major protocol deviations will be summarized by treatment group and over all subjects 
combined for the ITT Population. Major protocol deviations will be identified, reviewed, and entered into the database as described in a separate Protocol Deviation Management Guideline document.  
All major protocol deviations will be determined and appropriately categorized prior to 
database lock and prior to breaking the blind of the treatment group assignments. The 
number and percentage of subjects with any major protocol deviations as well as the 
number and percentage of subjects with deviations within each category will be 
presented.   
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 20 of 39  7.4 Efficacy  
7.4.1 Datasets Analyzed 
All efficacy summaries will be based the ITT Population; select efficacy summaries will 
also be produced on the PP Population. A data listing of subjects excluded from the ITT 
or PP Population, to include the reason for exclusion, will be presented. 
7.4.2 Demo graphic and Other Baseline Characteristics 
Demographic variables including age, sex, ethnicity and race, will be summarized by 
treatment group and over all subjects combined for the S afety, ITT , and PP Populations. 
Age will be calculated relative to date o f informed consent, as follows: 
• If the month and day portion of the informed consent date is prior to the month and day portion of the birth date, age will be calculated as the year of informed consent minus the year of birth, minus one; 
• If the month and day portion of the informed consent date is on or after the month and day portion of the birthdate, age will be calculated as the year of informed consent minus the year of birth. 
Age will be summarized using descriptive statistics. Sex, ethnicity , and race will be 
summarized with the number and percent age of subjects in each parameter category.  
Baseline characteristics include: medical history , disease history (type of histology, stage 
of MPM, any radiation or surgery treatment for actual cancer ), height, weight, B SA, and 
Eastern Cooperative Oncology Group ( ECOG) performance status. Height, weight, and 
body mass index ( BMI ) at baseline will be summarized using descriptive statistics. 
ECOG performance status and disease history will be summarized usi ng frequency 
counts and percentages. S ubjects reporting abnormal medical history will be presented 
only in subject data listings by subject and body system. All other b aseline characteristics 
will be summarized by treatment group and over all subjects combined for the Safety, 
ITT, and PP Populations .  
7.4.3 Primary Efficacy Endpoint Analysis Methods  
7.4.3.1 Objective Response Rate 
The analysis of RR will be performed at the first interim analysis at the end of the phase 2 
portion. The number and percentages of subjects responding (CR or PR) as well as the number and percentages of subjects in each best tumor response category (CR, PR, SD, PD, missing or not evaluable) will be summarized by treatment group. The objective 
response rat e will be compared between treatment groups using the Cochran- Mantel -
Haenszel (CMH) test, stratified by tumor histology ( biphasic versus sarcomatoid) . The  
point estimate of the  relative risk ratio and the corresponding two-sided confidence 
interval will be  provided.  The significance level and coverage probability to be used in 
the RR analysis will be based on α=0.05 (two-sided). The RR will only be tested once at 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 21 of 39  the end of the phase 2 regardless of its significance.  The analysis will be based on the ITT 
Population. Summaries will also be provided for the PP population.  
7.4.3.2 Overall Survival  
The primary analysis of OS will be performed at the final analysis. Results will be 
presented by treatment group. The Kaplan -Meier method will be used to provide 
estimates of the OS curves, including the median, 25th and 75th percentiles and their 
corresponding 95% CIs. The number and percentage of subjects with an OS  event and 
those who are censored will be presented along with minimum and maximum survival 
times . The Kaplan -Meier curves will also be plotted. A Cox proportional hazard model 
with an adjustment for tumor histology (biphasic versus sarcomatoid) will be used to compute the estimated hazard ratio and two -sided 95% confidence interval. The treatment 
effec t on OS will be evaluated  using the stratified log -rank test (stratified by tumor 
histology). The significance level to be used in the OS analysis at the final analysis will 
be based on α=0.04999 (two -sided) . The analysis will be based on the ITT Population. 
Summaries will also be provided for the PP population. 
There will be an interim analys is of OS once 50% of the planned OS events for phase 3 
have occurred  and will be used to determine whether to terminate the study for futility or 
for possible sample s ize re -estimation for the phase 3 portion of the trial as described in 
Section 7.4.5.3. An administrative penalty of α=0.00001 will be paid for this interim 
analysis, and the allocated α=0.04999 will be used for the final analysis. Based on DSMB 
recommendations, the deaths for the original planned final analysis of OS will be changed from 338 to the actual number of deaths occurring by August 14, 2022. 
To take into consideration  subjects who received therapies for MPM after the end of 
study treatment , a sensitivity analysis using rank preserving structural failure time models 
(Robins and Tsiatis, 1991) will be performed to evaluate the impacts introduced by such 
actions.  
7.4.4 Secondary Efficacy Endpoint Analysis Methods 
The secondary efficacy endpoint for phase 2 to be performed at the first interim analysis 
is DOR.  DOR will be analyzed using the K- M curves to estimate its median and 95% 
confidence intervals.  
The secondary efficacy endpoint for phase 3 to be performed at the final analysis is PFS , 
which will be analyzed only if the analysis of OS is statistically significant at the final 
analysis, with alpha level of 0.05 two -sided  using the same statistical methodologies as 
applied to OS as described in Section  7.4.3.2.  
Summaries of secondary efficacy endpoints will be provided for the ITT and PP 
populations.  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 22 of 39  7.4.5 Statistical/Analytical Issues  
7.4.5.1 Adjustments for Covariates 
The analyses of each of the primary and secondary efficacy endpoints will be adjusted for 
the randomization stratification factor (biphasic histology versus sarcomatoid histology).  
7.4.5.2 Handling of Dropouts or Missing Data 
Subjects with no post-baseline tumor response will be included in the denominator for 
calculation of RR  and will be treated as non -responders.  
For time to event endpoints (OS, PFS, DOR), subjects with no follow-up assessment will 
be censored using a censored value of 1 day.  
No other imputation s of missing data will be made.  
7.4.5.3 Interim Analyses and Data Monitoring 
This st udy will include two separate interim analyses : 
• The first interim analysis will be conducted at the end of the phase 2 portion, after 
adequate response assessment  of the first 176 subject s enrolled .  This  interim 
analysis will evaluate the treatment effect on RR in the ITT population.  
• The second interim analysis will be performed once 50% of the planned OS 
events for phase 3 have occurred ( ie, 169 of the 338 planned OS events).  This 
interim analysis will evaluate OS in the ITT population in an unblinded manner .   
The RR data will be analyzed at the end of the phase 2 portion to support accelerated 
approval.  The  OS data at the second interim analysis will be analyzed to support the 
following decisions: 
• Futility stopping: T erminate the stu dy due to futility  at the interim analysis.  
• Sample size re- estimation: Increase the target number of OS events after the  
second  interim analysis.  
A futility stopping rule will be applied at the second interim analysis to support a 
decision to terminate the study due to futility.  The treatment’s futility will be evaluated 
based on the comparison of the median OS times in the ADIPemPlatinum or 
PlaceboPemPlatinum groups.  The study may be terminated if the median OS in the 
ADIPemPlatinum group is less than that in the PlaceboPemPlatinum group.  Th is futility 
stopping rule will be  non-binding and can be overridden by the Data Safety Monitoring 
Board  (DSMB) and/or Polaris . 
A sample size re -estimation rule will be applied at the second interim analysis to support 
a decision to increase the target number of OS events .  The target number of OS events 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 23 of 39  may be modified based on the conditional power (CP)  for the OS evaluation in the ITT 
population.  
The following sample size re -estimation rule will be applied: 
• Option 1: Retain the planned target number of OS events, i.e., 338 events, if CP is 
greater than 80% or less than 50% and the futility stopping rule is not met.   
 
• Option 2: Increase  the target number of OS events if CP is between  50% and 
80%, and the futility stopping rule is not met.  The target number of OS events 
will be increased to achieve CP of 80% or increased  by 30% , whichever is smaller  
based on Chen et al. (2004). Target enrollment adjustments  will be accomplished 
using standard event forecasting methods ( Anisimov 2011).  
An administrative penalty of α=0.00001 will be paid for second interim analysis, and the allocated α=0.04999 will be used for the final analysis. Based on Chen et al. (2004), the final test statistic after the sample size re- estimation will be the conventional test 
statistical which is identical to that used in a group sequential design. 
A DSMB will be instituted for this study to ensure the safety  of the subjects. 
Recommendations for continuation of the study will be guided by safety evaluations at 
safety data reviews. The committee will include two independent oncologists with experience in thoracic oncology and an independent statistician. Safety meetings will be 
held as per the DSMB charter, approximately every 6 months and more often if deemed necessary. Decisions on study termination, amendment, or cessation of subject recruitment, based on safety or outcome findings, will be made after recommendations from the DSMB have been assessed by Polaris. The DSMB will not be expected to conduct the efficacy analyses at the interim or final analyses. 
7.4.5.4 Multicenter Studies  
This is a global, multicenter study. Efficacy data collected from all study centers w ill be 
pooled for data analysis. The effect of study center on the efficacy analysis results may be 
explored post-hoc, as needed. 
7.4.5.5 Multiple Comparisons/Multiplicity  
The efficacy  endpoint (RR) will be evaluated at the end of the phase 2 portion at α = 0.05 
(two-sided) for the purpose of determining if the data supports accelerated approval.  
Since comparison of RR will only be tested at the end of the phase 2 portion for the 
purpose of providing support for accelerated approval, the type I error for phase 3 w ill be 
maintained at α = 0.05.  
The primary endpoint (OS) will be tested at α = 0.04999 ( two-sided) at the final analysis  
at the end of the phase 3 portion.  The analysis of OS at the second interim analysis will be performed for the purposes of testing for futility and possible re- estimation of sample 
size as described in Section 7.4.5.3. Analysis at the interim and final analysis will be 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 24 of 39  performed  based on Chen et al. (2004) in order to maintain  the type 1 error at α = 0.05 
for OS at the final analysis.  An administrative penalty of α=0.00001 will be paid for 
second  interim analysis, and the allocated α=0.04999 will be used for the final analysis. 
The s econdary endpoint of PFS will be tested only if the primary analysis of OS is 
statistically significant, thus maintaining the type 1 error at α = 0.05. 
7.4.5.6 Use of an “Efficacy Subset” of Subjects  
The primary efficacy analysis will be performed on the ITT population; the PP 
population will be utilized as a sensitivity analysis. The PP population will exclude subjects who have major protocol violations  that may potentially affect the primary and 
secondary efficacy measures.  
7.4.5.7 Examination of Subgroups 
There are no planned analyses to assess efficacy results by subgroups.  
7.4.6 Pharmacodynamics 
Blood levels of arginine and citrulline will be summarized for ADI -PEG 20  treated 
subjects. Descriptive statistics (including n, mean, SD , median, Q1, Q3, minimum, and 
maximum values ) will be presented for results and change from baseline at each visit 
where blood samples were scheduled to be collected.  The baseline value will be defined 
as the last value reported prior to first study drug administration . The number and 
percentage of subjects with arginine depletion and citrulline increase will also be 
presented at each visit.  Blood levels of arginine and citrulline will also be displayed 
graphically over time.  
Arginine and citrulline r esults may also be correlated with RR and OS by exa mining RR 
and OS results for subjects who demonstrate arginine depletion or citrulline increase at select time points compared to those subjects who do not. 
7.4.7 Immunogenicity  
Blood levels of antibodies to ADI-PEG 20 and anti-PEG antibodies will be summarized for ADI -PEG 20  treated  subjects. Descriptive statistics will be presented for results and 
change from baseline at each vis it where blood samples were scheduled to be collected.  
The baseline value will be defined as the last value reported prior to first study drug 
administration . Blood levels of antibodies to ADI-PEG 20 and anti-PEG antibodies will 
also be displayed graphically over time.  
7.4.8 Pharmacokinetics 
Blood concentration levels of ADI -PEG 20 will be summarized for ADI -PEG 20  treated 
subjects. Descriptive statistics will be presented for observed concentrations at each visit 
where blood samples were scheduled to be collected.  Blood concentration levels of 
ADI-PEG 20 will also be displayed graphically over time.  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 25 of 39  Analysis of derived pharmacokinetic parameters or correlation to efficacy endpoints may 
be performed and summarized in a separate report and is outside the scope of this SAP.  
7.5 Safety Analysis 
Safety analy sis will be carried out for the Safety Population, to include all subjects who 
receive at least one dose of study drug. Subjects who do not complete the study, for 
whatever reason, will have all available data up until the time of termination included in the analysis. For safety analysis presented by study visit, the baseline value will be defined as the last value reported prior to first study drug administration . 
7.5.1 Extent of Exposure and Treatment Compliance  
Extent of exposure to study treatment will be sum marized for the Safety P opulation by 
treatment group. The number of doses taken and the total dose administered will be summarized for each study drug: ADI-PEG 20/Placebo, Pemetrexed, Cisplatin, and Carboplatin.  The number and percentages of subjects who had at least one dose withheld and the number and percentages of subjects who at least one dose reduced along with the corresponding reasons for doses being withheld or reduced for each study drug, where applicable, will be summarized .  
Compliance will not be evaluated as study drug is administered by staff in the clinic..  
7.5.2 Adverse Events 
Treatment -emergent adverse events (TEAEs) are defined as those AEs with onset after 
the first dose of study drug or existing events that worsened after the first dose duri ng the 
study. Treatment -emergent AEs  will be summarized by treatment group. Events reported 
with a partial onset date (e.g., month and year are reported but the day is missing) will be considered to be treatment- emergent if it cannot be confirmed that the event onset was 
prior to the first dose of study drug based on the available date entries. 
Verbatim terms on case report forms will be mapped to preferred terms and system organ 
classes using the Medical Dictionary for Regulatory Activities (MedDRA, versio n 19.0 
or most current version at the time of analysis ).   
Summaries that are displayed by system organ class and preferred terms will be ordered 
by descending incidence of system organ class and preferred term within each system organ class. Summaries dis played by preferred term only will be ordered by descending 
incidence of preferred term. Summaries of the following types will be presented:  
• Overall summary of number of unique TEAEs and treatment- emergent serious 
adverse events (SAEs) and subject incidence of TEAEs meeting various criteria;  
• Subject incidence of TEAEs by MedDRA system organ class and preferred term ; 
• Subject incidence of the most frequently- occurring TEAEs ( e.g., TEAEs 
occurring in ≥ 10% of the Safety Population) by MedDRA preferred term ; 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 26 of 39  • Subject incidence of TEAEs by c ommon terminology criteria for adverse events  
(CTCAE ) grade, MedDRA system organ  class, and preferred term ; 
• Subject incidence of TEAEs by relationship to ADI-PEG 20/Placebo, MedDRA 
system organ class, and preferred term ;  
• Subject incidence of TEAEs by relationship to Pemetrexed, MedDRA system 
organ class, and preferred term ;  
• Subject incidence of TEAEs by relationship to the Platinum agent (Cisplatin  or 
Carboplatin), MedDRA system organ class, and preferred term;  
• Subject incidence of ≥ Grade 3  TEAEs related to ADI-PEG 20/Placebo  by 
MedDRA system organ class and preferred term ;  
• Subject incidence of ≥ Grade 3  TEAEs related to Pemetrexed  by MedDRA 
system organ class and preferred term;  
• Subject incidence of ≥ Grade 3  TEAEs related to the Platinum agent (Cisplatin  or 
Carboplatin) by MedDRA system organ class and preferred term ;  
• Subject incidence of TEAEs leading to discontinuation of ADI -PEG 20/Placebo  
by MedDRA system organ class and preferred term ;  
• Subject incidenc e of TEAEs leading to discontinuation of Pemetrexed  by 
MedDRA system organ class and preferred term ;  
• Subject incidence of TEAEs leading to discontinuation of the Platinum agent 
(Cisplatin  or Carboplatin) by MedDRA system organ class and preferred term ; 
and 
• Subject incidence of SAEs  by MedDRA system organ class and preferred term. 
At each level of summarization (e.g., any AE , system organ class, and preferred term), 
subjects experiencing more than one TEAE will be counted only once. In the summary of 
TEAEs by CTCAE  grade, subjects will be counted once at the highest CTCAE grade  
reported at each level of summarization; in the summary of TEAEs by relationship, subjects will be counted once at the closest relationship to study drug.  
Adve rse event data will be presented in data listings by subject , treatment group , and 
event. Serious AEs  and AEs  leading to discontinuation of ADI-PEG 20/Placebo, 
Pemetrexed, Cisplatin, and Carboplatin will be presented in separate data listings.  
7.5.3 Deaths, Othe r Serious Adverse Events, and Other Significant Adverse 
Events 
All deaths during the study, including the post treatment follow -up period, will be listed 
by subject, to include the primary cause of death. Serious AEs  and AEs  that led to 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 27 of 39  withdrawal, interru ption, or dose reduction of ADI -PEG 20/Placebo, Pemetrexed, 
Cisplatin, and Carboplatin, will be provided in separate subject data listings. 
7.5.4 Clinical Laboratory Evaluation 
All descriptive summaries of laboratory results will be based on data analyzed by th e 
central laboratory  and presented in Système International (SI) units, as suggested by the 
Center for Biologics Evaluation and Research and the Center for Drug Evaluation and 
Research  Position on Use of SI Units for Lab Tests  (Oct 2013 ). All data will be included 
in by- subject data listings. Laboratory measurements identified as abnorm al (i.e., outside 
the normal range) will also be listed separately by subject, laboratory test, and unit. 
Clinical laboratory measureme nts, including serum chemistry and hematology, will be 
summarized by treatment group . Descriptive statistics will be presented for observed 
values and changes from baseline at each visit where parameters were scheduled to be collected per the clinical stud y protocol.  
Where applicable, hematology and chemistry results for select parameters will be assigned a toxicity grade based on the U.S. Department of Health and Human Services Common Terminology Criteria for Adverse Events (CTCAE) , version 4.03 ( Jun 2010). 
Five-by-five contingency tables will be presented for lab tests where toxicity grading can 
be applied to summarize the shift from the baseline grade to the worst post- baseline 
grade. Grades will be presented as none (Grade 0), m ild (Grade 1), moderate (Grade 2), 
severe (Grade 3), or life -threatening (Grade 4). Death related to AE (i.e., Grade 5) cannot 
be determined with available laboratory -based data collection and, thus, will not be 
summarized as a category. Summary results wi ll include the count and percentage of 
subjects within each shift category.  
Where applicable, laboratory results will be classified as “low,” “normal,” or “high” with respect to the parameter- specific reference ranges ( i.e., below the lower limit of the 
normal range, within the normal range, or above the upper limit of the normal range). Three -by-three contingency tables will be presented for laboratory parameter that cannot 
be assigned a CTCAE toxicity grade to summarize the shift from the baseline category to 
the worst post- baseline measurement, defined as the value numerically farthest outside of 
the normal range across all post -baseline visits through the end of the study. Summary 
results will include the count and percentage of subjects within each shift category and treatment group.  
7.5.5 Vital Signs , Physical Findings, and Other Observations Related to Safety  
7.5.5.1 Vital Signs  
Vital sign parameter measurements will be presented in subject data listings by subject and study visit. 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 28 of 39  7.5.5.2 12-Lead Electrocardiogram 
Twelve -Lead ECG interval parameters will be summarized by treatment group. 
Descriptive statistics will be presented for observed values and changes from baseline at 
each visit where parameters were scheduled to be collected.  
Twelve -lead ECG will be classified by the investigator as “normal,” “abnormal, not 
clinically significant,” or “abnormal, clinically significant.” Three-by-three contingency 
tables will be presented to summarize the shift from the baseline category to the worst post- baseline value. Summary results will include the count and percentage of subjects 
within each shift category and treatment group. 
Prolonged QT intervals will be summarized as QTcF measurements (msec) that are 
> 450, > 470, and > 500 at each visit where ECG is routinely collected per the clinical study protocol. Change from baseline categories will also be summarized for measurements that represent a change > 30 or > 60 relative to the baseline value. Summary results will include the per centage of subjects within each category  and 
treatment group . 
7.5.5.3 Physical Examination 
Results of any symptom directed physical examination will be presented in subject data 
listings by subject and study visit. 
7.5.5.4 Prior and Concomitant Medications  
Medications will be coded using the World Health Organization (WHO Drug 2016Q1, 
enhanced) dictionary. Medications entered on the e CRF  will be mapped to Anatomic 
Therapeutic C hemical (ATC) drug class  (level 4) and drug name.  
Concomitant medications will be summarized by treatment group  for all medications 
reported on the Concomitant Medications eCRF. The number and percentage of subjects 
receiving any medication will be summarized  by treatment group , as will the number and 
percentage receiving any medication by ATC drug class and generi c drug name. Subjects 
reporting use of more than one medication at each level of summarization (any medication received, ATC class, and generic drug name) will be counted only once. ATC class terms will be displayed by descending order of incidence, as wil l generic drug 
names within each ATC class.   
7.6 Determination of Sample Size  
The sample size calculation for the phase 2 primary endpoint ( RR) assumed that the 
objective response rate in the PlaceboPem Platinum arm was 15%.  A total sample size of 
176 subjects (88 per arm) in the phase 2 portion of the study will provide approximately 
87% power to detect an improvement in the RR from 15% to 35% at the interim analysis  
at the end of the phase 2 portion. 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 29 of 39  The sample size calculation for the phase 3  primary endpoint (OS) assumed that the 
median OS was 6 months in the PlaceboPem Platinum arm.  Assuming a median OS of 
8.4 months in the ADIPemPlatinum arm (corresponding to a HR of 0.714), 338 OS 
events will provide  power of approximately 87% for the OS an alysis.  Assuming uniform 
accrual over a 24 -month period and a total study duration of 36 months, the planned total 
sample size in the study was 386 subjects. The target number of events may be increased 
at the second interim analysis, which will affect the total number of subjects.  
The study will include an unblinded interim analysis once 50%  of the planned OS events 
for phase 3 have occurred, which will be performed by an Independent A nalysis Group.  
The DSMB will review the interim analysis  report and provide final recommendations  
related to futility stopping and sample size re -estimation after the second interim analysis .  
The interim analysis decision rules  are defined  in Section  7.4.5.3. 
Based on DSMB recommendations, the original planned sample size will be changed 
from 386 subjects to all  enrolled up to August 15, 2021 (249 subjects); and the deaths for 
the original planned final analysis of OS will be changed from 338 to the actual number of deaths o ccurr ing by August 14, 2022. The estimated power with 249 subjects would be 
in a range of 73% to 80% if the true HR is in a range of 0.71 to 0.68. 
7.7 Changes in the Conduct of the Study or Planned Analyses  
This SAP follows  the planned analyses as described in  the protocol (Version 6; 
September 20 21). Changes from the previous versions of the SAP and protocol are 
specified in Section 4.  As mentioned above, the original planned sample size will be changed from 386 subjects 
to all enrolled up to August 15, 2021 (249 subjects) ; and the deaths for the original 
planned final analysis of OS will be changed from 338 to the actual number of deaths occurring by August 14, 2022.  
8 REFERENCE  LIST  
1. International Conference on Harmonization of Technical Requirements for 
Regis tration of Pharmaceuticals for Human Use. Statistical principles for clinical 
trials (E9). International Conference on Harmonization; 1998. 
2. M2 eCTD: Electronic Common Technical Document Specification Appendix 7, provided by the International Conference on Harmonization. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073240.pdf 
3. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257–260. 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 30 of 39  4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey 
J, Arbuch S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247. 
5. Anisimov V. Predictive event modelling in multicentre clinical trials with waiting time to response. Pharmaceutical Statistics 2011 ; 10:517-522.  
6. Chen YHJ,  DeMets DL, Lan KKG, Increasing the sample size when the unblinded interim result is promising, Statistics in medicine 2004; 23:1023 –1038 
7. Robins JM, Tsiatis AA, Correcting for non-compliance in randomized trials using rank preserving structural failure time models, Communication in statistics – 
theory and methods  1991; 20 (8): 2609-2631. 
8. Data Standards: Position on Use of SI Units for Lab Tests. U.S Food and Drug Administration; 25 October 2013. Available from: http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/ucm372553.htm  
9. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 14 June 2010. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf 
 
 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 31 of 39  APPENDIX  A: LIST OF TABLES , FIGURES AND DATA LISTINGS  
List of Tables  
Number  Description  Analysis Set  Source 
Listing(s)  
14.1 Demographic Data 
Summaries    
14.1.1.1  Subject Disposition  All Randomized 
Subjects  16.2.1  
14.1.1.2  Subject Disposition by Study 
Center  All Randomized 
Subjects  16.2.1  
14.1.2  Major Protocol Deviations  ITT Population  16.2.2 .1 
14.1.3.1  Demographic Characteristics  Safety 
Population  16.2.4.1  
14.1.3. 2 Demographic Characteristics  ITT Population  16.2.4.1  
14.1.3. 3 Demographic Characteristics  PP Population  16.2.4.1  
14.1.4 .1 Baseline Characteristics  Safety 
Population  16.2.9.1 , 16.2.9.5  
14.1.4 .2 Baseline Characteristics  ITT Population  16.2.9.1, 16.2.9.5  
14.1.4 .3 Baseline Characteristics  PP Population  16.2.9.1, 16.2.9.5  
14.1. 5.1 Disease History   Safety 
Population  16.2. 2.2, 
16.2.4.3, 16.2.4.4  
14.1. 5.2 Disease History  ITT Population  16.2.2.2, 
16.2.4.3, 16.2.4.4  
14.1. 5.3 Disease History  PP Population  16.2.2.2, 
16.2.4.3, 16.2.4.4  
14.2 Efficacy Data Summary 
Tables    
14.2.1.1  Objective Response Rate  – 
Phase 2 Subjects  ITT Population  16.2.6.1  
14.2.1. 2 Objective Response Rate  – 
Phase 2 Subjects  PP Population  16.2.6.1  
14.2.2.1  Duration of Response  – Phase 
2 Subjects  ITT Population  16.2.6. 1 
14.2.2. 2 Duration of Response  – Phase 
2 Subjects  PP Population  16.2.6. 1 
14.2.3.1  Overall Survival   ITT Population  16.2.6. 1 
14.2.3. 2 Overall Survival  PP Population  16.2.6. 1 
14.2.3.3  Overall Survival by Tumor 
Histology  ITT Population  16.2.6. 1 
14.2.3.4  Overall Survival by Tumor 
Histology  PP Population  16.2.6. 1 
14.2.4.1  Progression Free Survival  ITT Population  16.2.6. 1 
14.2.4. 2 Progression Free Survival  PP Population  16.2.6. 1 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 32 of 39  Number  Description  Analysis Set  Source 
Listing(s)  
14.2.4.3  Progression Free Survival by 
Tumor Histology  ITT Population  16.2.6. 1 
14.2.4.4  Progression Free Survival by 
Tumor Histology  PP Population  16.2.6. 1 
14.2.5.1  Pharmacodynamic Parameters   ITT Population  16.2. 5.6 
14.2.5. 2 Immunogenicity Parameters  ITT Population  16.2. 5.7 
14.2.5. 3 Pharmacokinetic 
Concentrations   ITT Population  16.2. 5.8 
14.3 Safety Data Summaries    
14.3.1  Displays of Adverse Events    
14.3.1.1  Overall Summary of 
Treatment -Emergent Adverse 
Events  Safety 
Population 16.2.7  
14.3.1.2  Treatment -Emergent Adverse 
Events by System Organ Class 
and Preferred Term  Safety 
Population 16.2.7  
14.3.1.3  Most Frequently -Occurring (≥ 
10% Overall) Treatment-
Emergent Adverse Events by 
Preferred Term   Safety 
Population 16.2.7  
14.3.1.4  Treatment -Emergent Adverse 
Events by CT CAE Grade, 
System Organ Class, and 
Preferred Term  Safety 
Population 16.2.7  
14.3.1.5  Treatment -Emergent Adverse 
Events by Relationship to ADI-PEG 20/Placebo, System 
Organ Class , and Preferred 
Term  Safety 
Population 16.2.7  
14.3.1. 6 Treatment -Emergent Adverse 
Events by Relationship to Pemetrexed, System Organ 
Class , and Preferred Term  Safety 
Population 16.2.7  
14.3.1. 7 Treatme nt-Emergent Adverse 
Events by Relationship to the Platinum Agent, System Organ 
Class , and Preferred Term  Safety 
Population 16.2.7  
14.3.1. 8 Treatment -Emergent ≥ Grade 3  
Adverse Events Related to ADI-PEG 20/Placebo  by 
System Organ Class and 
Preferred Term  Safety 
Population 16.2.7  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 33 of 39  Number  Description  Analysis Set  Source 
Listing(s)  
14.3.1. 9 Treatment -Emergent ≥ Grade 3  
Adverse Events Related to 
Pemetrexed  by System Organ 
Class  and Preferred Term  Safety 
Population 16.2.7  
14.3.1. 10 Treatment -Emergent ≥ Grade 3  
Adverse Events Related to the 
Platimun Agent by System Organ Class  and Preferred 
Term  Safety 
Population 16.2.7  
14.3.1. 11 Treatment -Emergent Adverse 
Events Leading to Discontinuation of ADI-PEG  20/Placebo  by 
System Organ Class and 
Preferred Term  Safety 
Population 16.2.7  
14.3.1. 12 Treatment -Emergent Adverse 
Events Leading to Discontinuation of Pemetrexed  
by System Organ Class and 
Preferred Term  Safety 
Population 16.2.7  
14.3.1. 13 Treatment -Emergent Adverse 
Events Leading to Discontinuation of the 
Platinu m Agent by System 
Organ Class  and Preferred 
Term  Safety 
Population 16.2.7  
14.3.1. 14 Treatment -Emergent Serious 
Adverse Events by System 
Organ Class and Preferred 
Term  Safety 
Population 16.2.7, 14.3.2.2  
14.3.2  Listing of Deaths, Other 
Serious and Significant 
Adverse Events    
14.3.2.1  Listing of Deaths  Safety 
Population  N/A 
14.3.2.2  Listing of Serious Adverse 
Events  Safety 
Population  N/A 
14.3.2.3  Listing of Adverse Events 
Leading to ADI-PEG 20/ 
Placebo  Discontinuation or 
Interruption  Safety 
Population N/A 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 34 of 39  Number  Description  Analysis Set  Source 
Listing(s)  
14.3.2. 4 Listing of Adverse Events 
Leading to Pemetrexed  
Discontinuation, Reduction or 
Interruption  Safety 
Population N/A 
14.3.2. 5 Listing of Adverse Events 
Leading to Cisplatin  
Discontinuation, Reduction or 
Interruption  Safety 
Population N/A 
14.3.2. 6 Listing of Adverse Events 
Leading to Carboplatin 
Discontinuation, Reduction or 
Interruption  Safety 
Population N/A 
14.3.3  Narratives of Deaths, Other 
Serious Adverse Events, and 
Certain Other Significant 
Adverse Events*   
14.3.4  Abnormal Laboratory 
Values Listing    
14.3.4.1  Listing of Abnormal 
Hematology Values  Safety 
Population  N/A 
14.3.4.2  Listing of Abnormal Chemistry 
Values  Safety 
Population  N/A 
14.3.5  Extent of Exposure    
14.3.5.1  Extent of Exposure  Safety 
Population  16.2.5.1 , 
16.2.5.2, 
16.2.5.3, 16.2.5.4  
14.3.6  Laboratory Summaries    
14.3.6.1  Hematology – Univariate 
Summary by Parameter and 
Visit  Safety 
Population 14.3.4.1, 16.2.8.1  
14.3.6.2  Hematology – Shift from 
Baseline to Worst Post -
Baseline Value by Parameter  Safety 
Population 14.3.4.1, 16.2.8.1  
14.3.6.3  Chemistry – Univariate 
Summary by Parameter and 
Visit  Safety 
Population 14.3.4.2, 16.2.8.2  
14.3.6.4  Chemistry – Shift from 
Baseline t o Worst Post -
Baseline Value by Parameter  Safety 
Population 14.3.4.2, 16.2.8.2  
14.3.6.5  Shift from Baseline to Worst 
Post-Baseline NCI CTCAE 
Toxicity Grade by Laboratory 
Parameter  Safety 
Population 14.3.4.1, 
14.3.4.2, 16.2.8.1, 16.2.8.2 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 35 of 39  Number  Description  Analysis Set  Source 
Listing(s)  
14.3.7  Vital Signs, Physical Findings 
and Other Observations    
14.3.7. 1 12-Lead Electrocardiogram – 
Univariate Summary by 
Parameter and Visit  Safety 
Population 16.2.9.3  
14.3.7. 2 12-Lead Electrocardiogram 
Interpretation – Shift from 
Baseline to Worst Post-
Baseline Value  Safety 
Population 16.2.9.3  
14.3.7. 3 12-Lead Electrocardiogram – 
QT Interval Categories  Safety 
Population  16.2.9.3  
14.3.7. 4 Concomitant Medications  Safety 
Population  16.2.9.4  
*Narratives of deaths, other serious adverse events, and certain other significant adverse 
events will not be generated by analysis programming and are outside the scope of this 
analysis plan.    
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 36 of 39  List of Figures  
Number  Description  Analysis Set  Source Tables  
and/or Listing(s)  
14.4 Efficacy Data Figures    
14.4.1.1 Overall Survival   ITT Population  14.2.1.1, 16.2.6.1  
14.4.1. 2 Overall Survival   PP Population  14.2.1.1, 16.2.6.1  
14.4. 2.1 Progression Free Survival   ITT Population  14.2.1.1, 16.2.6.1  
14.4. 2.2 Progression Free Survival   PP Population  14.2.1.1, 16.2.6.1  
14.4. 3.1 Arginine  Blood Levels Over 
Time  ITT Population  16.2.5.6  
14.4. 3.2 Citrulline Blood Levels Over 
Time  ITT Population  16.2.5.6  
14.4. 3.3 ADI-PEG 20 Antibody Blood 
Levels Over Time  ITT Population  16.2.5. 7 
14.4. 3.4 Anti-PEG Antibody Blood 
Levels Over Time  ITT Population  16.2.5. 7 
14.4. 3.5 ADI-PEG 20 Concentration 
Levels Over Time  ITT Population  16.2.5. 8 
  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 37 of 39  Subject  Data Listings 
Number  Description  
16.1.7  Randomization  
16.1.7  Randomization Scheme and Codes  
16.2.1  Discontinued Subjects  
16.2.1  Subject Disposition  
16.2.2  Protocol Deviations  
16.2.2 .1 Major Protocol Deviations  
16.2.2.2  Informed Consent and Eligibility Criteria  
16.2.3  Subjects Excluded from the Efficacy Analysis  
16.2.3  Subjects  Excluded from the Efficacy Analysis  
16.2.4  Demographic Data  
16.2.4.1  Demographics  
16.2.4. 2 Medical History  
16.2.4. 3 Prior Radiation Treatments to Treat Cancer  
16.2.4.4  Prior Surgeries to Treat Cancer  
16.2.5  Compliance and/or Drug Concentration Data  
16.2.5.1  ADI-PEG 20/ Placebo  Administration  
16.2.5.2  Pemetrexed Administration  
16.2.5.3  Cisplatin Administration  
16.2.5.4  Carboplatin Administration  
16.2.5. 5 Pharmacodynamic and Immunogenicity Blood Sampling  
16.2.5. 6 ADI-PEG 20 Concentration Data  
16.2.6  Individual Efficacy Response Data  
16.2.6.1  Derived Efficacy Data  
16.2.6.2  Response Assessment: RECIST Criteria  – Phase 2 Subjects  
16.2.6.3  Target Lesions  – Phase 2 Subjects  
16.2.6.4  Non Target Lesions  – Phase 2 Subjects  
16.2.6.5  New Lesions  – Phase 2 Subjects  
16.2.6.6  Survival Status  
16.2.7  Adverse Events  
16.2.7  Adverse Events  
16.2.8  Listing of Individual Laboratory Measurements  
16.2.8.1  Hematology  
16.2.8.2  Chemistry  
16.2.8.3  Pregnancy Test  
16.2.9  Additional Safety Listings  
16.2.9.1  Vital Signs  
16.2.9.2  Physical Examination  
16.2.9.3  12-Lead Electrocardiogram  
16.2.9. 4 Chest X -ray 
16.2.9. 5 ECOG Performance Status  
16.2.9. 6 Concomitant Medications  
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January 2022 
 
 
Confidential   Page 38 of 39  Number  Description  
16.2.9.7  Non-Medication Therapies or Treatment/Procedures  
16.2.9.8  Therapeutic Procedures After End of Treatment  
 
 
Polaris Group  Statistical Analysis Plan  
POLARIS2015 -003  Version 4.0; 4 January  2022 
 
 
Confidential   Page 39 of 39   
Page Intentionally Left Blank 
 